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CHAPTER! 
Introduction 
INTRODUCTION. 
TRENDS IN INCIDENCE AND MORTALITY IN PROSTATE CANCER 
Prostatic carcinoma is the second most diagnosed malignant tumor in the Netherlands, only 
carcinoma of the lung is more frequent. In 1991 4343 men were diagnosed with prostate 
cancer, making up 14.1% of all diagnosed malignant tumors. In the age-group 60-74 years the 
incidence was second after pulmonary carcinoma, and in the age-group >75 years it is the most 
frequently diagnosed malignancy. In 1991 2108 patients died because of prostate cancer. The 
mortality/incidence ratio is 0,49; which means that about 50% of the patients will die because 
of their prostatic malignancy'. The incidence of prostatic cancer in developed countries is 
rising. Lu-Yao reported an increase in the incidence-rates of prostatic cancer in the United 
States of America of6.4% per year between 1983 and 1989'. This increase appeared to be 
due to the detection of early-stage disease, but there was no increase in the incidence-rate of 
metastatic cancer. There was no increase in mortality rates during this study-period. In the 
Netherlands 3% of all mortality among men was due to prostate cancer (1989) 3. In 1994 van 
der Gulden reported on the trends in mortality-rates for patients with prostate cancer in the 
Netherlands'. The age-adjusted mortality-rates rose between 1950 and 1989 with an average 
increase of 1 % per year. A continuous increase of mortality from prostate cancer was found in 
consecutive birth-cohorts (defined by combining age and calender-time periods on the basis of 
their central year of birth). There was a steep rise in the mortality from prostate cancer with 
age; for the age-category 55-59 years the prostate cancer mortality-rate was 11.2 per 100.000 
man-years, but for the category >85 years this was 921.8. This rise in the incidence and morta-
lity of prostate cancer points out that this disease will become more and more important in the 
years to come. Since more cancers tend to be localized, the role of radical prostatectomy in the 
treatment of prostatic carcinoma will become even more important than it is today. 
HISTORY AND CONTEMPORARY DEVELOPMENTS IN RAPICAL PROST ATECTO-
MY 
The introduction of anaesthesiology in the nineteenth century made more extensive surgery 
possible. The first examples of prostatic surgery are found in the second half of this century: all 
used a perineal incision, since this was the best known procedure, because it was used in 
perineal lithotomy, which was in use since the times of the roman empire (Celsus described the 
curved perineal incision in 25 A.D.) '. 
In 1867 Billroth perfomlCd the first partial perineal prostatectomy'. After this initial step 
several surgeons practised partial perineal prostatectomy, however their patients rarely survi-
ved longer then one year after the operation. Kiistner performed a total cystectomy and 
prostatectomy with anastomosis ofthe ureters to the bowel in 1891, using a combined supra-
pubic and perineal incision 1. A radical suprapubic prostatectomy for prostatic cancer was 
described by Fuller in 1898, who also removed a part of the bladder wall'. The patient died of 
recurrence after II months. In 1905 Young described the first radical perineal prostatectomy 
with excision of the seminal vesicles, ampullae of the vasa, and the surrounding fascia 9,10 Tllis 
technique continued to be used with minor modifications suggested by Belt ", Lowsley ", and 
Vest n In recent years the renewed interest in the perineal approach due to the developement 
of laparoscopie lymph node dissecti"on , has resulted in applicating a nerve sparing technique. 
The retropubic approach was first described by Millin". During the last 15 years the insights 
into the periprostatic anatomy have evolved. Reiner and Walsh described a technique for 
2 
control of the bleeding of the dorsal vein complex ". This enabled a more anatomic approach. 
After this the anatomy of the branches of the pelvic plexus which innervate the corpora caver-
nosa, was identified; this lead to modifications of the surgical technique allowing the saving of 
the neurovascular bundles 16.". These modifications and the excellent results for continence and 
potency reported (92% and 68%) 18.1', gave a strong impuls to the performance of radical 
prostatectomy, which is considered the first treatment of choice in patients with localized 
prostate cancer. In the last decade the number of radical prostatectomies performed has 
increased dramatically. Lu Yao even reported a nearly sixfold increase '. This increase may be 
due to the increased incidence of localized prostate cancer 20, caused by earlier detection 
because of increased public and doctors awareness and the induction of screening programs 'I, 
enabled by the introduction of Prostate Specific Antigen (PSA) for routine use in 1986. 
Clinically organ-confined prostatic cancer is sometimes difficult to distinguish from locally 
advanced disease, in which the tumor extends outside the prostate, or invades the seminal 
vesicles. This explains the high percentage of under staging reported in series ofpatients 
undergoing radical prostatectomy for clinically organ-confined disease (43-75%) ,,23.". Many 
of these patients with pT3fpstage C disease do well after radical prostatectomy however, 
despite the fact that the tumor has crossed the limits of the prostate. This brings up the questi-
on whether radical prostatectomy can be a meaningful treatment in patients with clinical T3fC 
disease. FurtherolOre overstaging is known to occur in 17-30% in patients with T3 25."; these 
patients may be denied a curative procedure because of staging errors. In the literature only a 
few studies performing radical prostatectomy for locally advanced tumors can be found, and in 
all studies all or a substantial percentage ofthe patients received adjuvant therapy (hormonal or 
radiotherapy).The results for T3-patients treated with radical prostatectomy as a monotherapy 
are therefore not known. Considering the fact that hormonal therapy is a palliative therapy, 
which will not prolong life, and that radiotherapy is only a local therapy, which has no effect on 
(occult) distant metastases already present at the time of surgery, and considering the fact that 
both therapies can give complications, the effect of radical prostatectomy alone should be 
known to make a deliberate treatment decision for patients with locally advanced disease. 
GOALS OF THIS THESIS 
The studies presented in this thesis were performed to define the place of radical surgery in the 
treatment of locally advanced prostatic carcinoma, and to determine prognostic factors for 
progression and survival, that can support the decision-making for the use of adjuvant therapy. 
To achieve this goal, the sub-goals of this thesis were: 
I. To study the infiuence of pathological variables determined in the radical prostatectomy-
specimen on progression and survival in patients undergoing radical prostatectomy for clinical-
ly localized prostate cancer (organ-confined and locally advanced). 
2. To study the influence on progression of residual carcinoma after radical prostatectomy in 
patients with positive margins of resection; and the relation ofthe occurrence of positive 
margins of resection and other pathological variables. 
3. To study the outcome of disease-control in patients with locally advanced prostate cancer 
treated by radical prostatectomy without adjuvant treatment, and to compare these results to 
those reported in the literature for clinical and pathological T3fC disease, treated with surgery 
or radiotherapy with or without adjuvant treatment. 
4. To study which category of patients ,vith locally advanced disease might benefit of adjuvant 
treatment after radical prostatectomy. 
3 
5. To study the mortality and morbidity associated with radical prostatectomy, and the influence 
of clinical stage on the complication-rate. 
6. To study the disease outcome in patients with clinically localized and locally advanced prostate 
cancer, who were candidates for radical surgery, but didn't undergo the radical prostatectomy 
because of the detection oflymph node metastases on frozen sections during the pelvine lymph 
node dissection preceding the radical prostatectomy; and to evaluate the influence of early 
versus delayed endocrine therapy on tumor-control in these patient-group. 
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PART! 
RADICAL PROSTATECTOMY FOR 
LOCALLY ADVANCED PROSTATIC 
CARCINOMA 

CHAPTER 2 
Locally advanced disease: surgery: is there a rationale? 
D. van den Ouden, F.R. Schroder. 
Department of Urology, Erasmus University 
and Academic Hospital Rotterdam. 
Adapted from: 
Locally advanced disease: surgery: is there a rationale? 
In: Urologic Malignancies, Hamdy,F., Basler,J., Neal,D., Catalona,W. 
Churchill Livingstone Ed., chapt. 2.6.2.2, in press. 
LOCALLY AOVANCED DISEASE: SURGERY: IS THERE A RATIONALE? 
Dies van den Ouden, Fritz H, Schroder 
INCIDENCE 
Locally advanced disease (clinical stage T3 or C) Is present In 12 to 40% of all newly 
diagnosed prostate cancer patlents,'·2.3 In recent years the Incidence of localized disease at 
the time of diagnosis has Increased from 27,7% In 1985 to 48,5% In 1990.' The Increasing 
public and doctors awareness and the Induction of screening programs for prostate cancer, 
will probably result In earlier detection of prostate cancer, and a shift towards lower stage at 
dlagnosls!l 
DEFINITIONS 
Locally advanced prostatic cancer Is defined as tumor extending outside the prostate, with 
perforation of the prostatic capsule, and/or tumor invasion of the seminal vesicles. This 
situation Is classified as stage III or C (Cl or 2) In the Whitmore claSSification', and stage T3 
In the T.N.M. classification of 1992, according to the U.I.C.C. (Union International Contra 
Cancer). The latter has gained worldwide acceptance in recent years, and allows a 
subclassification In T38: unilateral extracapsular extension, T3b: bilateral extra capsular 
extension, and T3c: invasion of the seminal vesicles."? This subclassification can Identify 
subgroups with different outcome and has therefore prognostic value. Tumor extending Into 
neighbouring organs Is classified as T 4. (C3 In the Whitmore classification). 
STAGING 
Oyer lunderstaglng 
Despite the development of new techniques (MRI, PSA) and the Improvement of existing 
techniques (TRUS, Ct-scannlng), It remains difficult to differentiate between locally confined 
and locally advanced disease. This Is reflected not only in the understaglng of T2 disease, 
which in 43-75% turns out to be histological pT3 dlseaseu.l~, but also In the overstaging of T3 
disease, which varies from 8_30%.II.U.U.Ul This means that In 8-30% of the clinical T3 patients, 
the disease Is locally confined, and that they are candidates for radical surgery according to 
generally accepted standards. This treatment may be denied because of staging errors. 
Clinical overstaglng was significantly associated with the preoperative tumor grade (p"0.04): 
in well and moderately differentiated tumors overstaglng Is more frequent than In poorly 
dlHerentiated carcinoma. I:).) 
Understaglng in clinical T3 disease occurs In 4%u, whlch Is pathologically pT4. These patients 
will suffer local recurrence and disease progression, despite surgery and are therefore not 
candidates for radical prostatectomy. In cases of doubt, T 4 can be diagnosed performing a 
cystoscopy and blmanuel examination under anaesthesia. 
Role of digital rectal examination (ORE), transrectal ultrasonography (JRUS), and magnetic 
resonance imaging (MAl) In detecting local extension of disease 
Ohorl'" Investigated 117 patients with clinically localized prostate cancer by ORE and TRUS. 
The sensitivity for detection of extracapsular extenslon(ECE) was 67% for DRE and 58% for 
TAUS. The positive and negative predictive values(PPV and NPV)for ORE and TRUS were 74% 
and 64%, and 82% and 63% respectively. When ORE and TRUS were combined, the PPV was 
79% and the NPV 86%. There was however a big difference In sensitivity according to the 
localisation of the tumor: for anteriorly located tumors the sensitivity was 14%, compared to 
60% for posterolateral and 86% for dorsally located tumors. Andrlole ls however, found 
10 
understaglng of locally advanced disease by TRUS In 62%. McSherry found a PPV of 100% for 
ORE and 83% for TRUS. The NPV of ORE and TRUS however (I.e. the ability to exclude ECE) 
was 36% and 37% respectively"'. These data Indicate Ihat there Is a wide variation of the 
reliability of ORE and TRUS for determining ECE, probably because they are operator· 
dependent examinations, which depend on the personal skill of the Investigator. 
McSherry '" reviewed the IIlerature for Ihe ability of MRI to Identify ECE, and found PPV's 
varying from 66·82%, and NPV's from 30·90%, which again Indicates a wide variation of 
reliability. 
Role of prostate specific antigen (PSA) In detecting local extension of disease 
PSA> 10 ng/ml has a sensitivity of 61% and a specificity of 88% for detection of ECE. The 
PPV Is 88% and the NPV 62%~. Only 2% of the patients with a PSA> 15ng/ml have organ 
confined disease. Kaballn showed that Ihe pre-operative PSA values correlate with cancer 
volume, grade, ECE, and the occurrence of lymph node metastases, and developped a PSA-
based rating scale for use In treatment decisions. PSA did not significantly correlate with 
seminal vesicle Involvement. A PSA> 10 ng/ml Indicates a 40%, and a PSA> 25ng/ml a 50% 
chance of ECE". Narayan el all Investigated biopsy-based staging In combination with pre-
operative PSA and biopsy Gleason score for detecting eXlraprostatlc disease, and established 
probability plots for these variables, which give a prediction of the presence of ECE, seminal 
vesicle Involvement and lymph node metastasesC1• 
Lymph node metastases In clinical T3 carcinoma. 
Lymph node metastases (LNM) are frequently found In patients with clinical T3 carcinoma of 
the prostate; percentages of 33-56% are reported. II ,' 2,U,11I Once the pelvic lymph nodes are 
Involved, the disease Is no longer localized but systemic, and local radical therapy can not 
control the dlsease,l1 
Ct-scannlng Is of limited value In detecting LNM: Bosch described a sensitivity of only 35% for 
Ihe detection of LNM, a PPV of 75% and a NPV of 59%." MRI performs even worse, with a 
sensitivity for detecting LNM of 25%." Wolf stales Ihat the probabJllty of LNM should be 45% 
to make Imaging beneficial. Partin developed nomograms which Indicate a 50% risk for LNM 
when the Gleason score Is 8-10 and the PSA Is over 25 ng/ml." Bluestein found LNM In 43% 
of patients with a PSA over 20 ng/ml and a primary Gleason grade 4 or 5.~ If any doubt 
exists about the presence of LNM, a staging laparoscoplc lymph node dissection should be 
performed. or frozen sections of the lymph nodes must be Investigated Intra operatively prior 
to the radical prostatectomy. 
Influence of high grade disease on prognosiS In T3 carcinoma 
High grade disease (poorly differentiated carcinoma) Is associated with high mortality due to 
prostate cancer (10 limes higher than well or moderately differentiated carcinoma), and a high 
morbidity due to a high metastallc rate. (74% at 10 years post-diagnosis even In locally 
confined disease) In conservatively managed prostatic carclnoma.~1 Therefore effective therapy 
Is urgently needed for this group of biologically agresslve carcinomas. This aggressiveness Is 
expressed In a high percentage of T3 disease (55-92%),m, and a high percentage of 
aneuploidy, measured by ONA flowcytometry." Natlv showed however that ploidy had no 
Significant Influence on progression once the tumor Is poorly dlfferentlated.~ 
Ohorl found progreSSion In 0% of the organ confined and In 80% of the non organ confined 
tumors with Gleason sum > 8. n Partin showed that 24% of the specimen confined tumors 
with Gleason > 8 progressed after 3 years, compared to 82% of the non-specimen confined 
tumors.2"J 80th concluded that rad/cal prostatectomy tor high grade disease Is to be limited to 
locally confined tumors. . 
Van den Ouden reported on a group qf 100 patients with clinical T3 carcinoma, which 
contained f 5 pallents with T3pT3G3 carcinomas, treated by radical prostatectomy without 
adjuvant therapy. Of these pallents 14 (93%) progressed within 2 years post surgery", 
ii 
whereas patients with T3pT3Gl and 2 had similar progression rates as T2 disease. 
Lerner performed radical prostatectomy In 501 patients with T3 Gleason > 7: 48% of the 
patients received adjuvant hormonal therapy. The actuarial cause specific survival rate at 5, 10 
and 15 years Was ± 80%, ± 70% and ± 50%11, which may Indicate a good response on the 
administration of adjuvant therapy In this high risk group, despite strong Indications that 
adjuvant hormonal therapy probably does not Influence survival. 
In conclusion: patients with high grade tumors and stage T3 are not good candidates for 
radical prostatectomy. If radical prostatectomy Is performed In selected cases (for example In 
young patients) for T3G3 carcinoma, adjuvant therapy Is desirable. 
NATURAL HISTORY 
In recent years a number of studies Is published on natural history of locally confined cancer, 
however the natural history of locally advanced prostate cancer Is only rarely reported. This Is 
probably due to the high risk for progression and death In these carcinomas, which appeals 
to the physician to start Immediate treatment to prevent progression and to try to delay death 
due to cancer. Table 1 contains the studies concerning the natural history of locally advanced 
disease which were published In the last 30 years. Also some studies concerning locally 
confined carcinoma were summarized, since understaglng Is known to be a frequent event . 
For this reason especially the not very recent studies were selected, because staging In those 
days was less sophisticated than In the last decade, which added CT-scannlng and transrectal 
ultrasonography to the diagnostic armamentarium (despite these further staging possibilities 
understaglng stili occurs In 43-75% In T2-dlsease). Since high stage-tumor Is also known to 
correlate with a relatively high percentage of high grade and lymph node metastases, special 
attention was given to the composition of the reported groups In this matter. Therefore also a 
recent study concerning the natural history of lymph node positive patients was Included 129. 
The nalural history of a disease may be defined as the clinical and pathological features 
characterizing the behaviour of the disease from its inception over time in the untreated 
patient. The important features are growth rate and metastatic potential. A Simple form to 
describe growth rate Is by relating tumor volume to a uniform and exponential increase In 
cells dependent only on the doubling time. A single cancer cell with a diameter of 10 micron 
takes 16 years to grow out to a tumor of 1 cm In diameter ( 30 doubllngs to produce 10 ~ 
cells, with a doubling lime of 6 months ). Concerning the local progression rates listed In 
table 1, which vary between 22 and 84% in only 5 years, this means that all tumors were 
already long eXisting before they were diagnosed. This explanes the rapid local progression In 
some series \23. Metastatic potential is the most important feature In prostate cancer, since 
most patients dying of prostate cancer do so because of metastases. Lymph nodes are often 
the first site of extraprostatic metastases. Once lymph node metastases occur, further 
dissemination of the tumor can be expected by the lymphatic chain, and its connection to the 
circulatory system. It is therefore not surprlzing that the only series which has established 
lymph node metastases 129 , shows a higher metastatic rate at 5 years than the series where 
no lymph node metastases were expected: 39% versus 0-25%. 
Fuks IN Is the only one who reports 10-year metastatic rates, In a group of patients who were 
treated by U$I-!mplantatlon: this treatment Is nowadays considered less effective for tumor-
control, and may oHer therefore an opportunity to study the natural history of prostate cancer. 
The metastatic rate Increases with Increasing grade. but there are to few patients In the G3-
group, which may explain the lower percentage of metastases for these patients. The patient-
groups reported by Aus 111, Adolfsson 12\ Whitmore lU, Byar 11!S, and Graversen 127 contain no, 
or a very limited number of high-grade patients «5%). Since high grade Is more common In 
patients with locally advanced disease, these groups represent therefore a selection of 
patients with a relatively good prognosis , compared to the total population of patients with 
T3/C disease. 
Overall survival is reported to vary from 10-92% at 5 years, 14-78% at 10 years, and 0-78% at 
15 years. Whitmore In even reports a 20- and 25-year survival of 51 and 49%. These large 
differences Indicate that these groups are hard to compare because of differences In: Initial 
stage, grade, lymph node involvement, follow-up, and treatment when progreSSion occurs. The 
12 
Table 1: Clinical progression, local progression, distant metastases, overall survival and cancer specific 
survival in patient with locally advanced untreated prostate cancer 
Reference N stage CP LP DM os CSS 
5yr(%) 5yr(%) 5yr(%) 10yr(%) 5yr(%) 10yr(%) 15yr(%) 5yr(%) 10yr(%) 15yr(%) 
Aus (117) 88 T2b-T3MOGl-2 89 72' 
Nesbit (118) 765 T3 10 
Moskovitz (119) 17 T3 13 ) 42 42 
Jones (120) 6 B2 83 17 0 
7 C" 71 14 0 
Adolfsson (121) 50 T3NxMOGl-2" 64 24 37 4 ) 64 374) 88 704) 
Whitmore (122) 37 B2 38 35 11 92 70 57~) 86 78 78') 
9 B3 22 22 0 89 78 78') 100 100 100') 
George (123) 120 Tl-3MO 84 25 35~) 60 
Fuks (124) 33 B3-CNOGI1Q) 2711) 
62 B3-CNOG210) 5611) 
10 B3-CNOG310) 5011) 
Vacurg (125) 248 III (placebo) 58 
251 III (orchidectomy) 56 
256 III (estrogen) 53 
237 III (orchidectomy + 
estrogen)- 45 
Byar (126) 20 II 
Graversen (127) 18 II 
Davidson (128) 36 T3-4Nl-3MO 
1)9 year 
2)treated by 12~ I-implant 
3)only 2 patients G3 
4)9 year 
~)20yr: 51%; 25yr: 49% 
"20yr: 78%; 25yr: 78% 
"20yr: 64% 
w 
35 
751::) 361:1:) 391:1:) 
., 
" 
20yr: 100% 
7 year 
84 
39 
1D) all pt. underwent 1::5I-implantation 
11) after 4-9 years follow-up 
1:1:) after a median follow-up of 41 months 
13) all patients underwent non-radical prostatectomy 
VACURG-study Is often referred to because It Is the first study for untreated patients versus 
trealment patients In a randomized fashion. The articles by Byar II't and Graversen U1 are 
follow-up studies of this report. Unlortunately several methodological flaws diminish the value 
of these observations: 22% of the patients had to be removed from the study because of 
protocol-violations, 75% of those had a second treatment; staging was Inaccurate compared 
to modern standarts (no lymph node evaluation, no bone-scan); weak statistical power: Byar 
,. Indicated only a 33% chance of detecting a 50% dlHerence In clinical progression, and 
Graversen 121 described a 47·90% chance to miss statistically significant differences In this 
material. So no definite conclusions can be drawn from these reports. 
Cancer specific survival was only reported In 5 studies, After 5 years of follow-up the cancer 
specific survival varied between 60-100%, at 10 years from 70-100%, and at 15 years from 78-
100%, In the study by George .u several stages (T1-3) were reported together, but most 
patients must have had large tumors, considering the high local progression-rate and the fact 
that 90% was obstructed at the time of diagnosis, George does not describe the grade In his 
group, No patient had metastases at diagnosis, This, and the presence of large (and therefore 
probably many locally advanced) tumors leads to the suggestion that these patients represent 
a population with a selection for a non,metastatlc phenotype, Despite this George reports the 
lowest percentage of cancer specific survival (60%), The other series reporting cancer speCific 
survival, contain hardly any patients with high-grade disease, and are therefore selecting 
patients with a relatively favourable prognosis, 
The fact that the patients described here did not receive curative treatment, did not mean that 
they had no treatment at all. Moskovitz lIt and Handley nit performed non-radical 
prostatectomy In 100- and 95% of their patients. Whitmore m performed transurethral 
resection of the prostate In 31% of his patients, because of obstruction during follow-up, and 
hormonal therapy In 24%, Adolfsson III did TUA of the prostate In 22% to relieve obstruction; 
58% received hormonal·, and 12% radio-therapy because of progression. 
The natural history of locally advanced prostate cancer Is not suHlclently understood, The 
articles reporting on this matter contain either patients who are not fit to undergo curative 
treatment, or they describe subgroups with a relatively good prognosis, In both ways a 
selection Is made, so these results cannot be applied to the total population of patients with 
T3/C cancer, 
RESULTS OF RADICAL SURGERY IN CLINICALLY LOCALLY ADYANCED DISEASE (STAGE 
IWl 
Overall Survival (O.S) 
Table 2 shows the results for overall survival and cancer specific survival for patients with 
clinically advanced (stage T3/C) prostate cancer, treated by radical prostatectomy, There are 
many more reports in the literature concerning pathological stage T3/C, but this classification 
Is only known after radical prostatectomy, when the major treatment decision has already 
been made; therefore these reports are summarized separately. 
Overall survival depends, besides tumor control, on age (for all series the median age is 
about 65 years) and general health. This can make comparison with other treatments difficult, 
because patients fit to undergo radical surgery are generally in a better condition than their 
age-matched controls, who are treated with radiotherapy or conservative (hormonal) treatment. 
Overall survival ranged from 64-95% at 5 years, from 12,5·72% at 10 years and from 20·51% 
at 15 years post treatment, These differences can be explained by the difference In time 
(Jewett 1958 v.s. lerner 1995): nowadays better postoperative care and better techniques of 
surgery are available. Many studies from early data do not evaluate lNM, since the 
prostatectomy is performed perlneal/y_ Therefore many patients with lNM may have early 
pr9gresslon and death_ Cancer specific survival Is not reported In most studies before 1980_ 
Zincke" reported 5 and 10 years survival of 80 and 65%, this was not significantly different 
from the survival In a group of men of the same age In the general population. This finding 
Indicates excellent chances for patients with T3 carcinoma treated by radical prostatectomy, 
however these patients represent a selection of otherwise very healthy persons, because they 
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Table 2: overall Survival and Cancer Specific Survival for patients with clinically diagnosed T3 or 
stage C prostate cancer. 
Reference N Therapy 
Jewett (26) 48 RP 
Scott (27) 39 RP 
Flocks (28) 69 RP 
Tomlinson (29) 24 RP 
Schroeder (30) 213 RP + PLND 
Zincke (31) 49 RP + PLND 
von Flamm (32) 20 RP 
Morgan (33) 232 RP + PLND 
Yamada (34) 25 RP + PLND 
van den Ouden (12) 59 RP + PLND 
Lerner (11) 812 RP + PLND 
Gerber (133) 289 RP + PLND 
* during the observation period 
RP = Radical prostatectomy 
PLND = pel vine lymph node dissection 
HT = hormonal therapy 
RT = radiation therapy 
Adjuvant 
Therapy 
HT (all) 
Au 198 
HT (43%) 
HT (50%) 
HT\RT(39%) 
HT (90%) 
HT (54%) 
RT/HT 
HT/RT (60%) 
RT/HT (?) 
Au 198 = interstitial radio active gold seeds implantation 
- = not reported 
V> 
Overall 
Survival 
5 10 
(%)survival 
15yr 
12,5 
74 61 29 
74 67 28 
82 
64 36 20 
65 
46 
84 72 
84 
83 
86 70 51 
Cancer specific 
(%) 
5 10 15yr 
83 79 68 
70* 
89 82 
92 
90 
90 80 69 
88 70 
are fit to undergo major surgery. Furthermore, many underwent hormonal therapy which has 
Impact on short and Intermediate term results. 
Cancer specific survival ceSS) 
CSS is the best parameter to evaluate the results of treatment for prostate cancer for survival, 
since Intercurrent death by other diseases are excluded and the parameter relates more to the 
dIsease under study. CSS at 5, 10 and 15 years post treatment ranges from 85·92%; 70·82%; 
and 68·70% respectively. These ranges are remarkably narrow, considering the fact that a 25 
years time difference lies between the flrst Z7 and the last report. II Unfortunately this means 
also that little progress Is made In the treatment of T3 carcinoma. Most studies administer 
either hormonal or adjuvant radiation treatment to a part of their patient populations. This 
however does not affect survival slgnlflcantly.1I 
Clinical progression (CP) 
Clinical progression, local recurrence and biochemical progression are listed In table 3. 
Clinical progression means (biopsy proven) local recurrence, and/or the occurrence of distant 
metastasis as detected by bone scans, ultrasonography or Ct-scans. Biochemical progression 
means a rise In PSA over a certain value; this value differs between the different reported 
series. 
The clinIcal progressIon rates vary from 12·45% at 5 years, 39·49% at 10 years and 50-71% 
at 15 years post treatment. The progression rates for patients who did not have adjuvant 
treatment12•U were not very different from those who dld.21.31.33 The other studies contain too 
few patients to be reliable In this matter. This Is surprising since adjuvant hormonal therapy is 
known to prolong the Interval to progression II."; this effect does not seem to last longer than 
5 years. 
Local recurrence (LR) 
Local recurrence is expected when there Is residual disease because of a positive margin of 
resection. The limited amount of periprostatic tissue and the presence of extra capsular 
extension (ECE) leads to a higher percentage of positive margins with Increasing stage31. In T3 
disease 47·81% have positive surgical marglns.31.," Many surgeons hesitate therefore to save 
the neurovascular bundles In T3 disease. Partin showed positive margins after radical 
prostatectomy for ECE positive disease In 55% when the bundle was saved, versus 42% when 
it was sacrificed. Margin positive patients had a decreased time to disease recurrence (not 
sIgnIficant), but after 3 years both groups showed bIochemIcal progressIon In 70%. ThIs may 
be due to occult metastasis In ECE patients at the time of surgery and suggests that fate Is 
not determined by the margins but by the extent of the tumor.39 Epstein Investigated 
secondary resection of the bUndle (during the same operation) after initially saving it in 
patients In whom a positive margin was expected. In 40% no tumor was found In the resected 
bundle~. ThIs IndIcates the Ineff/ciency of decIsIon makIng Intra operatIvely. Despite the hIgh 
percentage of positive margins, the local recurrence rate is low Indicating that radical 
prostatectomy for T3 disease leads to an excellent local control (table 3). 
Biochemical progression (BPl 
Data on biochemical progression are only available In 4 studies In this review. These were 
published after 1986, when PSA became available for routine·use. As can be seen in table 3 
there are but little differences between the progression rates for the different groups, with 
exception of the group who received no adjuvant therapy, which showed a 5 year progression 
of 63%. All other groups admInIstered hormonal and/or radIation adjuvant therapy In a 
considerable percentage of their patients (54-100%). The biochemical progression rates are 
higher than the clinical progression rates In all groups. The knowledge that biochemical 
progreSSion preceeds clinical progression by 3-5 years4 \ and that all biochemically progressed 
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Table 3: Clinical progression, local recurrence and biochemical progression in patients with clinically 
diagnosed T3 or stage C prostate cancer. 
Reference N Clinical progression (%) Local Recurrence (%) Biochemical progression (%) 
5 10 15yr 5 10 15yr 5 10yr 
Scott (27) 39 38 49 7 
Flocks (28) 69 4 
Tomlinson (29) 24 9 
Schroeder (30) 213 13* 
Zincke (31) 49 45 18 
Morgan (33) 232 31 44 10 18 49 62 
Yamada (34) 25 12 48 
van den Ouden (12) 59 36 63 
Lerner (11) 812 39 50 20 29 42 59 
Olsson (35) 7 14 
Bosch (36) 15 36 
* during the observation period 
not reported 
-> 
patients will suHer clinical progression, reveals a gloomy scenario for these patients. 
COMPLICATIONS 
The mortality rate of surgery in T3 disease Is 0,4-1,5%·11,11 The overall complication rate Is 
43%,H Stenosis of the anastomosis, requiring dilatation was present In 9-32%; Incontinence in 
14-23%, and Impotence in 69%,11,n Davidson compared the complication rates of clinical stage 
T3 and T < 3, and found no significant differences. 
RESULTS OF RADICAL SURGERY IN PATHOLOGICAL LOCALLY ADVANCED DISEASE (STAGE 
plUQ) 
Radical prostatectomy Is a well established therapy for patients with clinically locally confined 
disease. However due to staging errors 43-75% of the patients with clinically confined disease 
turn out to have locally advanced disease (pT3/C}u.lo, Based on local tumor extension these 
patients should have survival and progression rates, which are comparable to clinical stage T3 
patients, since both have locally advanced disease. It Is to be expected however, that In clini-
cally T3 disease, the percentage of high grade tumors and LNM Is higher, which leads to 
lower survival and higher progression rates, 
In many patients with locally advanced disease adjuvant treatment Is administered. Neo-
adjuvant hormonal therapy Is given pre·operatlvely, with the expectation that this may 
downstage the disease. Most patients however recleve postoperative adjuvant treatment, 
mostly radlotherapy(RT). To evaluate the effects on survival and progression, patient-groups 
with and without adjuvant treatment are reported separately here, 
RESULTS OF RADICAL SURGERY IN PATHOLOGICAL LOCALLY ADVANCED DISEASE (STAGE 
pT3IC) IN PATIENTS TREATED WITH SURGERY ONLY 
Overall sllrvlva! 
The results of overall survival in patients with pathological locally advanced prostate cancer In 
patients treated with surgery only are listed In table 4.The overall survival rates at 5,10, and 
15 years range from 75-88%, 33-92%, and 13-21% respectively. Whereas the results of 5-year 
survival are quite comparable, there Is a wide range In 1 Q-year survival, This may be due to 
patient selection and treatment variables. The low percentage of survival noted by Elder(33%}9 
and Glbbons(39%t may be the result of occult LNM at the time of surgery, since In both 
groups perineal prostatectomy was performed, without lymph node dlssectlon.(in the group of 
Gibbons 5 out of 23 did undergo LND). On the other hand In the study with the highest 
percentage of survivors, which Is also reported by Glbbons(92%t , the lymph nodes were 
only evaluated by fine needle aspiration In selected patients with high risk for LNM,(tumor 
bulk> 1,5 cm; bilateral tumor diagnosed by biopsy or high grade lesion). Patients with LNM 
which are not noted at the time of surgery may have the highest mortality In the period 5-10 
years after operation, This explaines the large difference In survival at 5 and 10 years In the 
study by Eldere• Further evidence Is found In the study by Herlng10, where cancer specific 
survlval(CSS) drops from 83% at 5 year to 0% at 10 year(all patients died at 9 years 
postoperatively). In this group 55% of the patients had LNM at the time of surgery, which may 
explalne the drop In survival. 
Cancer specific survival 
CSS for patients with pathological stage pT3jC treated by surgery only Is also listed In table 
4. The CSS rates at 5,10, and 15 years range from 80-100%, 0-90%, and 25-89%. The consi-
derations already made on behalf of the overall survival are also of concern for these 
numbers. The 0% CSS reported by Hering .. Is due to the high number of LNM(55%) In this 
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Table 4: Overall survival and cancer specific survival for patients with pathological stage pT3 or p-stage 
C prostate cancer, treated with surgery only. 
Reference N 
Elder (9) 35 
Gibbons (48) 49 
Middleton (49) ECE 18 
SV + 10 
Gibbons (50) 23 
Anscher (51) 113 
Fried (52) 6 
Shevlin (53) 57 
Gibbons (54) 9 
Hering (10) 68 
Frohmuller (55) 22 
Stein (56) SV - 82 
SV + 33 
Eisbruch (57) 43 
Hawkins (58) 660 
* after average 9,2 year 
** after 9 year' 
- = not reported 
'-0 
Overall survival (%) Cancer specific survival 
5 10 15yr 5 10 15yr 
75 33 13 
92 
100 
80 
39* 
82 63 21 90 75 25 
83 67 100 83 
88 80 
89 
83 0** 
55 68 
90 
63 
55 
84 
N 
o 
Table 5: Clinical progression, local recurrence and biochemical progression in patients with pathological 
stage pT3 or C prostate cancer, treated with surgery only. 
Reference 
Elder (9) 
Gibbons (48) 
Middleton (49)ECE 
Gibbons (50) 
Anscher(51) 
Schellhammer 
Fried (52) 
Catalona (60) 
Shevlin (53) 
Gibbons (54) 
Mukamel (61) 
SV + 
(59) 
ECE 
SV -
SV + 
Hering (10) 
Frohmuller (55) 
Stein (56) SV -
SV + 
Epstein (62) 
N 
35 
49 
18 
10 
23 
113 
16 
6 
9 
57 
9 
48 
104 
35 
68 
22 
82 
33 
focal ECE 93 
established ECE 103 
Catalona (63) ECE 227 
SV + 86 
Eisbruch (57) 43 
Zietman (38) 32 
Hawkins (58) 
diploid 660 
non-diploid 
* after 41,8 months 
+ after average 9,2 years 
x 8 years 
, after 9 years 
clinical progression (%) Local Recurrence (%) 
5 10 
25 66 
18 
11* 
50 
39+ 
0 17 
33 33 
25 50' 
3 16' 
31 58' 
48 74' 
45 
21 38 
42 
35 
15yr 5 10 15yr 
87 
0 
20 
30" 
25 51 68 
31 31 
0 
11 
20 28 
22 
17' 
16 
- after average 51 months 
includes 115 organ-confined tumors 
after 4 years 
ECE = extracapsular extension 
Biochemical progression (%) 
5 10yr 
39' 59" 
18 
35 
26 
68 
73' 
41 65 
50 72 
not reported 
SV seminal vesicle 
invasion 
group. After elimination of this study the range from 63-90% seems more reasonable. The 
89% 15·year CSS reported by Glbbons~ Is remarkable, since none of these patients underwent 
LND. The group Is however very small(only 9 patients), and a selection Is made: the report 
considers only the patients who did not undergo adjuvant treatment after the finding of 
pathological stage T3 disease. It seems therefore logical that these patients represent a very 
favourable selection, and the excellent survival reported Is not valid for the average pT3 
patient. 
Clinical progression 
The results concerning the clinical progression (CP) In patients with pT3 treated by surgery 
only are listed In table 5. The CP·rates at 5 and 10 years range from 0·50%, 16·74% 
respectively. At 15 years only Elder' reports a 87% progression rate. The presence of LNM In 
55% of the patients explanes the high progression rates reported by Herlng'o. Mlddleton-lQ and 
Mukamel51 reported the progression rates separately for patients with seminal vesicle 
Involvement, which has a negative Influence on progression. 
Local recurrence 
The results are also listed In table 5. Local recurrence{LR) Is of special Importance, since In 
many patients with locally advanced disease positive margins of resection occur, which point 
to local residual disease. This Is the reason why adjuvant treatment Is so frequently 
administered In this group of patients. 
The local recurrence rates at 5, 10, and 15 years range from 0-31%, 17-51%, and 22-68% 
respectively. Mukamel found a significant difference between patients with only extracapsular 
extension and those with seminal vesicle Involvement (0 versus 20%). The 0% LR reported by 
Fried'~ Is in a very small group: only 6 patients. Schellhammer~ found the same percentage 
(3t%) LR at 5 and 15 years, Indicating that LR occurs In the first 5 years postoperatively. 
There was a marked difference In LR between patients with extracapsular extension only and 
those with seminal vesicle Involvement: 0 versus 44%. The study by Anscher5 ! however shows 
an increasing percentage LR from 5 to 10 years. Considering that both groups are 
comparable for the percentage of high grade tumor and seminal vesicle Involvement, this 
difference cannot be explained. 
Biochemical progression 
Biochemical progression for patients with pT3 treated by surgery only Is listed In table 5, and 
ranges from 18-73% at 5 years and from 59-72% at 10 years. Since PSA only became a 
routine laboratory Investigation In 1986, all 10 year progression rates are proJections, and not 
observed values. For the same reason 15 year progression rates are not available. Since after 
a radical prostatectomy all prostatic tissue should be removed, the PSA should be 0, and 
therefore any elevation can be considered proof for residual prostatic tfssue(and possibly 
cancer). The definition of BP varies among the different studies: Epsteln&l and HawklnsM use a 
limit of PSA>O,2 ng./ml; StelnM of PSA>O,4 ng./ml; Catalona~ of PSA>O,6 ng./ml to define 
BP, whereas Zietman3G only speaks of detectable PSA. These differences make the comparison 
between the different studies difficult. It Is however clear that the BP rates exceed the CP 
rates, and given the fact that patients with BP will devellop CP In the line of time, the CP 
rates will rise with extended observation-time. 
THE ROLE OF ADJUVANT TREATMENT IN THE MANAGEMENT OF LOCALLY ADVANCED 
PROSTATIC CANCER (STAGE pT3/C) 
. Neoadluvant treatment 
Neoadjuvant hormonal treatment Is the administration of hormonal therapy before radical 
surgery, most often in locally advanced prostatic tumors, with the intent to downstage the 
tumor and make a radical resection possible. The rationale tor neoadjuvant treatment is stated 
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Table 6: Downstaging by neo-adjuvant hormonal therapy prior to surgery for locally advanced prostate 
carcinoma. 
Reference N Initial staging 
Kennedy (67) 7 C stage C 
Labrie (68) 8 C stage C 1 
7 C stage C 2 
Pummer (69) 25 C stage B 2/C 
Fair (64) 55 C stage B 2/3 
C 
DO 
Thompson (70) 24 C stage C 
Morgan (71) 36 C stage C 
Hellstrom (66) 35 C stage T3 
Flamm (72) 21 C stage T3 
Schulman (13 0 ) 15 C stage T3 
LHRH = Luteinizing hermon releasing hermon 
CPA = Cyproteron acetate 
Neo-adjuvant hormonal 
treatment 
LHRH-agonist 
2-5 months 
LHRH-agonist 
+ Flutamide 
3 months 
LHRH-agonist 
5 pt + Flutamine 
4 months 
DES 
8-32 weeks 
LHRH-agonist 
+ Flutamide 
3 months 
Megace + Estradiol 
cyclophosphamide (22pt) 
3 months 
LHRH-agonist (+ CPA) 
3 months (CPA: 3 weeks) 
LHRH-agonist 
+ Flutamide 
3 months 
LHRH-agonist + Flutamide 
2-12 months 
Down staged to pathologic 
stage T1/2 (A/B) (%) 
29 
75 
71 
4 
39 
26 
40 
13 
11 
50 
33 
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by Falr'\ and formulated In 5 points: 1 :most prostatic tumors are significantly understaged; 2: 
hormonal therapy(HT) reduces the volume of the prostate gland and Is standard therapy for 
metastatic prostate cancer; 3: animal studies wlth- androgen sensitive tumors Indicate that HT 
markedly depletes the tumor stam cell population; 4: the availability of PSA, TRUS, and 
Improved blopty techniques allow earlier detection of disease progression, and therefore the 
h'npact of a given treatment can be evaluated earlier (we do not have to walt for survival 
data); 5: some data Indicate that combined hormonal and surgical therapy Is beneficial. 
The Initial enthouslasm for combined HT and surgery was raised by the study of Scottn In 
1969, who administered HT to patients with locally advanced disease, who were therefore not 
candidates for surgery. In those patients who had a good respons to this treatment (I.e. a 
shrinkage of the tumor), radfcal perineal prostatectomy was performed. It fs evident that this 
method of working contains a selection of patients: those who did not respond to HT did not 
undergo surgery. Scott reported excellent CSS of 68% at 15 years (see table 2). More 
recently Plleplch reported the results of a study In patients with bulky prlmalry lesions (Clinical 
stage B or C); one group was treated with Goserellne and Flutamlde 2 months prior to 
radiotherapy, the other group received only radiotherapy (65·70 Gy.). At 3 years there was a 
significant advantage In local control (84 versus 71%), survival free of clinical disease (61 
versus 43%) and survival free of biochemical disease (46 versus 26%, BP Is defined as 
PSA> 4,0 ng./ml), and no significant advantage In the development of distant metastases (25 
versus 30%)65. These early results seem encouraging, however since It Is known that HT 
prolongs the time to progression, they are not surprlzlng. Long-term results, and especially 
CSS have to be awaited. In a recent thesis Hellstrom reports the results of 2 groups of 
patients, who underwent radical prostatectomy; group 1 had no neoadjuvant treatment, group 
2 received a LHRH analoge 3 months before surgery. At 3 years the observed BP was only 
16% In group 1 versus 43% In group 2. The latter contained however patients with more 
advanced disease, so these results have to be Interpreted with caution$/!. Soloway reported on 
the results of a prospective randomized trial In which the patients with clinical stage T2b 
prostate cancerwere treated by radical prostatectomy alone, or In combination with 
neoad]uvant hormonal therapy (Ieuprollde and flutamlde for 3 months). Despite the fact that 
the patients who recleved neoadjuvant androgen blockade showed a significant lower 
percentage of positive margins, the biochemical progression (PSA> 0.4) at 12 months post 
surgery was not significantly different from the patient group that was treated with radical 
prostatectomy alone (BP: radical prostatectomy alone: 12%, radical prostatectomy and 
neoad]uvant hormonal therapy: 16%; p=0.5). This finding was noted even after adjusting for 
preoperative PSA and Gleason score. 131 These findings are supported by a prospective 
multlcentre randomized trial conducted by the Canadian Uro-Oncology Group, In which 
patients with stage A2, B1, or 82 were randomized for radical prostatectomy alone, or surgery 
after 12 weeks of Cyproterone acetate. No significant differences were found In post-
treatment PSA at 6 and 12 months post-treatment between the two groups, despite the fact 
that the group who received neoadJuvant hormonal therapy showed a significantly lower 
percentage of positive margins of resection, lower prostatic weights, smaller tumor nodules, 
lower tumor volume, and higher Gleason scores. m Therefore long-term reports of progression 
and survival have to be awaIted before neoadjuvant hormonal therapy can be considered 
beneficial. 
Table 6 summarises some recent studIes concerning the effect of downstaging by HI In 
locally advanced disease to organ confined disease. It is clear that there Is a wide range in 
the results of downstaglng by neoadjuvant HT. The high percentage of downstaglng reported 
by Labrleell Is remarkable, however: In the same study there was a control group of 7 patients 
with Cl and 5 patients with C2 disease who did not receive HT. Downstaglng In these groups 
occurred In 57 and 20%. Especially the 57% downstaglng In the stage Cl·group raises 
questions about the accuracy of pre-treatment staging. In other studies concerning T3 patients 
downstaglng without neoadjuvant HT occurs In 17_30%"·I2,U. When these numbers a~e 
compared to the numbers in table 6, the downstaglng by neoadjuvant therapy seems not very 
significant. Furthermore it has to be remembered that neoadjuvant HT causes histological 
changes. Hellstrom describes glandular atrophy, nuclear pyknosis, cytoplasmic vacuollsatlon, 
squamous metaplasia and an increase In the relative amount of stroma after the 
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administration of neoadjuvant hormonal therapy (LHAH agonist for 3 months and Cyproterone 
acetate for 3 weeks)'3, These changes were not correlated to the pre·treatment tumor grade 
or volume of residual tumor. These changes make It more difficult to Interpret the 
postoperative pathological histology, which may lead to postoperative staging errors, 
especially by pathologists who are not familiar with these changes. These staging errors may 
lead to a relatively high percentage of organ confined disease, since changed tumor cells 
outside the capsule are not recognized, 
In conclusion: neoadjuvant HT Is not recommended as standard treatment in locally advanced 
prostatic cancer. The results of downstaging are not Impressive, and the results on survival 
are not yet known. Therefore It Is advised to use neoadjuvant HT only In an experimental 
setting (preferably a randomized multi-center study). 
Postoperative adjuvant treatment 
Locally advanced disease treated by radical prostatectomy carries a relatively high risk of 
residual disease. Therefore many urologists tried to diminish the risk by the use of adjuvant 
treatment. Most studies reported are using radiotherapy, administered to the pelvis, and an 
extra boost for the prostatic bed. The total radiation-dose amounts to about 65 Gy., which Is 
the same dose used In prlmalry RT for locally advanced prostate cancer. The ratio for this 
adjuvant radlotherapy(AAT) Is to eradicate all possible residual disease, to prevent local 
recurrence. Antagonists of this treatment argue that most patients with locally adVanced 
prostate cancer die because of distant metastases and not of LRn. ART does not eradicate 
these micro-metastases, which are present, but unnoticed, at the time of surgeryu. Lange 
treated 15 patients with persistent elavated PSA after AP with Immediate AAT(60 Gy.); the 
PSA level decreased to female levels In 53%, Indicating that In 47% active prostatic tissue Is 
left, which Is not treated by local Irradiation. Furthermore In 29 patients with BP, without 
evident CP, LA was found In 19 patients after blopty of the anastomosis. All patients received 
AT, but In no patient with LA the PSA level decreased to female levels, Indicating that they 
had metastases elsewhere. Lange therefor advises adJuvant HT In patients with elevated PSA 
post-surgery7S. 
Link reported on t 2 patients with persistent elevated PSA Immediately after surgery, who 
received Immediately AAT(6000-7000 radio After 30 months only t out of 12 patients had a 
durable respons(PSA<0,3 ng./ml),all others had progressed, Indicating that metastases were 
present at the time of RTn. 
As for local control: not all patients with positive margIns of resection actually have local 
residual disease"", and not all patients with positive margins experience progression. PaulsonT1• 
In re-evaluatlng the patient-group reported by Anscher5" failed to Identify any benefit of 
postoperative AAT in patients with postage C disease. McCarthy treated 2 patient-groups with 
either Immediate or or delayed (after BP) AT post-surgery, and found no difference In survival 
with no evidence of disease (67 and 68% respectlvely)n. Since AAT has also complications, 
and causes discomfort for the patient, It seems safe to walt with the administration until LR 
actually occurs. 
Adjuvant hormonal therapy(AHT) Is given In some patients with locally advanced tumors (see 
table 7-8). HT Is however a palliative treatment, since only androgen·dependent cells respond 
to this treatment. Since the only established effect of AHT Is the prolonged time to 
progression, only patients with a very high risk of early progression (like those with high-
grade tumors) may benefit. An eventual survival-benefit Is stili a matter of debate. 
Overall survival 
The results of overall survival for patients with pT3 treated by surgery and adjuvant treatment 
are listed In table 7. OS at 5, 10, and 15 years ranges from 60-tOO%, 29-92%, and 17-90% 
respectively. 8eUN also reports a 12% observed survival at 20 years. The survival reported In 
the early series, by BeltN , Boxerw,and Pllepich,r Is worse then in later series. This may be due 
to the fact that patients In this series had a perineal prostatectomy, without LND. Therefore 
those groups may contain many patients with lymph node positive disease. who are at risk for 
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Table 7: Overall survival and cancer specific survival for patients with pathological stage pT3 or C 
prostate cancer, treated with surgery and adjuvant treatment. 
Reference N Adjuvant treatment Overall survival (%) Cancer specific survival (%) 
5 10 15yr 5 10 15yr 
Belt (79) 267 222 pt oral estrogens 63 37 17 
Boxer (80) 74 most pt 1-5 mg estrogens 67 29 
Pilepich (81) 18 RT: 6.000 - 7.000 RAD 60 
Hanks (82) 11 RT: 60 GY 86 
Lange (83) 24 RT: 6.000 RAD 79 
Gibbons (50) 22 RT: 6.325 RAD 73· 
Forman (84) 16 RT: 65 GY 100 
Anscher (51) 46 RT: 45-65 GY 
Some pt hormonal therapy 96 90 90 96 91 90 
Ami sidi (85) 30 RT: 6.000 RAD 76 
Fried (52) 6 RT: 50-65 GY 100 100 
Carter (86) 31 RT: 45-55 GY 92x 92X 
Shevlin (53) 16 RT: 45-72 GY 92 76 
Terhorst (87) 51 RT in 9 pt (18%) and 
HT in 12 pt (24%) 98" 
Cheng (88) 1035 HT only: 103 pt (10%) 
RT only: 131 pt (13%) 91 68 46 96 81 66 
all other pt: HT + RT 
Freeman (89) 95 RT: ± 45 Gy,15 pt(DES)pre-OK 94 70 99 78 
Eisbruch (57) 29 RT: 50-60 GY, 10 pt HT 46X 
Hawkins (58) 131 RT: 60 GY 98 
103 Orchidectomy 95 
x survival free of disease RT = radiotherapy 
* after average 9,2 years HT = hormonal therapy 
+ after 4 years DES = diethylstilboestro1 
- = not reported 
N 
0-
Table 8: Clinical and biochemical progression in patients with pathological stage pT3 or C prostate cancer, 
treated with surgery and adjuvant treatment. 
Reference N 
Pilepich (81) 18 
Hanks (82) 11 
Lange (83) 24 
Gibbons (50) 22 
Forman (84) 16 
Anscher (51) 46 
Ami Sidi (85) 30 
Fried (52) 6 
Carter (86) ECE 31 
SV+ 6 
Shevlin (53) 16 
Terhorst (87) 51 
Kwon (90) 59 
Cheng (88) 1035 
Adjuvant treatment 
RT: 6.000 - 7.000 RAD 
RT: 60 GY 
RT: 6.000 RAD 
RT: 6.325 RAD 
RT: 65 GY 
RT: 45-65 GY 
Some pt hormonal therapy 
RT: 6.000 RAD 
RT: 50-65 GY 
RT: 45-55 GY 
RT: 45-72 GY 
RT in 9 pt (18%) and 
HT in 12 pt (24%) 
Radio-active gold seeds 
implantation 
HT only: (10%),RT only (13%) 
all other pt: HT + RT 
Clinical progression (%) 
5 10 15yr 
55 
14 
21 
9 
32 
24 
0 
8 
16 
24 
4· 
14 
22 
27' 
40 60 
o 
8 
16 
36 
21 
44 52 
Freeman (89) 95 RT: ± 45 Gy, 15 pt. DES pre-OK 6 13 
Eisbruch (57) 29 RT: 50-60 GY, 10 pt HT 
Hawkins (58) 131 RT: 60 GY 
103 Orchidectomy 
x after average 9,2 years 
. after 4 years 
RT = radiotherapy 
HT = hormonal therapy 
- = not reported 
45 
Biochemical progression (%) 
5 10yr 
36 54 
34 46 
28-40 37-58 
15-19 19-35 
Table 9: Local recurrence in patients with pathological stage pT3 or C prostate cancer, treated with surgery 
and adjuvant treatment. 
Reference N Adjuvant treatment 
Pilepich (81) 18 RT: 6.000 - 7.000 RAD 
Hanks (82) 11 RT: 60 GY 
Lange (83) 24 RT: 6.000 RAD 
Gibbons (50) 22 RT: 6.325 RAD 
Anscher (51) 46 RT: 45-65 GY 
Some pt hormonal therapy 
Ami Sidi (85) 30 RT: 6.000 RAD 
Fried (52) 6 RT: 50-65 GY 
Carter (86) 31 RT: 45-55 GY 
Shevlin (53) 16 RT: 45-72 GY 
Terhorst (87) 51 RT in 9 pt (18%) and 
HT in 12 pt (24%) 
Kwon (90) 59 Radio-active gold seeds 
implantation 
Eisbruch (57) 29 RT: 50-60 GY, 10 pt HT 
x after average 107 months 
"101 months 
• after 4 yr 
RT = radiotherapy 
HT = hormonal therapy 
- = not reported 
'" --J 
Local recurrence (%) 
5 10 15yr 
0 
0 
0 
5" 
4 4 4 
0 3" 
0 
3 
0 0 
O· 
2 
14 
early progression and death. 
Cancer specific survival 
Table 7 contains the results of CSS for patients treated with surgery and adjuvant treatment. 
The CSS at 5, 10, and 15 years range from 96-100%, 78-98%, and from 66-90% respectively. 
CSS Is reported only In series after 1987, so all patients underwent LND. This better selection 
may explain the excellent results. The series of Anscher51 and Frled52 show almost the same 
rates for OS and CSS, Indicating that these are very healthy populations, and when a patient 
dies, it Is of prostate cancer. The large study by Cheng8d(1035 patients), shows an Increasing 
difference between OS and CSS over the years, Indicating more Intercurrent deaths with time. 
Clinical and biochemical progression 
Clinical and biochemical progression rates for patients treated with surgery and adjuvant 
treatment are listed In table 8. The CP rates at 5, 10, and 15 years range from 0-55%, 0-44%, 
and 52-60%. The high percentage of progression reported by Plleplch may be the result of 
unnoticed micro-metastases, since 10 out of 18 patients did not undergo a LND. Fried reports 
no progression after 10 years, however this is a very small serle (6 patients only). Only 3 
studies report BP. The BP rates at 5, and 10 years range from 15·40% and from 19·58%. 
Freeman~uses a limit of PSA>0,4 ng./ml as Indicator for BP; the other studies use PSA>0,2 
ngim!. In the serle by Hawklns~ 2 progression rates are given; these are for diploid and non-
diploid tumors respectively. It Is evident that non·dlplold tumors experience more progression, 
which conflrmes the biological more agresslve behaviour of the5e tumors. Furthermore, tumors 
treated by HT did better than those treated by RT, whether they were diploid or non-diploid. 
These differences may reflect the presence of micro-metastases at the time of surgery, which 
are not treated by (local) RT, but which are (palliatively) treated by HT. 
Local recurrence 
The results for LR after surgery and adjuvant treatment for pT3 patients are listed In table 9. 
The LR rates at 5 and 10 years range from 0-14%, and 0-5%; only Anscher51 reports a 15 year 
LR rate of 4%. These rales are remarkably low. All patient-groups were treated with RT; these 
results confirm that excellent local control is achieved after ART. However when the LR rates 
are compared to the CP rates In table 8, large differences are evident. This means that when 
progreSSion occurs In these patients, It Is mostly the development of distant metastases, 
which cannot be prevented by local adjuvant treatment. Therefore delayed RT, which Is 
administered only In those patients with proven LR, stili remains a valid option; many patients 
will not develop LR and therefore do not need adjuvant RT. 
LOCALLY ADVANCED PROSTATIC CANCER (oT3IC) TREATED BY RADIOTHERAPY 
Since surgery for locally advanced carcinoma's has many difficulties, external beam 
radiotherapy has been the standard treatment for many years. Many patients however have a 
positive biopsy after RT, and it is known that this Increases the chance of failing, with both 
local and distant recurrence~l,92.93. Furthermore BP Is less easy to Interpret after RT, since the 
PSA nadir Is only reached after 1 year. Stamey found that in only 8% of the patients treated 
by RT the PSA levels continued to decrease after one year post-treatment. Of 80 patients 
observed over 1 year post-RT, the PSA values increased in 51%, and remained stable In 41%, 
indicating that In 51 % progression occurred after only one year. At 5 years only 11 % of 183 
patients had an undetectable PSA level9t• Schellhammer reported on 45 patients with clinical 
stage C treated with external beam radiotherapy: only 13% reached a PSA level <0,5 ng,jm!. 
There was no correlation between the PSA level and the finding of positive bloptles post-
treatment95• 
Porter described the role of AT In the rna,nagement of locally advanced prostate cancer; In 
28 
Table 10: Overall survival and cancer specific survival for patients with clinically stage T3 or C prostate 
cancer, treated by radiotherapy. 
Reference N stage 
Holzman (97) 121 C stage C 
Leibel (98) 324 T1,2,3: 102 pt T3 
Fowler (99) 81 C stage C 
Fellows (100) 88 T2-4; 50%, T3-4 
zagars (101) 602 C stage C 
Rosen (102) 88 C stage C 
Perez (103) 412 C stage C 
Del Regato (104) 372 C stage C 
Bagshaw (105) 385 C stage C 
Hanks (106) 296 C stage C 
Kaplan (107) 400 T3 
LR + 
LR -
Xread from curves 
- = not reported 
ti 
Overall survival (%) 
5 10 15yr 
75 
90 
47 
44x 
74 
61 
65 
66 
68 
56 
31 
22 
45 
35 
42 
38 
38 
32 
16 
31 
17 
20 
23 
Cancer specific survival (%) 
5 10 15yr 
83 43 
67 30 
35 
56 
25 
w 
o 
Table 11: Clinical progression, local recurrence, distant metastases and biochemical progression in 
patients with clinical stage T3 or C prostate cancer, treated by radiotherapy. 
Reference N Clinical progression (%) 
5 10 15yr 
Holzman (97) 121 
Leibel (98) 324 
Kaplan (107) 400 
Pilepich (65) 
HT+ 227 39 
HT- 230 57 
Fowler (99) 81 61 91 
Fellows (100) 88 
Zagars (101) 602 41 56 70 
Rosen (102) 88 47 65 
Perez (103) 412 
Bagshaw (105) 385 
Hanks (106) 296 
x after median 18 months 
~P = 2x PSA > 4,0 
-BP = PSA > 4,0 after one year 
• BP = PSA > 1,0 
- = not reported 
Local Recurrence (%) 
5 10 15yr 
43 
5x 
16 
29 
65 
14 
74 
24 
30 
40 
38 
30 
80 
39 
41 
Distant metastases (%) 
5 10 15yr 
50 75 75 
19x 
25 
30 
50 68 
75 
34 45 54 
42 
BP (%) 
5 10yr 
57" 
54· 
74· 
66+ 93" 
recent years 3 major radiotherapeutic modifications have been evaluated, which may lead to a 
better treatment of locally advanced prostate cancer9(!. 1: The relative Integral dose can be 
Increased using conformal external beam RT, photon therapy or brachytherapy; 2:The use of 
neoadjuvant HT to receive cyto-reductlon; 3: Altering radiobiologic parameters by using 
altered fractionation and neutron radiotherapy. However, long·term results of these treatment 
alterations are not yet available. 
Overall survival 
The numbers for OS for patients with clinical locally advanced carcinoma treated by RT are 
listed In table 10. The OS percentages at 5, 10, and 15 years range from 44·90%, 22·45%, 
and 16·31% respectively. Only the patients reported by Holzman" underwent a staging LND; 
these patients were fUrther treated by the Implantat/on of AU'M·seeds in the prostate, and 
external beam radiotherapy (6500·8000 radio The patients reported by Leibel~ underwent 
conformal RT with dose·escalatlon up to 81 Gy. All other groups used standard external beam 
AT (60·70 Gy.). The good results reported by Lelbel~ (90% OS at 5 years) are probably the 
result of the high radiation dose. 
Cancer specific survival 
Table 10 contains the results for patients with clinical T3/C disease treated by AT. There are 
unfortunately only a few studies that report this Important parameter. Holzman91 found ess 
rates of 83, 43, and 25% at 5, 10 and 15 years respectively, whereas Fowlern reports 67% 
ess at 5, and 30% ess at 10 years. KapJan '01 reports on ess dependent on the presence or 
absence of LA. At 10 years the CSS rate for patients without LA Is 56%, compared to only 
35% for those with LA. The author states that these numbers prove the Importance of local 
control for survival. 
Clinical progression 
The CP rates for patients with clinical T3/C treated by AT are listed In table 11. At 5 and 10 
years, these rates range from 39·61%, and 56·91%; and at 15 years, only one study reports 
70% CPo PlleplchM reports on 2 patlents·groups, one treated with AT with neo·adjuvant HT 
(GosereUne and Flutamlde for 2 months pre-treatment), and one group treated by RT only. He 
finds a clear difference In CP rates: 39 versus 57%. These numbers are however the results at 
3 years post-treatment, and even the best result doesn't differ very much of the results 
reported by Zagars 'OI and Rosen'02• Holzman", Leibel", Fellows!l)J, and Perez '03 do not report 
CP separately, however these studies report metastatic rates, which give an indication for the 
presence of CPo These metastatic rates range from 19-75%, 42-75%, and 54-75%,at 5, 10, and 
15 years.(table 11). 
Local recurrence 
The local recurrence rates for patients with clinical T3/C treated by AT are listed In table 11. 
At 5, 10, and 15 years these rates range from 5·65%, 24·74%, and 39·80%. The favourable 
5% LR rate reported by Lelbel96 Is after a median time of 18 months. The poor results for 
local control by RT alone are worrisome, considering the experlance of Kaplan ,01, who finds 
that local control Is Important for survival. Furthermore LR leads to patient discomfort and the 
need for treatment; Holzman" reports that 36% of his patients needed a TUR of the prostate 
because of obstructing symptoms. He concludes that RT alone Is not sufficient treatment for 
clinical stage C prostate cancer. 
Biochemical progression 
BP after AT for clinical stage T3/C disease Is only reported In 3 studies (see table 10). BP 
after RT Is a less sensitive parameter than after surgery, since there is always prostatic tissue 
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left and In most patients the PSA does not reach female levels. Furthermore the PSA nadir Is 
reached at about 1 year, so the occurrence of BP cannot be determined very reliably In the 
first year, except when there Is a rise of PSA after treatment, over the pre-treatment PSA 
value. Because of this limitations, the definition of BP after RT Is less clear than after surgery. 
The 3 studies listed here are using 3 different definitions for BP. Lelbel~ defines BP as 2 
consecutive PSA values > 4,0 ng/ml, Plleplch as a PSA > 4,0 ng/ml after one year post-
treatment, and Fowler as a PSA> 1,0 ng/ml. Desplle Ihese differences In definition, The BP 
rales are within a reasonable range of 54-74% al 5 years. The difference In BP In patlenl-
groups trealed with or wilhoul adjuvant HT , reported by Plleplch, Is considerably (54 versus 
74%), however since HT Is known to prolong the time to progression, It Is not spectacular. 
Only Fowler reports a BP rale al 10 years, of 93%. Given the knowledge Ihal all patients with 
BP will suffer CP In Ihe end, Ihls means Ihat almOSI all patlenls In Ihls group will suffer 
progression In Ihe end. 
SURGERY VERSUS RADIOTHERAPY IN THE TREATMENT OF LOCALLY ADVANCED PROSTATIC 
CARCINOMA 
The comparison of surgery and radiotherapy In the treatment of prostate cancer Is very 
dlHlcult In the absence of randomized studies. In 1988 Hanks1'" reported on the obstacles for 
comparing RP and RT. These Include Ihe crllerla for RP and RT (many patlenls who receive 
RT are not fll for RP because of a bad general condition), variations In endpoint reporting 
and melhod of dala analysis (eliminating patlenls lost 10 follow-up from Ihe calculated 
survival), Ihe use of adjuvanl HT, and differences In stage and grade belween Ihe dlfferenl 
sludles (In mosl patients trealed by RT, Ihe lymph nodes are nol evalualed). Conant el all 
compared RP and RT for localized prostate cancer In a retrospective study of patients treated 
belween 1950 and 1977, and found considerably better survival rales for pallents trealed by 
Rpl09, Lymph node status and grade are however not reported, which makes adeqate 
comparison difficult. 
Olsson» compared AP, the Implantation of I~I seeds and external beam RT In a group of 
patlenls wllh stage A2, B, and C. All patients had negative lymph nodes. RP and »>1 Ireatment 
did not differ Significantly for Ihe time of first evidence of treatment failure, whereas patients 
trealed by RT did significantly worse. Metastatic rales were 14% In patients trealed by RP, 
versus 50% In patients treated by RT. Local control was considerably better In patients treated 
by RP than In those wlth'HI Implantation. 
In 1995 Menon llo compared the results of a study in patients treated by AP in the Mayo 
cllnlclll 10 a study of patients treated by RTm for clinically localized prostate cancer. The 
results were stratified by stage and grade; RP treated patients had a better overall, cancer 
specific, and progreSSion-free survival then those treated by RT for all stages and grades. The 
marginal benefits In relative risks ranged from 1,10 to 1,79. In comparing patients Ireated by 
RP and RT with Ihose trealed by observation and delayed HT, they found belter CSS In Gl 
and 2 patients for RP treated patients, whereas RT treated patients had no survival advantage. 
In G3 patlenls both RP and RT had better CSS compared 10 observation. They conclude thai 
RP Increases survival In patients with G1 and 2 prostate cancer under the age of 65 years, 
and In patients with G3 under the age of 75 years. 
Paulson113 compared RT to delayed HT In patients with clinical stage C carcinoma, In a 
randomized study and found no stallstlcally significant difference In time 10 first evidence of 
treatment-failure. More recently Fellows compared patients with T2-4NxMO prostate cancer 
treated with RT alone, orchiectomy alone, or a combination In a randomized study. He found 
no differences In local disease control or In overall survival, but only a significant delay In the 
detection of distant metastases In the patients treated by orchiectomy or the combined 
Ireatment 'OO .The results of these studies might be that RT alone Is no better then HT for the 
treatment of localized prostate cancer; and that RP has a definite advantage In th~ treatment 
of localized prostate cancer. These studies comparing RP and RT are however done In 
localized cancer (slage<T3). Glbbonsll4 reports on 2 studies of the National Prostate Cancer 
Projects: the multi-Institutional protocols 900 and 1000. These protocols were conducted 
between 1978 and 1985, and contain respectively 55 patients treated by RT and 67 patients 
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Table 12 .. Average percentages for overall survival and cancer specific survival for patients treated by 
surgery or radiotherapy for clinical stage T3/c prostate cancer and patients with pathological 
pT3/C disease, treated by surgery with or without adjuvant therapy. The average numbers are 
calculated from table 1,3,6 and 9. 
overall 
survival (%) 
5yr 
10yr 
15yr 
Cancer specific 
survival (%) 
5yr 
..., 
..., 
10yr 
15yr 
clinical T3/c 
surgery 
80,6 
53,7 
32 
89,2 
80,3 
69 
clinical T3/c 
radiotherapy 
64,6 
35,4 
21,4 
75 
41 
25 
pathological pT3/c 
surgery only 
82 
60,5 
17 
90,6 
66,1 
57 
pathological pT3/c 
surgery + adjuvant 
treatment 
84,3 
64,6 
51 
97,8 
88,6 
78 
w 
... 
Table 13. Average percentages for clinical progression, local recurrence and biochemical progression for 
patients treated by surgery or radiotherapy for clinical stage T3/c prostate cancer and patients 
with pathological pT3/c disease, treated by surgery with or without adjuvant therapy. The average 
numbers are calculated from table 2,4,7,8 and 10. 
clinical T3/c 
surgery 
Clinical 
progression (%) 
5yr 30,3 
10yr 44 
l5yr 60,5 
Local recurrence (%) 
5yr 12,3 
10yr 19 
l5yr 15,3 
Biochemical 
progression (%) 
5yr 50,5 
10yr 60,5 
clinical T3/c 
radiotherapy 
49 
70,6 
70 
28,6 
39,3 
53,3 
62,8 
93 
pathological pT3/c 
surgery only 
26,3 
43,6 
87 
17 
32 
40,3 
43,8 
65,3 
pathological pT3/c 
surgery + adjuvant 
treatment 
19,6 
22,8 
56 
2,1 
3 
4 
28,7 
41,5 
treated by RP for clinical stage T3 carcinoma, In each protocol comparable percentages of 
patients were treated with cyclophosphamide, estramustlne, or no adjuvant treatment. There 
were no significant differences In overall survival and recurrence, regardless of the treatment. 
The results of studies that compare RP to RT for prostate cancer In the IItterature are 
theretore not unanimous, 
To estimate the outcome of RP versus RT In clinical T3 prostate cancer, we calculated the 
average percentages for survival and progression from the tables 1-4, and 6-10. The results 
are listed In table 12 and 13. It has to be stressed however that these numbers are only the 
average percentages of the studies reported In this chapter, and that they contain therefore a 
selection. The incorporation of other studies may alter these percentages. They have to be 
Interpreted with caution. 
It seems clear from the tables 12 and 13 that patients with locally advanced carcinoma 
treated by RP do better than those treated by RT, concerning overall and cancer specific 
survival, clinical and biochemical progression and In developplng local recurrence, at all times 
during follow-up. It has however to be considered that patients who underwent surgery 
represent a subgroup with a better general health than those treated by RT, and that most 
patients In the surgery-groups also received adjuvant HT (see table 1 and 2). FUrthermore the 
lymph nodes are only evaluated In one study concerning patients treated by RT, In contrast to 
patients treated by RP. A definite answer to the question which treatment Is better for 
patients with locally advanced proatate cancer Is therefore hard to give, altough there seems 
to be a trend that RP gives better results. 
When the results of treatment-outcome are compared for patients with pathological stage 
pT3/C treated with surgery with or without adjuvant treatment, the first group seems to have 
an advantage In overall and cancer specilic survival, at long-term follow-up (after 10-15 years), 
whereas the results at 5 years are comparable. Given the fact that RP Is only offered to 
patients with a life-expectancy of at least 10 years, this may be of major Importance In 
making a treatment decision: adjuvant therapy seems to offer an advantage. 
The progression rates for clinical and biochemical progression are better for patients treated 
by adjuvant treatment; the difference Is especially Impressive for local recurrence. It has 
however to be remembered that patients who have not received adjuvant treatment can have 
this treatment at the actual time when progresssion occurs, whereas patients who already had 
got this treatment cannot. A better comparison would be to compare the time to second 
progression In patients who are Initially not treated by adjuvant therapy, to the time of 
progreSSion of those who received Immediate adjuvant treatment. This has not been reported 
In the IItterature. 
Some studies have compared patients with pT3 treated with or without adjuvant treatmenl. 
Most studies confirm that progression rates are decreased after adjuvant treatment. A survival 
advantage Is however only reported by HawklnsM who finds a trend that the CSS Is better 
after adjuvant treatment. This trend however does not reach significance. Furthermore 
Anscher~ reported a survival advantage after radiotherapy; this patient-group was however re-
evaluated by Paulsonn, who excluded some patients who didn't have RP for prostate cancer. 
After this exclusion, the survival advantage was no longer existent. Lerneru did not find a 
survival advantage In patients treated by adjuvant HT. 
Recently the EORTC started a protocol (EORTC 22911) to evaluate the treatment outcome In 
patients with pT3 disease treated with or without adjuvant radlotherapy.Thls Is a randomized 
study, the results will have to be awaited. 
In conclusion: patients with clinical locally advanced prostate cancer treated with RP do better 
than those treated by RT; and patients with pathological pT3/C do better after the 
administration of adjuvant therapy_ 
CONCLUSIONS 
Radical prostatectomy for locally advanced (clinical stage T3 or C) disease Is possible with 
acceptable mortality and morbidity, and Is especially beneficial In patients who are down 
staged to pT2 (17-30%) and In those with well or moderately differentiated disease. Surgery 
for poorly dlHerentiated disease seems only advisable In combination with adjuvant treatmenl. 
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Patients with lymph node metastasis should not undergo rad/cal prostatectomy, but should be 
treated for systemic disease. For pathological T3-dlsease without adjuvant therapy, the 
survival· and progression rates are comparable to those for clinical T3-dlsease, some are even 
worse. The administration of adjuvant therapy (RT and/or HT) has some effect on CP and little 
effect on survival. The LR-rate Is however significantly decreased after adjuvant radiotherapy. 
Patients treated by radiotherapy for cflnlcal T3·dlsease have the worst O.S. and CSS-rates. 
They also experience more progression and have a higher LR-rate, compared to patients 
treated by surgery. Especially the significant difference In CSS Indicates that surgery 
(eventually combined with adjuvant therapy) Is superior to radiotherapy alone for the 
treatment of locally advanced prostate cancer. 
The results of pre-operative HT, given with the Intention of downstaglng the disease, are 
discouraging. Long-term results of survival and progress/on are not known; therefore this 
treatment cannot be advised as standard treatment. 
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Joumal of Urology, 151: 646-651,1994. 
RADICAL PROSTATECTOMY AS A MONOTHERAPY FOR LOCALLY 
ADVANCED (STAGE T3) PROSTATE CANCER 
DIES VAN DEN OUDEN, PETER J. T. DAVIDSON, \VIM HOP AND FRITZ H. SCHRODER 
From 1M Departments of Uro/I;gy and Epidemiolcgy/Biw/a/i.sti.:3, Eralmus Uni~'er~jty and Academic Hl)jpit(l~ Rotterdam, The Nethular,dt 
ABSTRACT 
Within a prospective protocol initiated in 1977. 100 patients with locally extensive prostate cancer 
(st.age T3, 1982 tumor, nodes and metastasis classification) were treated by pelvic node dissection 
and radical prostatectomy as monotherapy. Adjuvant treatment was not given until disease pro· 
gression. Radical prostatectomy, except for 3 young patients with a single micrometsstasis, was not 
done if positive lymph nodes were found at frozen section. Six patients had positive lymph nodes 
at permanent sections but not at frozen section. Average followup was 43.9 months (range 1 to 155 
months). Histological grade was determined according to the Mostofi system. Progression was 
determined biochemically (prostate specific antigen elevation) and clinically by evidence of met-
astatic disease, either histologically proved or evidenced as new hot spots on bone scan or chest x· 
rays. 
Of the 100 patients 41 did not undergo radical prostatectomy: 39 because of positive lymph nodes 
and 2 because of evidence of a stage pT4 tumor at surgical exploration. Of those 59 patients who 
underwent radical prostatectomy 9 had positive lymph nodes, while 2 had stage pT4. 39 stage pT3 
and 9 stage pT2 tumors. Only 1 of the 9 patients with lymph node metastases is free of biochemical 
or clinical progression. Disease also progressed in both stage pT4, 27 of 39 stage pT3 and none of 
the 9 stage pT2 cases. A total of 22 patients was free of clinical or biochemical progression. Clinical 
progression was evidenced in approximately half of the cases as distant and local progression. Data 
on stage T3 disease were compared to those of 129 patients with stages TO to T2 disease. There was 
a significant difference in interval to clinical progression for these 2 groups (p = 0,001). However, 
if grade 3 cases were excluded from the stage T3 group, this difference disappeared. 
Prognostic factors analyzed were pretreatment and posttreatment grade, pretreatment prostate 
specific antigen and prostatic acid phosphatase levels, positive margins, seminal vesicle invasion 
and nodal status. The analysis allows one to identify groups of patients who may benefit and others 
who certainly do not benefit from radical prostatectomy in this disease category. In the latter group 
effective adjuvant treatment is urgently indicated, 
KEY WORDS: prostatic noopl~ms. carcinoma, prostale(:tomy 
The treatment of locally advanced stage T3 prostate card-
noma (stage C) remains controversial. Stage T3 prostate cancer 
has been treated hy radical prostatectomy, radiotherapY, and 
hormonal and expectant treatment.1 Several studies report 
the results of radical prostatectomy for pathological stage pT3 
prostatic carcinoma, included as a result of clinical understag. 
ing.~--i Series reporting the results of radical prostatectomy in 
clinical stage T3 cases suffer from 2 problems: I} the lymph 
node status is often not known~ and 2) some form of postop' 
erative adjuvant therapy is included.6 The policy at our insti· 
tution, within an ongoing ptospecth'e study, is to treat patients 
with stage T3NOMO prostatic cancer by staging pelvic lymph· 
adenectomy and, if lymph nodes ale negative, radical prosta· 
tectomy. The early results were Ieported in 1987 by Bosch et 
a1.1 The updated results of the extended series are presented. 
MATF.RIALS AND M&THODS 
Between 1977 and 1991, 100 patients v.ith prostate cancer, 
clinically staged as T3NO~to before treatment, were considered 
candidates for radical prostatectomy. These patients are in· 
cluded in a prospecti\'e study. v.ith preoperative, perioperative 
and follo'.1."Up data being stored in a comprehensi\'e database. 
Average age of all patients with stage T3 disease who presented 
for operation was 63.7 year3 (range 42 to 76). Average follov.'Up 
of patients who subsequently undern'ent radical prostatectomy 
was 43.9 months (range 1 to 155). 
Clinical and pathological staging was done according to the 
Acctpted for publication September 3, 1993. 
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tumor, nodes and metastasis clll3Sification of 1982, in which a 
stage T3 tumor is one extending beyond the capsule, with or 
without involvement of the lateral sulci and/or seminal vesi-
cles.' The stage pT3 classification follows the stage T3 c1assi· 
fication and indicates carcinoma with invasion beyond the 
capsule and/or invasion of the seminal vesicles. Grading of 
these tumors was performed on the prostatic biopsy and on 
radical prostatectomy specimens according to the Mostofi sys· 
tern as either well (grade 1), moderately (grade 2) or poorly 
(grade 3) differentiated.g Cases in -which the tumor extended 
microscopically to the surgical margin were posith·e. Cases of 
extension into 1 or both seminal vesicle~ were considered 
seminal vesicle positive. All patients judged to be free of lymph 
node metastases (NO) and distant metastases (MO) by physical 
examination, computerized tomography, lymphangiography (in 
the early part of the series), bone scan and chest x·ray were 
considered candidates for pelvic lymph node dissection and 
radical pro~tatectomy. In all patients either prostatic acid phos. 
phatase (PAP) or prostate specific antigen (PSA) (Hybriteeh 
Tandem·R assay) levels were determined preoperatively but an 
elevated level of either did not influence the decision to operate, 
AU patients undern-ent staging pelvic lymphadenectomy and 
a froum section examination of the lymph nodes was per· 
formed. In 6 patients nodal metastases were missed on frozen 
section but disco\·ered on paraffin sections. Except for 3 pa· 
tients in the latter part of the series who unden-ent radical 
prostatectomy and had a single microscopic focus of well dif· 
ferentiated tumor, patients with lymph node positive disease 
did not undergo radical prostatectomy. Currently, a nerve spar-
ing radical retropubic prostatectomy as described by Walsh et 
aJl~·1I is performed. However, on the side(s) of the stage T3 
tumor, a wide resection is performed and no attempt is made 
to spare the neurovascular bundles. 
Patients were followed regularly with physical examination, 
PSA (PAP) levels, bone scans and, when indicated, other 
appropriate investigations. Clinical progression is defined as 
cytologically or histologically confirmed evidence of local re-
currence and/or the presence of distant metastases, diagnosed 
by either bone scans or other radiological techniques. Biochem-
ical progression was defined by a single PSA level of greater 
than LO Jig./I., or 2 consecutive PSA measurements of greater 
than 0.2 Jlg./I. (Hybritech assay). Patients with no evidence of 
clinical or bi<xhemical progression at the time of the study 
were determined to have no evidence of wsease. In this study 
no patient received any form of adjuvant treatment before 
clinical progression or preoperatively. Before 1987 PAP, deter-
mined according to the Abbott PAP sandwich solid phase 
enzyme immunassay using 2 different mon<xlonal antibodies, 
was used as a marker (normal value 2.2 J-Ig./I. or less). The 
statistical techniques used are the Kaplan-Meier projection of 
interval to propession, the logrank test, the chi·square test and 
the Wilcoxon rank sum test. 
RESUL'fS 
Of the 100 patients 39 had positive lymph nodes on frozen 
section examination and did not undergo radical prostatectomy, 
as was the case with 2 patients who clearly had stage T4 disease 
at operation, Of the remaining 69 patients undergoing radical 
prostatectomy 3 were known to have positive nodes on frozen 
section, while 6 had positive nodes on definitive paraffin sec-
tioning. Among the remaining 50 patients the disease was 
pathologically upstaged to pT4 in 2 (4%), pathologically down-
staged to pT2 in 9 (18%) and remained at pT3 in 39 (78%, fig. 
1). Of the 59 patients undergoing radical prostate<:tomy 1 was 
lost to (ollowup, 6 died of prostate cancer, 4 died ofintercunent 
illness, and 48 remain alive and under followup. Furthermore, 
at the time of the evaluation 21 patients (36%) had clinical 
progression, 16 (27%) had evidence of biochemical (increased 
PSA level) propession only and 22 (37%) remained with no 
evidence of disease. The characteristics of the latter 22 patients 
are shown in table 1. 
When compared with 129 stages 'TO to T2 cases from our 
study database, patients with stage T3 disease had a signifi· 
cantly greater risk of clinical progression (fig. 2, A). Among the 
patients with stage T3 tumors the postoperative pade was 
found to affect the probability of progression, with grade 3 
cancer patients having a significantly higher risk compared to 
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those with grade 1 or 2 tumors (fig. 2, B). Figure 3 shows the 
probability of progression in stage TO to T2 cases and in stage 
T3 cases divided into 2 groups according to preoperative grade 
(grades 1 plus 2 versus grade 3). There was no significant 
difference between patients with stage 'TO to 'T2 (all grades) 
and stage Ta grade less than 3 disease but a significant wffer-
ence did exist between these 2 poups and the stage T3 pade 3 
group (p <0.0l). The differences in the distribution of pade in 
figures 2, Band 3 are due to the use of preoperative versus 
postoperath'e grade in these figures. Table 2 shows the com· 
parison between preoperative and postoperative grading. Under 
grading of pretreatment biopsies upgraded to grade 3 was noted 
in only 6 of 41 patients (14.6%). Cwiowly, in 3 patients with 
grade 3 tumor at biopsy, pade 2 tumors were diagnosed on 
definitive histology. 
In stage T3pTaNO cases positive surgiCAl margins and sem-
inal vesicle invasion did not significantly alter the risk of 
progression. This interesting finding was discussed in peater 
detail previously. U In figure 4 interval to progression in 71 
patients from the data base who presenli_od with Jess than stage 
Ta but stage Pr3NO tumor is compared to that of 39 patients 
with stage P'f3NO tumors. The difference is significant (p = 
0.01). These data indicate that the clinical impression o( cap· 
sular perforation is an important prognostic parameter despite 
all inaccuracy that has been associated with this finding.' 
However, this may not be an independent variable if it were 
«Impaled to other ad~'erse factors present in the stage T3pT3 
poup. Patients with a preoperative PSA level of greater than 
20 Jig./I. had a 58% chance of positive lymph nodes by clinical 
and biochemical means, and only a 5% chance of remaining 
with no evidence of disease at evaluation (fig. 5, A). Of those 
witha PAP le~'el of greater than 2 Jig.fJ. 62% had positive nodes 
and 7% remained with no evidence oedisease (fig. 5, B). Dfthe 
patients with grade 3 cancer preoperatively 63% had positive 
nodes, while only 5% remained with no evidence of disease (fig. 
5, C). There was a significantly peater risk of nodal disease 
with increasing grade (p = 0.04, lable 3). Increasing PSA levels 
of greater than 20 J-Ig.fm!. or a PAP level of greater than 2 Jig./ 
m!. were not ass<xiated with a significantly elevated risk of 
positive nodes. Of those undergoing radical prostatectomy, 
patients with a preoperative PAP level of greater than 2 Jlg./I. 
had a significantly &'leater risk of progression (p = 0_02) than 
those with a PAP level of less than 2 Jlg./l. There was also a 
significant trend (p "" 0.0(2) in risk ofpropession by increasing 
preoperative grade. Increasing preoperative PSA values (less 
than 10, 11 to 20 and greater than 20 J-Ig./l.) did not Significantly 
affect the risk of progression. Numbers of patients at risk are, 
hO\'>'e\'er, few. The relationship between T categories and nodal 
metastases is shown in table 4. 
Most patients with positive nodes were randomized to 
early "ersus delayed endocrine treatment within European 
Organization for Research and Treatment of Cancer protocol 
31}846, and the results are not yet known. All patients except 
1 with negative frozen sections but positive paraffin sections 
who did undergo radical prostatectomy suffered propession. 
Of 15 patients 14 (93%) with stage T3pT3G3 tumors had 
progression. 
DISCUSSION 
Little is known about the natural course of stage T3 prostate 
cancer. Howe\'er, recently Adolfsson reported on 50 patients 
with stage T3 disease followed expectantly for a median of lOB 
months.1l The series included 29 patients (58%) with grade 1, 
19 (38%) with. grade 2 and only 2 (4%) with grade 3 tumors. 
For this and other reasons, the data cannot be compared to the 
results obtained in this study. Progression rates according to 
clinical and biochemical parameters are not indicated. The risk 
of progression to distant metastases was 24% at 5 years and 
37% at 9 years. In our series the S-year projected nonpropes-
sion rate was approximately 60%. 
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TABLE l. Pretreatment choroderi5tin of progreuion-free pamnt.! 
GlAde &minol FoU0""'P Pt..No. Vuide Mugiru PSA PAP 
p,top. PNtop. Tn\'olv~"l€nt (IIIO!.) 
C<l/fgOry T3pT2,\'OJfO, 9 plJ. 
, , , Ne~. Net· M 0.' 
" , , , Neg. N~i· 0.' 
'" 3 , , Ne~. Nel· (4.0 L' 
" , , 
, Neg. Neg. .,' ''0 
5 , , Neg. Nell· L' " , 3 3 Neg. Ne~. 19A 
" " , , , Neg. Neg. 
" 
53 , , , Neg. Neg L' '" , , , Neg. Nog. L> n 
C<lUgory T3pT3NO.\{O, 12 pes. 
, 3 POI. POI. ,., 39 , , Ne,. Po •. OS 3 
3 , Neg. P" •. '.0 
" , , Po •. N.~. 0'-
'" , , POI. Neg. 6O 
" , , Neg. Neg. H 5 , , N.g. Neg. 50 
" , , Nil· Neg. 13.9 
" , , Neg. No". ,., , 
" 
, Po,. N.g. u 
" " 
" 
, Neg. Neg. H 
" 
" 
, Neg. Neg. L> 3J 
TABU: 2. Preoperoth'e grading of «!re biopJies ,ompared to grading of 
,udirol prostatectomy spedmeru 
Preop. No. POS!Op. Grade (%) Total No. 
Grade (%) 
, 
, 
, 
Total.! 
0(0) 
1(3) 
0(0) 
IT21 
"'r - T3p13N~ 
01-, 
" I I 
pa~e,"\~alr;s" 
8 (SO) 
26 (84) 
3 (19) 
37 (65) 
'2 (?O) 
• (13) 
13 (81) 
19{3J) 
II) (18) 
31 (M) 
16 (28) 
~7 (lOO) 
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FIG. 4_ Probability of clinical nonpro81usion is compared for 71 
~atient.s with less than stage T3 disease hut stage pT3NO tumOT3 from 
data base to 39 with stage T3pT3 disuse hom study population. 
Significant differente indicates that Impression of stage 1'3 disease on 
neW examination ig ad\·erse prognO-Sl!c factor comr,ued v.ith ootQ· 
logical e~tablhhed penetration of pro;:tatic cap;:tl e. Kaplan-Meier 
proje-ction. 
Little information exists about the use of radical pros-
tatectomy as rnonotherapy for locally advanced (stage T3) 
prostatic carcinoma_ The policy at our institution is to offer 
patients with stage T3 tumors of the prostate evaluation for 
potentially curative management within an ongoing study pro· 
tocol. No adjuvant therapy is given until clinical progression 
occurs. The early results of this series were reported by Bosch 
etal,1'u 
Staging pelvic lymphadenectomy always proceeded radical 
prostatectomy and in 48% of the stage T3 cases tumor·involved 
lymph nodes were found. This rate is similar to the 51% rate 
reported by Zincke et al in their cases of clinical stage C 
disesse.6 Six patients had positive lymph nodes on paraffin 
sectioning that were not detected by frozen section and all 
positive frozen sections were confirmed by paramn section, for 
a sensitivity of 88% and a specificity of 100% for the frozen 
section, which compares fs\-orably with other reported se-
ries_I$.'~ Because positive lymph nodes predict a shorter interval 
50 
A % PaUents 
OUTCOME (40 patients] 
B % PaUenls 
LH. CP SP HEO 
OUTCOME (73 pallen lsI 
c % Patients 
til. CP SP HEO 
OUTCOME 1100 pallenls] 
FlO. 6. Outcome fot pN+ category clinical {lIOgre:!Jion (CP), bio-
chemical progression (HP) and no eVidence of dISease (NED) status is 
corcelatw. to plMperath'c le~'eb of PSA (A) and PAP (8), and to 
preoperath"e ~ade of differentiation (C). While statistkally significant 
correlation WIth pre:!ence of nodal metasta5es hag been ShOIHI only for 
prwperative grade (table 3), all 3 parameteu Indhidually correlate 
significantly ... ith presente or absence of progression. Patients "ith 
PSA of more than 20 ng./ml. PAP of more than 2 pg./l. or grade 
3 tumou have only 5 to 10% chance of having no e~·idence of disease 
at 43 months. Numbers abo\'e bars indicate numbeu of patients in 
given subgroups in whom this test result was a\'ailable at entry into 
study. PSA was done since 1981. PAP was not always done later. 
Percentages on abscissa Indicate (01 lymph node posith'e group (LN+) 
proportion of patients with posith'e modes. For lymph node negatll"e 
pahents ... ·ho actually underwent radical prostatectomy proportions 
v.ith clinical progression, biochemical progression and no evidence o( 
disease are indicated separately. 
TABLE 3. Re/alwrnhip 0{ pr~rati<'e grOOe, PSA and PAP to 
positk .. rvx1u and progreuwn 
Proop. Node POl. Proll"u.!ion 
Grade p ~ 0.04 P ~O.OO2 
PSA Not ,ignificAnt Not signifi~anl 
PAP l'.'oIlignificant 1'=0.02 
TABLE 4. Tumor, nodes ond metrutasis ckr..sJi/ulJtion, nodal 
meta.stasu and progressvm in 100 patients with stag~ 1'3 proMote 
(oncer 
No.P~ No. Radkal No. CI&.;lific~t'on No. L)-mph Noon Pco.tate.:tomy P,ogH~ion ('l 
T3pT%Gl ! ! 0 
TSpT1G2 IS IS 0 
T3pTlG3 
'" " 
0 
T3pTI:Gt·2 , ! , (1) 
TIp1'2Gl ) 0 ! 0 (OJ 
T3pTIGl-2 
" • " 
20 (&3) 
TJpTIG3 15 • 15 Ii (93) T3pT4GI-2 3 0 ! 1 (33) 
T-JpTWl ! 0 ! 1 {tOO) 
to progressioni7 and a worse survival ratela radical prostatec' 
tomy is not performed in patients demonstrated to ha\'e lymph 
node positive disease by frozen s~tion. Radical prostatectomy 
was done in 3 young patients, with a single microscopic focus 
of well differentiated tumor noted on frozen section. All 3 men 
had evidence of biochemical progression but have not yet 
demonstrated clinical progression. Only 1 of the 9patient.s with 
positive nodes on paraffin s~tion and who underv.·ent radical 
plostat~tomy remains without evidence of disease (grade 2 
tumor with a 21·month follolVUp), lending aupport to the con· 
cept that lymph node positive disease, even if limited to 1 
microscopic focus, is a manifestation of systemic disease. 
In this series 50 patients were free of lymph node disease 
and underv.·ent radical prostatectomy. Of these men the disease 
was upstaged toataga pT4 in only 2. This low number is possibly 
due to the fact that in cases when there is any doubt urethro· 
cystoscopy and bimanual examination with the patient under 
anesthesia were performed to exclude extension into either the 
external sphincter or bladder neck regions. Nine cases (18%) 
were pathologically downstaged to stage pT2, which is less than 
the 30% rat.e demonstrated by Boxer et alt and Rannikko and 
Salo/~ the 26% late reported by Zincke et 11.1 6 and the 24% rate 
found in the earlier evaluation of this series by Bosch et a1.1 
This relatively high incidence of downstaging ahould be consid· 
ered when evaluating the results of phase 2 trials assessing 
androgen deprh'ation in stage T3 cases before radical prosta' 
tectomy. All 9 patients whose disease was downstaged to stage 
pT2 remained free of clinical and biochemical progression at 
the time of the study. 
Of 39 patients in whom the histological stage (pT3pNO) 
matched the clinical staging (T3NO), 38% had evidence of 
clinical progression and 31% of biochemical progression at 
evaluation. Of those with clinical progression 11 had evidence 
of local progression and 12 of metastatic disease. This high 
incidence of metastatic disease and the short interval to pro· 
gression support the concept that in many cases stage T3 
prostate cancer is aheady a systemic disease. 
Histopathological grade of the radical prostatectomy speci· 
men has been sho\\ll pre~'iously to be an important prognostic 
factor in assessing the risk of progression.'i"O In this series the 
patients with stage T3 disease treated by radical prostatectomy 
who had grade 3 tumors form a subgroup with a particularly 
high risk of progression. It is interesting to note that when this 
subgroup was eliminated, no significant difference in the risk 
of progression was shown between stages T3 and less than 1'3 
tumors. 
Involvement of the seminal vesicles and posith'e resection 
margins are belie\·ed by many to be important prognostic 
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factors in assessing the risk of progression. In this series neither 
of these factors had a significant. independent effect on the 
risk of progression in patients with stage T3pT3NO tumors. 
Clearly, the presence of a stage T3 tumor is an overruling 
prognostic (actor. 
All patients were followed by regular PSA or PAP measure-
ments postoperatively. At this institution the detectable limit 
of PSA is 0.1 J<g./I. However, there were se\'erai patients with 
a single spurious result greater than 0.1 ng./m!. but this was 
never greater than 1.0 ng.frol. and always decreased to unde· 
tectable levels with subsequent measurement. Since no patient 
with a PSA level of greater than 0.2 ng.fml. on 2 consecutive 
tests or with a single PSA value of greater than 1.0 ng.fm!. 
subsequently had an undetectable PSA value these were used 
as the indicators of an increased PSA level. Lange et al showed 
that all patients in their series with a PSA level of greater than 
0.4 flg./I. subsequently had clinical progression' ! and Bentvel· 
with the present limited followup in these patients is not 
significantly different when compared to those with locally 
confined (stages TO to T2) tumors, it' stage T3 grade 3 cases 
are excluded. Patients with poorly differentiated tumors (grade 
3) represent a subgroup with an unfavorable prognosis within 
the stage T3 group. Whether radical prostatectomy offers ad· 
vantag-es in local control, or whether adjuvant therapy can 
improve progression·free survival rates in these patients is 
unknown and will need to be the subject of further studies. 
Complications encountered during and after the o~ration were 
comparable in stages T3 and T2 cases. There was no increased 
requirement for blood transfusioM and no increase of periop' 
erativa complications, incontinence or urethral stenosis. These 
data are subject to a separate report.:6 
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Radical Prostatectomy: 
Prospective Assessment of 
Mortality and Morbidity 
Abstract 
Objecth'e: To prospectively analyse the morbidity of radical prostatectomy. 
Methods: Morbidity data from 188 consecutive radical prostatectomy pa-
tients were collected prospectively. Mortality. intraoperative. early postopera-
tive and late postoperative complications were analysed. Results: 1.5% mOf-
tality. 3.7% suffered an intraoperative complication. Early postoperative 
problems were common (43%). Of those with greater than 1 year follow-lIP, 
5.9% remained with some incontinence, and a further 11 patients had artifi-
cial sphincters implanted; 32% had narrowingoflhe anastomosis, requiring at 
least I dilation; 43% of patients retained their potency. Conclusion: It is con-
cluded that radical prostatectomy can be perfonned with minimal mortality 
and acceptable morbidity. 
The combination of modifications to the operation of 
radical prostatectomy and the prostate- specific antigen 
drivcn upsurge in early dctection of prostate cancer have 
led to both an increase in the popularity and numbers of 
radical prostatectomies performed. At the authors' insti-
tution, radical prostatectomy is being performed since 
1971. The complications from these procedures are reo 
viewed, 
o~rative and follow.up data wen: stored in a comprehensiw data-
base. The average patient age was 63 years (range 4S-16) and the 
operations were all performed between 1917 and April 1991. 
Clink-a! and pathological stagingis according to the TN~t classifi· 
cation of 1982. At follow-up, each patient was asked specific que~· 
tions about continence and the presence or absence of obstructive 
symptoms. From the beginningof 1987 onwards, questionson poten-
cywue i neluded in the follow-up questionnaire. 
Continence was deflned as beingcomp!ctelydry and requiring no 
pads. Grade 1 incontinence was where a patient needed 1-2 pads per 
day and grade 2 required more than 2 pads p.!! day. Further, pads 
were weighed in those who were incontinent after initial removal of 
the catheter. Anastomotic steno;;i;; was defined as symptoms of out-
flow obstruction requiring a dilatation. A patient was comidered 
potent if he could attain an erection sufficient for intercourse. Impo-
tence was the inability to attain such an erection. All patients were 
asked preoperatively as to whether they were sc .... ually active. 
Patients and Methods 
The patient population consists of 18S patients with prostate can-
cer. Five of the earlier patients had a radical perineal prostatectomy, 
and the rest were treated by radical retropubic pro;tat-xtomy. In 
19S6. the modifications described b)' Walsh (I] were adopted. The 
patients were included in a prosp<:("tive stud)~ preoperative, p.!ri. 
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lale complications were analysed for risk factors. Age (older or 
younga than 70), previous transurethral re;-xtion of the prostate 
(TURP), T stage, pT stage, e.\IXrience of the surgeon, presence or 
absence of e:l.tra\";lsalion on postop.!rath·e cystogram, and timing of 
the operation (before or after 1987) were all assessed. The cutoft- of 
1987 as a divider b~twe~n an earlr and a late study group was cbosen 
for tllO reasons: tbe first was that the number of radical prostatec· 
tomieslXrfonncd each year rose to greater tban 20 at that time. The 
second rcason for thiscutt..atT date was tbat it was the first yearv.here 
the technical modifications of the 'nerve-sparing' technique were 
universaHy adapted, hal'ingbeen introduced in 1986. Thce.,perience 
of the surgeon was assessed by comparing surgoon I (Ilho had per-
fanned 58% of the operations) with the otber surgeons collectively. 
Total number of units of blood transfu~ed during hospital admission 
was chosen as a representation of operative blood loss. It was found 
that the recorded intraoperatil"e blood loss was influenced by too 
many extraneous factors to be a reliable indicator. 
The Fishaexact test was used to test the impact of the risk factors 
on late postoperatil'e complications. 
Results 
There were 3 posloperaUye deaths in this series. One 
patient had an autopsy-confirmed pulmonary embolus on 
the 10th postoperative day_ He had suflered a previous 
embolus at the time of vascular surgery 13 years before, 
and had both subcutaneous heparin and graduated com-
pression stocking prophylaxis before his prostatectomy. 
The second patient collapsed at home on the 17th postop-
erative day. The cause of death was presumed to be a pul· 
monary embolus, although this was not confirmed by 
postmortem examination. He also had both heparin and 
stocking prophylaxis at the time of the operation. The last 
patient was one of the first in the series. He had consider-
able intraoperath'c blood loss and developed a hematoma 
postoperatively. Following this, he had prolonged drain· 
age from his anastomotic site. He then bC('ame septic and 
died after a protracted intensive care, At postmortem 
examination he was found to have an aspiration pneumo-
nia, myocardial infarction and peritonitis secondary to 
his drain perforating a loop of the ileum. All 3 of these 
deaths occurred in the early part of the series. 
There were 7 intraoperath'e complications, Four of 
these were rectal injuries. Two of these were simply over· 
sewn in twolayeTs and 2 required colostomies. There were 
no sequelae from these injuries. Two external iliac vein 
injuries and I ureter injury were caused during lymph 
node dissection. All were immediately recognised and 
repaired without further consequences. The mean num· 
ber of transfused units was 5.3, but this figure is skewed 
by 2 early cases requiring massive transfusions. The me· 
dian number of transfused units was 4. Blood require· 
ments decreased over the duration of the study. 
The most common early postoperati\'e complications 
are ShO\\11 in table I. The most common were wound 
infections, prolonged lymph drainage, lymphoceie and 
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Table 1. The most common earl)' post· 
o~rati\'e complications seen in 81/(88 can· 
secuti\·c patients after radical prostatc.:tomy 
Patients, % 
Lymph drainage >2 weeks 17 
L)'mphoceiedrained 7 
Postoperatil'<! bleeding 6 
Thromboembolic j 
Pneumonia 2 
Fistula I 
Myocardial infarction 2 
Ureteric obstruction I 
Other 16 
1071188 (57%) were free from complica-
tions. 
Table 2, Remaining postoperative com-
plications of radical prostatc.:tomy in 188 
patients 
UTI 9 
Pyrexia unknov.n origin 4 
Epidid>mitis 2 
Superficial thrombophlebitis 
Lymphedema 
Ulnar nerve palsy 
Femoral nerve palsy 
Obturator nerve neuropra>;ia 
Acute atrial fibrillation 
Temporary unexplained jaundice 
Urethritis 
Acute psychosis 
Urosep,is(ICU) 
Burst balloon (OT) 
Appendicitis (OT) 
Wound dehiscence (OT) 
Total 30 
OT " Returned to operating theatrc; 
leu " required transfa to intensive care 
unit. 
bleeding. Theotherearly postoperative complications are 
listed in table 2_ Of the 188 patients, 81 had one or more 
complications, leaving 107 (57%) with a completely un· 
complicated postoperati\'e course. The number of early 
postoperative complications per patient decreased over 
the course of the study (fig. J). 
2 
After catheter femo~ed 
At 3 months 
At 12. months 
YEARS 
Incontinent at 1 year 
10mBS (56%) 
401188 (2.1%) 
241170 (14%) 
(3 patients were irlcoot;nen! prior 10 
raoical prostatectomy a!'\d rema;"ed $0) 
Incontinence was very common after removal of the 
catheter, with 107 (56%) requiring pads. The mean mea-
sured urinary loss in these patients over 24 h was 226 mL 
The amount of this initial loss did not predict time to 
rt.--gaining continence. Hundred and eightr-eight patients 
had been folIowed for 3 months and 40 (21 %) were still 
incontinent; 170 patients had been followed for more 
than 12 months, and of these, 10 (5.9%) had grade 1 and 
14 (S.2%)grade 2 incontinence. At the time of study, II of 
these patients had been implanted with AMS artificial 
sphincters and were continent. Three of the patients with 
grade 2 incontinence were incontinent prior to surgery, 
and if these arc excluded, then of those with> 12 months 
follow-up al the time of study 8 patients (4.7%) remain 
with gr,lde 1 and 2 (1.2%) with grade 2 incontinence 
(fig. 2). 
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L-__________________________ ~3 
Fig. 1. Average numb~r of ~arly postoperative complio;-ations per 
patient, according to )'ear of operation. 
Fig. 2. Incontinence in 188 patients following radical prostate-;Io-
my. 
Fig. 3. Percentage of 61 patients r~quiring treatment for anasto-
motic stenosis who received each fonn of treatment. Some patients 
were tre.ated by more than one modality. Oil = Dilatation; ICSC = 
intennit{ent clean sc!f-catheterization; BNlrrUR = incision or trans-
urethral resection of anastomosis; catheter = p.!rmanent indwelling 
Fo!eycatheter. 
Sixty-one patients required at least one dilatation of 
the anastomosis, and were therefore considered by defini-
tion to have a postoperativc anastomotic stenosis. The 
majority of these were cured by simplc dilatation (fig. 3). 
AU ofthosc R"'quiring a bladder neck incision, TUR oflhe 
bladder neck or a permanent catheter were from the early 
pari of the series, before the modifications described by 
Walsh (1]. 
Hundred and one patients had their potency status 
assessed on follow-up. Fifteen of these were impotent pre-
operatively and another 10 were potent but not sexually 
active. Intraoperative details of nerve sparing were not 
available in 3 of the earlier patients. Of the remaining 83 
preoperath'e1y potent patients, 42 had a bilateral nerve-
sparing procedure; of these 18 (43%) were potent at the 
time ofthe study. Four of 17 patients undergoing a unilat-
Table 3, Risk factors for complications in 188 patients after radical prostat<'Ctomy 
Anastomotic Ag' TURP 
leakage «10n.>10) 
Stenosis NS NS NS 
Incontinence NS p",0.02 NS 
Impotence i\S NS NS 
NS '" p > 0.05; NIA,. not applicabk 
eral nerve-sparing procedUre (24%) and 4 of 24 (17%) 
with no attempted nerve sparing were also potent at the 
time of the study. Of the 26 patients regaining their poten-
cy, 18 (69%) had done so by 15 months. Thcrc were also 8 
patients who regained their potcncy between 18 and 30 
months postoperatively. 
The analysis of risk factors for thc various complica-
tions is prescnted in table 3. The operator seemed only to 
have an influence on thc risk of developing an anastomot-
ic stenosis. The ycar of surgery influcnccd both the risk of 
anastomotic stricture and incontinence. Being oldcr than 
70 years of age increased the risk of incontinence. Pre-
vious transurethral resection, T stage, pT stage and leak-
age on cystogram influenced neither incontinence nor ste-
nosis or impotence. 
Discussion and Conclusions 
In the interpretation of these data, several pertinent 
points must be made. The first is that this is a prospective 
study with data collection that is likely to be more com-
plete than in studies based on chart reviews. The second 
point is that we arc curren!!y undertaking a parallel study 
on the eflectiycness of radical prostatectomy in paticnts 
with TJ prostate cancer. For this reason, we havc 3 I and 
75% patients who arc clinically and pathologically, re-
spectively,judged to be extracapsular. This large cohort of 
bulky tumors may introduce unrecognised biases. Lastly, 
this is not the series of onc person, but rather represcnts 
the workload of 4-6 surgeons sharing 25-40 cases per 
year. 
The mortality in the study is low. Two of the postoper· 
ativc deaths were suddcn deaths despite prophylactic 
measures, whilc thc other was as a direct result of the pro-
cedure itself. 
The intraoperative complications included 4 rectal 
injuries. In thc early part of the series these werc treated 
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Ex~rience Date Tstage pT stage 
(sursoon I H.others) «&7 n.>81) «T,V>.>T,) «pTln.>pT» 
p<O,OI NS NS 1\S 
NS p"'O.O~ NS 1\S 
NS N/A NS 1\S 
with defunctioning colostomy. With the more recent inju-
ries we havc simply overscwn the rectum and pcrformed 
an anal dilatation as proposed by Borland and Walsh [2}. 
These patients have had uncomplicated courses. The 
intraoperative blood loss has decreased in the more recent 
part of the series compared with the earlier cases, Hypo-
tensive techniques are not employed in these paticnts and 
the use of temporary hypogastric artery occlusion is not 
routine. Perhaps with these modifications blood loss 
could be further reduced although the eOect of hypogas-
tric occlusion has becn debated (3). Previous TURP was 
the only other factor influencing blood loss. 
The decrease in early postoperative complications over 
the course of the serics is more likely duc to improve-
ments in anesthesia and postoperative care than surgical 
technique. Thc high incidencc of wound infections was a 
surprise. Thc patients did not routinely receive prophy-
lactic antibiotics. All but 4 positive cultures grew Slaphy-
lococC/ls mm?/ts, and gram-negativc organisms were secn 
in only 2, In the earlier part of the series, all patienls 
recei\'ed both subcutaneous heparin and graduated com-
pression stockings. The heparin may have contributed to 
the high numbcr of patients needing drainage of a Jym-
phoeele or having prolonged lymph drainage in the early 
part ofthc series. It is interesting to note that not only did 
these conlplications decrease after ceasing the use ofhepa-
rin, but that thcre was also no increase in the numbcr of 
thromboembolic events, wilh 7 out of 10 (including the 
fatal e\'ents) occurring before this time. 
Incontinence must always be interpreted with the defi· 
nition kept in mind. The criteria in this series werc strict. 
Continent patients were completely dry without use of a 
pad. A number of our grade I incontinent patients wore 
their pad for 'security', even though they claimed to bc 
'dry with an occasional drip', Any patient wearing more 
than 2 pads pcr day were categorized gradc 2 incontinent, 
regardless of how much urincwason those pads. Just ovcr 
half the patients wcrc considered incontinent on removal 
ofthcircatheterand by 3 months the proportion requiring 
pads had fallen to 21 %. Over the study period, the imme-
diate incontinence rate did not change. Both the 3·month 
and 12-month incontinence rates decreased as the study 
progressed. Of the 11 artificial sphincters implanted, 9 
were in patients who had their radical prostatectomy 
prior to the adaptation of the 'nerve-sparing' tcrhnique, 
many of whom had concurrent problems with anastomot-
ic stenoses. This improvement in both the incidence and 
severity of in co ntinence may be due to increasing experi· 
ence, but is more likely a result of the modifications to the 
operative tcrhnique. Recent adoption ofthe further adap-
tations suggested by Walsh [4] should reduce the risk of 
incontinence e\'en further. 
All II patients who were implanted with artificial 
sphincters received the A~'IS800 device. Continence was 
achie\'ed in all patients. This high success rate with this 
device for incontinence after prostatectomy was con-
firmed by others [5J. In aU these patients, urodynamic 
studies were performed and showed sphincter weakness. 
In this small number of patients we did not see additional 
significant bladder dysfunction in contrast to Leach et al. 
[6] who found such dysfunction in 60% of their patients. 
We have, however, found low compliance in patients 
referred secondarily to us with post prostatectomy inconti-
nence, suggesting that technical nuances may playa role. 
Presti et al. [7) found detrusor instability in 25% of their 
incontinent patients, but this was similar to their conti-
nent group, whereas measures of sphincteric integrity 
were significantly diflerent between the two groups. 
5 patients with grade 2 incontinence (including 3 who 
were incontinent preoperatively) did not wish to have a 
sphincter placed. They could possibly have benefitted 
from the peri·urethral polytetrafluoroethylene injections 
as suggested by Sianisic et al. (S}. Our finding that the 
patients over the age of 70 years were more at risk of 
becoming incontinent is in contrast to the findings oroth-
ers (9-11). 
Thirty-two percent of the patients required at least one 
dilatation of the bladder neck. The definition required 
that anyone having a sound passed be recorded as requir-
ing a dilatation. Many of these patients had minor symp-
toms and the sounds passed with ease. Although the inci-
dence of stenosis did not change with time, the severity 
did. All of the severe strictures requiring bladder neck 
incision, resection of the anastomosis Or long-term cathe-
ters were operated on prior to 1987 and prior to the adap-
tation of the 'nerve-sparing' tcchnique. The surgeon's 
experience decreased the likelihood of stenosis. In con-
trast to the findings ofSurya et al. [12], we did not find 
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that blood loss, extravasation of urine at the anastomotic 
site or prior contributed to the deyelopment of a stric-
ture. 
In patients where either a bilateral or a unilateral 
nerye-sparing procedure was attempted, the potency rates 
of 43 and 24%, respectively, arc lower than others quoted 
in the literature [13-15J. This may in part be explaincd by 
the high incidence of pathological extracapsularextension 
(75%) in this series compared with those ofCatalona and 
Bigg[ 13], Leandri et a1. [14] and Quinlan et al. (15}, which 
were 43, 55 and 42%, respectively. Extracapsular exten-
sion has been shown to decrease the likelihood ofpostop-
eratiye potency [13]. Although in the present series extra-
capsular extension was not statistically significantly dif-
ferent as concerns recovery of potency, this is almost cer-
tainly due to the small numbers, as a trend was indeed 
seen. JI was interesting to note that, although all patients 
were offered impotence therapy, only 21% of patients 
accepted the oOer of treatment, suggesting that for many 
this is not an important issue. Of those who were treated 
with papaverine, an average or66 mg (range 25-100 mg) 
was required intracorporeaUy for an erection. Two pa-
tients were unable to achieve an erection on 100 mg. This 
suggests that the etiology of impotence in many patients is 
not entirely neurogenic, and that there is most likely an 
additional vasculogenic component, as proposed by 
Bahnson and Catalona [16}. In the current series, we did 
not find that patient age, previous TURP, surgeon, or 
presence of extravasation impacted on potency. Again the 
small numbers may have masked any such impact. Final-
ly, we were surprised that almost a third of the patients 
who regained their potcncy did so more than 12 months 
after surgery. 
In assessing the impact of radical prostatectomy on 
men 70 years and over, Middelton [9J found that the rates 
of both perioperative and postoperative complications 
were not different in those patients under 70 years when 
compared to those over 70. Our findings were similar in 
all aspects except incontinence. The impact of prior 
TURP has previously been addressed. We found that 
there was an increase in the median number of blood 
units transrused, but no change in risk for any of the com-
plications assessed. This supports the concepts that 
TURP lIlay make an operation more dimcult, but docs 
not make it more dangerous. 
This serics extended over a decade and a halt: O\·er 
this period the operation has been JXrformed more often. 
There ha\'e also been many modifications to the tech-
nique. These factors have dccreased both the incidence 
and the severity of the complications. Although the expe-
rience gained with the larger number of patients operated 
on may be contributory, it is interesting to note that in aU 
aspects except the risk of stenosis there was no difference 
between the most experienced surgeon (surgeon 1) and 
the olhersurgeons. This suggests that the decrease in mor· 
bidityshould be ascribed to the improvements in the tech· 
nique. 
In summary, this prospective study shows that radical 
prostatectomy can be performed with minimal mortality 
and acceptable morbidity. Complications, if they occur, 
lend to be of limited duration or can be satisfactorily 
treated. Technical modifications have significantly de-
creased the morbidity oflhe procedure. 
References 
\\'alIh pc; Radkai retropubk ph»tate\toml~ 
ill Walsh Pc. Gines RF, Perlmuller AD, Sla-
me)o"TA(edsJ:Campbdl's Urolozy.ed S. Phila-
delphia. Saunders, 1986. \"013. pp 2754-2775. 
Borland RN, Walsh PC; The mlnagement of 
r«lal injury during udkal relropubic prostl-
Ie.:tomy. J Uwl (991:147;90S-907. 
3 Kl\'OU5Si lR, 1-lrer> lA, Cata(olll \\'J; Eff«t 
of tempOrary 0..-..:lu5ion of h} .... ..",trk arteries 
on bll.'Od loss during radical prostate.::!omy. J 
UroI1991:1~6:362-365. 
Walsh pc, Quinlan Dl-l, Morten RA, Steiner 
MS: Radkal retropubic prostate.::tomF 1m· 
prowd an3.stomosis and urirury (Ontinence. 
Urol Gin North Am 1990; 17:679-68~. 
S Gundian]C, Bamtt D~I, Parulkar IlG: ~Ia}'o 
clinic e_'~rience \\ith us~ oflhe AMSSOO arti· 
fkial urinal)' sphincter for urinary inconti· 
nence foIlo\\ing radical prosll!e.:tom}'. 1 Uro! 
1989;142: 1459-1 ~61. 
6 leach GE, Yip CM, DonoHn BI: POl!·pw,ta-
(<<tomy ineonti nence: The influence ofb laddu 
d)sfunction.1 Uroll987;IJS:974-978. 
Pc.:;ti lC, &hmidt RA, Nara}an PA, Carroll 
PR, Tanagho fA: Pathophysiology of urinary 
jncvnlinenc~ after udical pcos!at~tomy. J 
Uro! 1990;143:975-978. 
Slanilic Til, leonings CE, Miller 11: Pol~telra­
flumoxth) lene inje.:l ion for post·proltate.;tom)o" 
incontinence: f~perience ",jth 20 patienlS duro 
ing 3 yem. J UroI1991;146:IS7S-1577. 
Middleton A\\': Radical pcol!Jt<xtomr for car· 
~inoma in men more than 69 yeM> old. J Urol 
1987;08:1185-1188. 
10 Ramon J, leandri p. Ro>signol G. Gautier JR: 
Urin3£)' rontinencc follo\\ing radical rehopu, 
bic prmtat«tomy. Br 1 UroI199J;71:47-SI. 
1 I Steiner MS. Morton RA, Walsh PC; Imp..lct of 
anatomical radical pro\tate.::tomy on urinary 
(Onlin~n,,'. J Uro( 1991:145;S 12-515. 
61 
12 Su£)'a BY, Pront J. Johanson KE. Bro\\n I: 
AnastomotiC strktures follo\\in& radical pro;;· 
tat~ctom)'; Ri,k f~c(ors and m~nlgement. J 
Uro! 19m;143;755-7SS. 
I3 CatJ.ion3 WI, Bigg SW; Ner.e·spann& radicJ.i 
prostat<Xtom): E\-J.iuJtion of re>uln afur 250 
p..ltients. J Urol 1990;IHS38-5~4. 
14 leandri p, Rossignol G, Gautier JR, Ramon J: 
Radi.al wropubic prolta!e.:toml': ~Iorbidit)' 
and quality of life. f~peri~Dce II ith 650 con~­
uti\-eca~s. ] UroI1991;147:8S3-SS1. 
15 Quinla!) D~I, Epstein 11. Carter BS. Wal5h PC: 
s.:,uJi [unction rollo'~ing radical proltate.::!o-
m~: Innuenc~ of preS{r.·ation ofneuro'J.cubr 
bundle;;. I UroI1991;14S:99S-IOO1. 
16 Bahnson RR. C"atalona WJ; Paron-anne Uiling 
of impot~ot pltieDt\ follo,",ing ner.-e-sparing 
radkal pro\tate.:tom)". J Urol 1988;139;773-
774. 

PART 2 
THE INFLUENCE OF PATHOLOGICAL 
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SUMMARY. 
Objective.Most studies reporting the results of radical prostatectomy for prostate cancer 
originate in centers with a very large experience, obtained by a few surgeons, where large 
numbers of patients are operated, and therefore much experience is at hand. The rise in 
detection-rate oflocally confined prostate cancers in the last decade, and the associated rise in 
the number of radical prostatectomies, will lead to the performance of radical prostatectomies 
by urologists who are less experienced. This article reports the results from a clinic where 6 
urologists shared about 50 radical prostatectomies a year, in the later years of the study-period 
(1977-1994). The radical prostatectomy-specimens were processed in a routine manner, no 
elaborate sampling was performed. 
Material and methods. Radical prostatectomy was performed in 273 patients who were 
followed prospectively. The radical prostatectomy-specimens were evaluated for: pathological 
stage, histological grade, capsular perforation, positive lateral and apical margins of resection, 
seminal vesicle invasion, perineural invasion, vascular invasion, and the lymph node status was 
determined. The relation between these variables and the following outcome parameters was 
assessed: clinical progression, local recurrence, distant metastases, biochemical progression, 
overall survival, and cancer specific survival. 
Results. All evaluated variables were significantly predictive for clinical and biochemical 
progression in the univariate analyses, and all but perineural invasion and lymph node status for 
cancer specific survival.Multivariate analysis showed vascular invasion to be the most impor-
tant prognostic variable, followed by capsular perforation, positive margins of resection and 
poorly differentiated carcinoma. The overall results for the evaluated parameters were compa-
rable to the results ofthe centers with a larger experience. 
Conclusions. The treatment-outcome in a clinic where 6 urologists share 50 radical prostatec-
tomies a year is similar to the results of more experienced clinics. The routine work-up of the 
radical prostatectomy specimens produces pathological variables which are important prognos-
tic factors. Vascular invasion, capsular perforation, positive margins of resection, and poorly 
differentiated carcinoma are the most significant prognostic factors. Vascular invasion should 
be part of the routine evaluation of radical prostatectomy-specimens. 
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INTRODUCTION. 
In recent years the incidence of locally confined prostatic carcinoma has increased from 27,5% 
in 1985 to 48,5% in 1990 of all prostate cancers identified in the US National Database (I). 
This trend is probably the result of increasing public and doctors awareness and the induction 
of screening programs for prostate cancer (2). Since more prostate cancer is locally confined at 
the time of diagnosis, the percentage of patients that is treated by radical prostatectomy has 
increased. Lu Yao reported a nearly six-fold increase in the rate of radical prostatectomy use in 
this same period (3). 
Many studies reporting the results after radical prostatectomy for prostatic cancer, and 
especially those which contains large numbers of patients, originate from centers with a very 
large experience. However, with the recent increase in numbers of cases diagnosed, this 
operation will gain a more wide-spread use, and will become part of the standard armamentari-
um of urologists . Since it takes time and practice to build up a routine, the results in the 
beginning may be worse than those reported by centers of excellence, where more experience 
is at hand. We report the results of tumor control and survival after radical prostatectomy for 
clinically localized carcinoma ofthe prostate, from a clinic where 6 urologists share about 50 
radical prostatectomies a year, during the last years of the study-period. 
The role of pathological variables for progression and survival has also mostly been reported 
from centers with a large experience, where sometimes a very elaborate evaluation of the 
radical prostatectomy specimen was done. We report the influence of pathological variables on 
tumor control after a routine work-up of the radical prostatectomy specimen. 
MATERIAL AND METHODS. 
Between 1977 and 1994,273 patients underwent a pelvine lymph node dissection and radical-
retropubic prostatectomy for clinically localized or locally advanced carcinoma of the prostate. 
Originally, 375 patients were scheduled for surgery, but 102 patients appeared to have lymph 
node positive disease, detected by frozen sections, and therefore no radical prostatectomy was 
performed. 
Preoperative evalualioll. This included a digital rectal examination, histological biopsy of the 
prostate, determination of serum alkaline phosphatase and prostatic acid phosphatase,(from 
1987 on replaced by prostate specific antigen:PSA), a bone scan, CT-scanning of the pelvis 
and abdomen, and a transrectal ultrasonography. 
Patiellt-group characteristics. The median patient age was 63.8 years,(range 45-75 years). 
Staging was performed according to the TNM classilication of 1992 (4):Twenty-seven patients 
were c1assilied T1 (9.9%); 162 as T2 (59.3%); 83 as T3 (30.4%); and one as T4 (0.4%); 
however no subclassification in a,b or c was made, because ofthe small numbers in each 
group. The preoperative histological grading was done according to MD Anderson (5); 68 
patients had well differentiated carcinoma (GI:25%); 161 moderately differentiated carcinoma 
(G2: 59%); and44 poorly differentiated carcinoma (G3: 16%). All patients were classified as 
MO. All patients underwent a pelvine lymph node dissection, before proceeding with the radical 
prostatectomy. In 9 patients a single microscopic metastasis was detected in the lymph nodes. 
The decision to proceed was made intra-operatively, because of the young age, and good 
health of these patients.!n 18 patients, who had no evidence of tumor in the frozen sections, 
microscopic metastases were found on the paraffin sections; therefor 27 patients (10%) that 
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underwent surgery had lymph node metastases. All patients underwent a radical retropubic 
prostatectomy; the technique has been described before (6).In 143 patients an attempt was 
made to save the neurovascular bundles: in 84 patients bilaterally, and in 59 patients unilateral-
ly. In 130 patients the bundles were sacrificed, because of suspicion of tumor growth in the 
area of the bundle. No patient received adjuvant treatment until progression occurred. 
Pathological evaluation. The radical prostatectomy specimen was submitted in its entirety and 
cut in 5 mm thick slices, all of which were embedded in paraffine. Several 5 ~m thick slices 
were taken of each slice and stained with haematoxylinJeosine for pathological review. The 
parameters studied were: histopathological grade (MD Andersen), capsular perforation, apical 
and lateral margins of resection, seminal vesicle invasion, perineural invasion,vascular invasion, 
and pT category. The pelvic lymph node specimens were embedded in paraffine and entirely 
sectioned and evaluated to detect micro metastases. 
Follow-up. The median follow-up was 49 months (range 1-206 months).Patients were follo-
wed at regular intervals of3 months during the first 2 years; of6 months during year 3 till 5 
and once a year during further follow-up.During each visit a digital rectal examination was 
performed, and serum PSA and alkaline phosphatasis was determined. Bone scanning, compu-
ter tomography and TRUS-guided biopsy were only performed when progressive disease was 
suspected. No additional treatment was started until clinical progression was proved. 
All data were collected prospectively, and stored in a computer database which was especially 
designed for this study. 
Study endpoints and definitions. The study endpoints were: clinical progression, local recur-
rence, distant metastases, biochemical progression, overall survival, and cancer specific survi-
val.Clinical progression was defined as histologically confirmed evidence oflocal recurrence, 
and/or the presence of distant metastases diagnosed by bone scans, ultrasonography or CT-
scanning. Local recurrence was defined as the presence oftumor cells around the bladder-
urethra anastomosis, proved by biopsy. Distant metastases were considered by the presence of 
new hot spots on the bone scan, or by other imaging techniques (ultra sonography, chest X-
rays, CT-scans). The presence of an elevated PSA alone was not considered clinical progressi-
on. Biochemical progression was defined as the first occurrence oftwo consecutive PSA 
values >0.1 ng/ml. To avoid biased selection of patients, only those were included who had 
regular PSA determinations during follow-up. Therefore only the patients who had their first 
PSA measurement within 12 months after the operation were evaluated for biochemical 
progression (n~173). Overall survival was defined as the percentage of patients who did not 
die of any cause at a certain time post surgery. In calculating cancer specific survival patients 
were considered withdrawn from study at the time when they died from causes not related to 
prostate cancer, post-operative deaths were counted as death due to prostate cancer. 
Statistical analysis. Kaplan Meier projections of time to clinical progression(CP),local recur-
rence(LR),distant metastases(DM),biochemical progression(BP),overall survival(OS),and 
cancer specific survival(CSS) were used to calculate the actuarial progression and survival 
percentages at 5, 10, and 15 years.For the univariate analysis the statistical significance of 
differences was determined by the log-rank test. The Cox proportional hazards model was used 
to perform the multivariate analysis. P-values (two-tailed) <0.05 were considered significant. 
RESULTS. 
Under/over staging. Understaging occurred in 24/27 patients with Tl (89%); in 1111162 
,vith T2 (69%); and in 4/83 ,vith T3 (5%).Overstaging occurred in 3/27 patients ,vith Tl 
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{l1%);in 3/162 with T2 (2%); in 15/83 with T3 (18%); and in the one patient in whom stage 
T4 was suspected: this turned out to be stage T3c. It is evident that clinical staging methods 
are not very reliable since the total percentage ofunderstaged patients was 51%, and of 
overstaged patients 8%.Especially the 18% overstaging in clinical T3 disease is precarious; 
these patients may be denied a curative operation because of staging errors. 
Under/over grading. Undergrading was found in 27%. In biopsy G1 patients 49/68 (72%) 
turned out to have Grade 2 (44 patients) or Grade 3 (5 patients). In 25/161 G2 patients the 
tumor was up-graded to G3 (15%). Overgrading by the biopsy specimen was determined in 
15%; in 13/44 patients with G3 (29%),241161 with G2 {l5%),and 3/68 with GI (4%) the 
postoperative grade was lower then the biopsy grade.These differences are due to sampling 
errors. For the progression and survival percentages the postoperative grade was used. 
Observed progression mid survival.!n this group of273 patients, 75 experienced clinical 
progression (27%), at a median time of 110 months (range: 3-182 months).During the obser-
vation period 18 patients developped local recurrence (7%), 45 distant metastases (l7%), and 
12 patients had both (4%).Biochemical progression occurred in 66 of 173 patients (38%), at a 
median time of 58 months (range 2-84 months). During follow-up 53/273 patients died (19%); 
of those who died 19 patients died of prostate cancer (36%), 3 (6%) in the postoperative 
period due to postoperative complications ( 2 died of pulmonary embolism, one of sepsis), 11 
(21%) ofa second malignancy, and 20 (37%) ofintercurrent disease. The 6-week postoperati-
ve mortality-rate was 1%. 
Actuarial 5,10, and 15 year cumulative percentages for clinical progression, local 
recurrence, distant metastases, biochemical progression, overall sunrival, and cancer 
specific survival, of 273' patients treated by radical prostatectomy for prostatic carci-
noma. 
Parameter 5 year(%)* 10 year(%)* 15 year(%)* 
clinical progression 27 (89) 53 (15) 63 (4) 
local recurrence 11 (106) 24 (20) 24 (5) 
distant metastases 21 (96) 41 (16) 53 (4) 
biochemical progressionl1 52(14) --- (0) --- (0) 
overall survival 82(115) 63 (22) 55 (5) 
cancer specific survival 92(115) 82 (22) 82 (5) 
*: numbers between parenthesis indicate patients at risk at indicated year. 
': values for biochemical progression based on 173 patients. 
---: not evaluable. 
Table 1. 
Actuarial progression and survival. The actuarial percentages for progression and survival 
at 5, 10, and 15 years are listed in table 1. The median interval for the development ofCP after 
the occurrence ofBP was 56 months. Two patients had CP prior to BP, in all other patients in 
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this group who had both CP and BP, BP preceded CPo 
There is a steady increase ofLR until 10 years postoperatively, but between 10 and 15 years 
no more LR developped (at 10 years only 20 patients were at risk for LR).DM and CP also 
show a steady increase until 10 years, which slowes down in the period 10-15 years. However 
since the numbers at risk are smaller in the last period, these percentages are less reliable than 
those at 5 and 10 years. Given the median age of 63 years at the time of operation, the 
percentages of OS are relatively high (a 15 year survival of55%), but it has to be considered 
that these patients had to be in good health to be candidates for surgery, which gave them an 
advantage over their age-matched controls. The CSS of92%, 82% and 82% at 5, 10, and 15 
years is excellent, especially when the patient-group is considered (30% of the patients had 
locally advanced carcinoma),and proves that radical prostatectomy is effective in many patients 
with locally confined carcinoma. 
Pathological variables.The frequency and percentages of the pathological variables are listed 
in table 2. The relatively high percentages of pT3 (63%), and G3 (22%), indicate that this is 
a patient-group with a high risk for progression. Furthermore about 10% of the patients had 
lymph node metastases, and 29% seminal vesicle invasion. The presence of positive margins of 
resection in 34% of the patients is not surprising, considering that 64% had capsular perforati-
on, and extension ofthe tumor into the peri-prostatic fat. The significant correlation between 
positive margins of resection and capsular perforation~ seminal vesicle invasion, apical 
margins of resection and the pathological T-category has been studied in an earlier report.(7). 
There was also a significant correlation between perineural invasion and capsular perforation. 
Vascular invasion was present in 12%. 
Univariate analysis. The results of the univariate statistical analysis for the different pathologi-
cal variables are listed in table 2. The p-values indicate the significance of the log-rank test. 
Due to small numbers in the evaluation some categories were combined. For the pT -category 
the difference between pTl/2 and pT3/4 was tested; for the pN-category pNO versus pN1I2; 
and for grade GO/I/2 versus G3. For all other variables the difference between presence and 
absence was evaluated. 
For CP all variables showed a significant difference.The difference in BP rates was significant 
for all variables. For CSS rates all variables except the pN-category and the presence of 
perineural invasion were significant, despite the fact that only 22 patients died due to prostate 
cancer. With extended follow-up and more cancer-deaths more variables may become signifi-
cant. 
A sub-group analysis was performed for the patients with pT3-tumors, to evaluate the effect of 
seminal vesicle involvement on clinical progression. Patients with capsular perforation only 
(pTJa-b: 100 patients) were compared to those with seminal vesicle invasion (pTJc: 72 
patients). A significant difference resulted: p~0.006, indicating that the invasion of tumor in the 
seminal vesicles determines a subgroup with a higher progression risk in the group of patients 
with locally advanced disease (PT3). 
Multivariate anaiysis. Table 3 contains the final results of the multivariate analysis for CP, BP 
and CSS for the pathological variables, by the Cox proportional hazard model. For CP vascular 
invasion, capsular perforation, poorly differentiated carcinoma, and positive lateral margins of 
resection were significant, with relative risks varying from 1.6-2.5. AU other variables were not 
of additional significant prognostic value. For BP only vascular invasion and capsular perforati-
on were significant; for grade 3 and positive lateral margins of resection there was a 
trend,which did not reach significance.CSS was significantly influenced by the presence of 
vascular invasion and positive lateral margins of resection; the other variables did not reach 
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Univariate analysis for the influence of the ditTerent pathological variables on clinical and 
biochemical pro~ression and cancer specific survival. 
Variable N % CP BP CSS 
p-value p-value p-value 
pT-category pTO 6 2 
pTi 0 0 
pT2 80 29 p<O.OOI p<O.OOI p~O.OI 
pTJ 173 63 
pT4 14 5 
pN-category pNO 246 90 
pNI 19 7 p~0.03 p<O.OOI p~0.80 
pN2 8 3 
vascular invasion present 33 12 
absent 240 88 
p<O.OOI p<O.OOI p<O.OOI 
perineural invasion present 207 76 
absent 66 24 
p<O.OOI p<O.OOI p~O.13 
seminal vesicle invasion present 78 29 
absent 195 72 
p<O.OOI p<O.OOI p~.OI 
positive lateral margins of re- present 92 34 
section 
absent 181 66 
p<O.OOI p<O.OOI p~O.OOI 
positive apical margins ofre- present 113 41 
section p~O.02 p<O.OOI p~0.03 
absent 160 59 
capsular perforation present 175 64 
absent 98 36 
p<O.OOI p<O.OOI p~O.OI 
grade GO 6 2 
GI 38 14 p<O.OOI p<O.OOI p~O.OI 
G2 168 62 
G3 61 22 
N~ number of patients BP: biochemical progression 
CP: clinical progression. CSS: cancer specific survival P-value: log-rank test 
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Multivariate analysis for the influence of the difTerent pathological variables on 
clinical and biochemical prog ression and cancer specific survival. 
variable relative risk 95% confidence p-value 
interval 
CLINICAL PROGRESSION 
vascular invasion 2.5 1.5 - 4.2 p~O.OOI 
capsular perforation 2.5 1.2 - 5.2 p~O.OI 
grade 3 1.8 1.1 - 2.9 p~0.02 
positive lateral margin 1.6 1.0 - 2.7 p~0.05 
BIOCHEMICAL PROGRESSION 
vascular invasion 2.3 1.2 - 4.2 p~0.007 
capsular perf oral ion 2.6 1.2 - 5.5 p~O.OI 
grade 3 1.6 1.1 - 2.9 p~O.07 
positive laleral margin 1.6 0.9 - 2.7 p~0.08 
CANCER SPECIFIC SURVIVAL 
vascular invasion 2.7 1.1 -6.7 p~0.03 
capsular perforalion 2.4 0.5 - 11.6 p~0.27 
grade 3 1.9 0.8 - 4.5 p~0.17 
positive laleral margin 2.5 1.0 - 6.2 p~0.05 
Table 3. 
significance The occurrence of more cancer-deaths al extended follow-up may alter Ihese 
results. 
Actuarial percelltages of 5 mId 10 year progressioll and survival. Table 4 shows the aCluarial 5 
and 10 year percentages ofCP, LR, DM, BP, OS and CSS, according to the different palholo-
gical variables. BP was only evalualed at 5 years, since no palienl had 10 years of follow-up 
afier the inlroduction ofPSA. No palienl was classified pT!, and no patienl wilh pT4 survived 
afier 5 years. The 15 year progression and survival rales were nol evalualed, since the numbers 
in the subgroups were too small to give reliable resulls. 
DISCUSSION. 
The palienl-group reported is characlerized by a high percenlage ofpalienls wilh clinical T3 
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Actuarial 5 and 10 year cumulative percentages of clinical progression, local recurrence, 
distant metastases, biochemical progression, overall survival, and cancer specific survival 
according to pathological variables. 
CP(%) LR(%) DM(%) BP(%) OS(%) CSS(%) 
variable N 5yr IOyr 5yr IOyr 5yr 10yr 5yr lOyr 5yr lOyr 5yr 10yJ 
capsular present 175 37 77 13 39 29 58 69 ... 80 57 89 73 
perforation 
absent 98 9 18 5 8 6 13 21 88 74 97 97 ... 
lateral positive 92 43 80 20 36 33 71 72 ... 74 54 79 63 
margins 
negative 181 20 45 6 19 17 35 39 86 65 96 88 ... 
apical positive 113 35 72 15 37 27 49 72 _ .. 80 62 87 74 
margins 
negative 160 21 43 7 17 17 34 30 84 64 96 87 ._. 
perineural present 207 34 63 12 26 27 46 64 ... 81 57 90 77 
invasion 
absent 66 7 29 5 19 5 22 14 ._. 88 78 96 96 
seminal present 78 46 80 21 47 33 65 89 ... 75 53 85 69 
vesicle 
invasion absent 195 19 39 6 15 16 29 37 -.. 86 68 95 89 
vascular present 33 68 81 36 36 39 68 83 ... 64 40 77 48 
invasion 
absent 240 21 49 7 23 19 37 47 ... 85 66 94 87 
grade 01112 206 22 49 9 17 16 38 44 ... 89 63 95 83 
3 61 46 75 16 53 42 57 100 ... 62 59 77 73 
pTO 6 0 0 0 0 0 0 0 ... 83 56 100 100 
pTi 0 ... ... . _ . ... ... ... ... ... ... . _ . . .. . .. 
pT pT2 80 7 17 3 6 7 15 18 ... 90 77 97 97 
pT3 173 34 75 14 39 26 55 67 ... 81 59 90 75 
pT4 14 100 100 17' ... 100 100 100 ._ . 0 0 0 0 
pNO 246 25 50 9 23 20 39 46 ... 83 64 92 82 
pN 
pNII2 27 48 79 23 34 30 66 94 79 50 90 82 ... 
N=number of patients 
CP:clinical progression BP:biochemical progression ... : not evaluable 
LR:local recurrence OS:overall survival *: after 4 years 
DM:distant metastases CSS:cancer specific survival 
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(30%) and Grade 3 (22%) tumors. This indicates that a considerable amount of patients has a 
high risk for progression and death due to prostate cancer. These circumstances also explain the 
low percentage of patients with histologically organ-confined tumors (PTO-2):32%. The high 
percentage of locally advanced tumors created an opportunity to study the pathological 
variables associated with this condition. 
Pathological stage. In 6 patients no residual tumor could be found in the radical 
prostatectomy-specimen; they were therefore classified pTO. All patients had a trans-urethral 
resection of the prostate prior to radical prostatectomy, and had probably only tumor in the 
transition-zone, which was resected during the TUR. Goldstein(8) reported on 13 patients with 
the "vanishing cancer phenomenon", who did not have a TUR before radical prostatectomy. 
After an elaborate work-up of the specimen cancer was found in II patients; the mean tumor 
volume was only 0.019 cc. No exhaustive sampling was performed in our patients, so some 
very small tumors may have been missed. The 0% progression rate and 100% CSS-rate after 
10 years offollow-up indicate however that these tumors were probably not clinically signifi-
cant. 
The majority of the patients were classified pT3(63%). Some urologists and radiotherapists 
consider these patients candidates for adjuvant radiotherapy, because of an elevated risk for 
local tumor recurrence. Kaplan stated that clinical local control improved CSS (9). In his 
series T3-patients were treated with external beam radiotherapy; the 10 years CSS-rate for 
those with local control was 56%, and for those with local recurrence 35%.!n the present 
series the LR-rate in pT3-patients was 14% at 5, and 39% at 10 years, the CSS-rates were 
90% and 75% respectively. The progression rates were however 34% and 75% at 5 and 10 
years, and it seems that many more patients experienced distant progression then local recur-
rence. Given these numbers, and considering the fact that adjuvant radiation therapy can cause 
complications and considerably patient discomfort, radiotherapy is not advised as standard 
treatment in pT3-patients. Currently the EORTC is running a protocol (EORTC 22911), which 
evaluates the results of tumor-control in pT3-patients with or ,vithout adjuvant radiotherapy. 
These results have to be awaited. 
Grade. It is well established that the presence of poorly differentiated tumor leads to signifi-
cantly higher rates ofCP(IO, II), BP(12) and CSS(13). Hawkins(l4) performed a multivariate 
analysis in pT3-patients, and found a relative risk of2.1 for systemic progression, 2.3 for BP, 
and 2.2 for CSS in patients with high grade tumors (Gleason> 7) compared to those with low 
grade tumors.!n the present series the multivariate analysis resulted in a relative risk ofpa-
tients with poorly difterentiated carcinoma's versus those with well or moderately carcinoma's 
of 1.8 for CP, 1.6 for BP, and 1.9 for CSS; however this was only significant for CP. For BP 
and CSS there was a trend which did not reach significance(p~0.07 and p~0.17). Longer 
follow-up and an extended patient-group may alter these results. Partin (15) studied a patient-
group ,vith high-grade carcinoma (Gleason>8) and tound BP at 5 years in 24% of the patients 
with specimen confined disease, versus 82% in those with non-specimen confined disease (in 
the latter group lymph node positive disease was present in 40%).Ohori(l6) reported a group 
of patients with Gleason> 8, and found as-year BP of 72%. When this group was divided in 
those with organ-confined and non-organ-confined cancer, the percentages were 0% and80% 
respectively. Since the presence of high-grade tumor did not infiuence the progression in 
organ-confined cancer, it seems that the anatomical barrier ofthe prostatic capsule is very 
important. 
Capsular peljoratioll.Capsular perforation is one ofthe most extensively studied pathological 
variables of the last decade. The clinical importance lies in the fact that in most centers patients 
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with capsular perforation(T3) are not considered candidates for radical surgery. Unfortunately 
clinical staging is often insufficient to detect extracapsular disease. In the present series 69% of 
the patients with clinical stage T2 turned out to have pT3. Capsular perforation is significantly 
associated with perneural invasion; Villers(17) described that in patients with clinical stage B 
cancer 50% ofthe capsular perforation consisted exclusively of perineural invasion, and only 
5% of the patients with capsular perforation had no perineural invasion. He concluded that the 
mechanism of capsular perforation may depend almost exclusively on perineural invasion. 
Perineural invasion was present in 76% of the patients in this series, and capsular perforation in 
64%. The presence of perineural invasion only was not considered capsular perforation. 
Perineural invasion was a significant prognostic factor in the univariate analysis, but not in the 
multivariate analysis, probably because of the close relationship with capsular perforation. The 
latter was a significant prognostic factor for CP, BP, but not for CSS in the multivariate 
analysis, with a relative risk of2.5; 2.6; and 2.4 respectively, when compared to those without 
capsular perforation. Epstein reported a significant difference between patients with focal 
(only a few tubules) and established capsular perforation; the 5-year BP-rates were 18% and 
35% respectively (18). Stein calculated an actuarial survival rate free of clinical disease of79% 
at 5- and 62% at 10 years (i.e. a CP-rate of21% and 38%). These results compare favourable 
to the 37% and 77% found in the present series, however they also included patients with 
capsular invasion only (and no perforation). Initially we divided the capsular status in 4 catego-
ries, as described by Stamey (19): I: no invasion, 2: invasion up to, but not into, 3: invasion, 
but no perforation, and 4: perforation ofthe capsule. The only significant prognostic category 
was perforation of the capsule; invasion into the capsule had no prognostic value, when 
compared to those without invasion. This must therefore be considered organ-confined disea-
se. 
A major concern in patients with capsular perforation is the occurrence of positive margins of 
resection and irradical tumor resection. McNeal found positive margins in 35 of38 patients 
with extracapsular tumor-extension, but only 44% of these were due to capsular perforation, 
and 56% to incision of the capsule during the operation (20). The local recurrence-rates for 
patients with capsular perforation were 13% at 5-, and 39% at 10 years in this series. Morton 
(21) reports a LR-rate of8% at 5 years, and Mukamel (II) a LR-rate of 17% at8 years of 
follow-up. 
Positive margins o/reseclion. Rosen (22) described the relation between extracapsular tumor-
extension and positive margins of resection. In clinical stage B-patients 63% had capsular 
perforation and 23% positive margins. Of the capsular perforation 87% occurred in the poste-
rolateral area; 57% of the positive margins were found in this area. The high percentage of 
capsular perforation in this area is due to the location of the neurovascular bundle (17); howe-
ver only 8 patients of31 in which the neurovascular bundle was saved, had positive margins 
(22). In an earlier report we found no correlation between saving the neurovascular bundles 
and the occurrence of positive margins (7). Epstein found no residual tumor in the neurovascu-
lar bundle in 40% of the patients who had a positive margin at the site of the bundle (23) .. 
Partin (24) found no difference in BP in patients with extracapsular tumor-extension, whether 
the bundle was resected or not: both groups had 70% BP after 3 years. He stated that radical 
prostatectomy cannot be advised in patients ,vith extracapsular extension. In the present series 
5-year BP occurred in 69% of the patients with capsular perforation and in 72% of those with 
positive margins. It has to be remembered however that a patient has no physical discomfort 
due to BP, and that CP follows BP at a distance of approximately 5 years. A 20% LR-rate at 5 
years was reported by Morton (21) in patients with positive surgical margins; in our series this 
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was also 20%. Therefore radical prostatectomy can be beneficial in some patients, who would 
otherwise have early problems oflocal progression. Adjuvant therapy can best be started when 
local recurrence actually occurs, since the majority of the patients with positive margins will 
not experience LR during their life-time. 
The apex is the site offtequent positive margins: 41% in this study. This high percentage was 
partly due to the method of evaluation of this margin (7). Stamey however also found 55% 
positive margins at the apex, and advised a wide resection of all tissues ftom the proximal 
membranous urethra to the levator muscles when an apical or near-apical node is present (25). 
We clearly visualize the apex and membranous urethra during operation, but carefully save the 
area of the external sphincter, since this is important for post-operative continence. 
Seminal vesicle invasion This occurred in 29% of the patients in this report. The results of the 
univariate analysis clearly indicate that the presence of seminal vesicle invasion significantly 
influences the progression and survival-rates in a negative way: the CP-rate was 46% at 5 
years. Similar results were reported by Stein (26) and Mukamel (II): 42% and 31 % CP at 5 
years. The CSS-rate in this series matches that reported by Stein (26): at 10 years the percenta-
ges CSS were 69% and 63%.When the patients in the pTJ-group were separated in those with 
capsular perforation only and those with seminal vesicle invasion, the latter had a significantly 
worse prognosis (p~0.006). It was therefore surprizing to find that seminal vesicle invasion 
was not significant in the multivariate analysis. The reason for this is probably the rather low 
number of deaths due to prostate cancer at this time in fOllow-up. 
Lymph node slallls.!n 27 patients ofthis study a radical prostatectomy was performed despite 
the fact that they had microscopic lymph node metastases. No patient received adjuvant 
treatment until progression occurred. The 5- and 10 years CP-rates of 48% and 79% are high, 
but comparable to those reported by Morton; 33% 5-year-CP (21), Hering; 35% CP at 3 years 
(27), and Frohrniiller who found 100% CP at 10 years in patients with pT2-3pNI-2 (28). 
Hering performed an analysis for the influence of the amount of tumor in the lymph nodes on 
progression: in the pN I-category tumors<5cm did equally well as those >5cm; 35% CP at 3 
years; but in the pN2-category all patients had progression after 3 year. The CSS-rates were 
respectively 80%, 100%, and 36%. In the present series the CSS-rates were 90% and 82% at 
5- and 10 years. This, and the fact that the pN-category was not a prognostic factor in the 
multivariate analysis indicate that these 27 patients had a relatively good prognosis. It has to be 
emphasized that these patients are a small and strongly selected group, with very small lymph 
node metastases, a young age and an excellent general health. These results are therfore not 
valid for all patients with lymph node metastases. 
Vascular invasion. Vascular invasion is an ominous sign in most tumors, indicating that they 
have already metastasized at the time of operation. However in prostatic cancer. with its 
relatively slow growth, tItis variable has attracted very little attention. Bahnson (29) reported 
an incidence of 51 % vascular andlor lymphatic invasion in a group of 55 patients after radical 
prostatectomy. The presence of vascular or lymphatic invasion implied a fourfold increase of 
the risk for progression. Salomao described the correlations between vascular invasion and 
other pathological variables, however his study contained no follow-up and the prognostic 
signilicance was not reported (30). In the present series vascular invasion occurred in 33 
patients (12%) and it was the most significant risk-factor in the multivariate analysis for both 
progression and survival, with a relative risk of2.5 for CP, 2.3 for BP, and 2.7 for CSS. We 
advise to evaluate this variable in all patients undergoing radical prostatectomy. 
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CONCLUSIONS. 
Radical prostatectomy is considered the treatment of first choice in patients with clinically 
locally confined prostate cancer. The reported results show that progression- and survival-rates 
are excellent, in a group which contained a relatively high percentage of patients with locally 
advanced carcinoma (TJ), and in a clinic where 6 urologists share about 50 radical prostatecto-
mies a year. 
The pathological variables evaluated were all significant for clinical and biochemical progressi-
on in the univariate analysis, and all except perineural invasion and the pN-category were 
significant in the univariate analysis for cancer specific survival. The multivariate analysis 
showed vascular invasion to be the most significant factor for progression and cancer specific 
survival, followed by capsular perforation, positive margins of resection, and poorly differenti-
ated carcinoma. The other evaluated variables did not reach significance. All variables were 
determined after a routine work-up of the radical prostatectomy-specimen, without elaborate 
sampling. The results show that in this way meaningfull prognostic information can be obtai-
ned. 
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CHAPTER 6 
Positive margins after radical prostatectomy: correlation with local 
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Positive Margins after Radical Prostatectomy: 
Correlation with Local Recurrence and Distant 
Progression 
D. VAN DEN OUDEN, F. M. BENTVELSEN, E. R. BOEV~ and F. H. SCHRODER 
Department of U/%gy. Erasmus University and Academic Hospital Rotterdam, The Netherlands 
Summary-The impact of positive and negative surgical margins of resection on the interval to and 
incidence of progression was analysed in 172 patients after radical retropubic prostatectomy 
combined with lymphadenectomy; 56 had positive margins. Lateral and apical positive margins 
were evaluated separately. 
The status of surgical margins was correlated with other prognostic factors, such as the T 
category, the presence or absence of seminal vesicle invasion and the G category. This analYSis 
showed that positive and negative margins significantly influenced time to progression 
independently of the other prognostic factors. Positive margins at the apex contrary to lateral 
margins did not significantly influence time to progression. This may be due to the definition of the 
status of apical margins used in this analysis. A total of 108 patients underwent a nerve-sparing 
radical prostatectomy, which did not lead to a higher incidence of positive margins than the 
standard procedure. 
Prostate specific antigen accurately predicted tumour recurrence after radical prostatectomy. A 
rise of ~ 1.0 ng/ml preceded other evidence of recurrence by a mean of 11 months. 
Positive margins ofresection are a frequent finding 
after radical prostatectomy. Their influence on 
progression has been insufficiently documented, 
since adjuvant therapy is usually administered 
immediately after the finding of positive margins. 
This report presents a prospective analysis of 172 
radical prostatectomies combined with pelvic 
lymph node dissection. The analysis examines the 
influence of positive margins of resection on time 
to progression and the correlation with other 
prognostic factors. 
Special attention is given to the pT3 classifica-
tion, which may need subdivision according to the 
status of surgical margins. The possible impact of 
the potency-preserving, nerve-sparing approach on 
surgical margins is analysed. 
Accepted for publication 6 August 1992 
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Patients and Methods 
Radical retropubic prostatectomy combined with 
limited pelvic lymph node dissection was carried 
out in 172 patients; 166 had negative lymph nodes 
at frozen section and 6 had microscopic foci of 
lymph node met<tstases. On paraffin sections posi-
tive lymph nodes were found in an additional 10 
patients. Eleven patients with lymph node positive 
disease had positive margins of resection and were 
included in this study. 
Pre-operative investigations included digital rec-
tal examination (DRE), histological and cytological 
biopsy, serum alkaline phosphatase (AP), prostatic 
acid phosphatase (PAP) (from 1987 on replaced by 
prostate specific antigen (PSA)), a bone scan, CT 
scanning of the pelvis and abdomen and a transrec-
tal ultrasonographic examination (TRUS) (5 MHz 
probe). 
This study was prospective. Patients were re-
cruited between 1977 and 1991. The average follow-
up was 42.6 months (range 1-165). Patients were 
followed up every 3 months during the first 2 years, 
every 6 months for the next 3 years and then once a 
year. During each visit a digital rectal examination 
was performed and the PAP and AP were deter-
mined. After 1987 the PAP measurement was 
replaced by prostate specific antigen determination 
in serum (Hybritech Tandem R Assay). During the 
initial phase a lower limit of 1.0 nglml was used but 
this was then changed toO. I ng/m!. For the purpose 
of this report a PSA level> 1.0 ng/ml was consid-
ered elevated after radical prostatectomy. TRUS-
guided biopsy, bone scanning and CT scans were 
performed only when progressive disease was 
suspected. The average age of the total population 
was 62.9 years (range 45-75). No additional treat-
ment was given unless local recurrence or metas-
tases occurred. 
The 1978/1982 TNM classification has been used 
(VICC, 1978). The distribution of clinical T 
categories, lymph node positive disease and grade 
of differentiation (Mostofi, 1975) is listed according 
to positive and negative margins in Table 1. 
There were 3 early deaths. One patient died 15 
days post·operatively because of a septic compli-
cation resulting from penetration of a drain into 
the intraperitoneal space and subsequent perfora· 
tion of a small bowel loop. Two other patients died 
15 days post-operatively from an acute cardio· 
vascular complication and pulmonary embolus 
respectively. 
The radical prostatectomy specimen was submit-
ted in its entirety and cut into 5-mm slices, all of 
which were embedded in paraffin. Several 5'~lm 
slices were taken from each slice and stained with 
haematoxylin and eosin. Differentiation was made 
between tumour not approaching or approaching 
the capsule up to I mm (organ-confined disease), 
invasion of the capsule (specimen'confined), pene-
tration into the periprostatic fat and positive 
margins. These findings led to a sub·c1assification 
ofthe pT2 and pT3 categories which will be subject 
to a separate analysis. Differentiation was made 
between lateral and apical positive margins. Lateral 
positive margins were defined as tumour at the 
lateral cut surface of the specimen. No distinction 
was made between posterolateral and lateral mar-
gins. 
The distal margin at the apex was defined as the 
presence of prostate cancer in the most distal 5 mm 
of the specimen. 
Progression was defined as cytologically or 
histologically confirmed evidence of local recurr-
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ence and/or the presence of distant metastases 
diagnosed on bone and CT scans. Elevation of 
serum markers alone was not regarded as progres· 
sion. 
In 108 of the 172 patients nerve-sparing radical 
prostatectomy was done. In 24 of these only I 
neurovascular bundle was preserved. Many of the 
patients who were not operated upon in a potentially 
potency-preserving fashion were treated prior to 
the development of this technique by Walsh et al. 
(1983). In other more recent cases the decision to 
preserve one or both bundles was made intraoper-
atively. 
Statistical analysis 
The statistical techniques used were the Kaplan-
Meier projection of time to progression, the 
Logrank test, the chi-squared test and Cox regres-
sion with time-dependent variables. 
Results 
The distribution of clinical T categories, grade of 
diffcrentiation and the incidenceoflocal recurrence 
and distant metastases are listed according to 
positive and negative margins in Table l. In 4 
patients in the TO group no more tumour was found 
in the radical prostatectomy specimen. Local 
recurrence and progression to the M I category 
occurred after an average period of 23.2 (range 1-
109) and 32.9 (range 4-142) months respectively. 
Figure 1 shows Kaplan·Meier projections of time 
to overall, local and distant progression. The overall 
progression and local recurrence rates were signifi-
cantlydifferent for the positive and negative margin 
groups. This significance persisted when a correc-
tion for the different pT categories had been done. 
The distant progression rate also showed a signifi-
cant difference for positive and negative margins. 
However, no significant difference was found 
between the different margin groups when correc-
tion for the different pT categories had been done 
(P=O.2). Local recurrence usually occurred prior 
to distant progression. A strong correlation was 
found between local recurrence and (iatcr in the 
follow-up) the incidence of distant metastases. The 
risk of developing distant metastases was 22 times 
higher in patients with local recurrence. 
Table 2 shows the mean values of pre-operative 
PSA, PAP and prostatic volume by TRUS for the 
positive and negative margin groups. 
Table 3 shows the correlation between the pT 
categories and surgical margins. When pT cate-
gories arc compared with the clinical T category, 
Table 1 Details of 172 Patients ¥.1th Locally Confined 
Prostate Cancer 
Margins 
TOlalno. POJiI{re ,vegatu:e 
Parameter a/patienlJ No. (%) No. (%) 
TO 26 4 (15) 22 (SS) 
TI iO 2 (20) 8 (80) 
T2 8J 25 (30) 58 (70) 
T3 53 25 (47) 28 (53) 
N 156 45 (29) III (71) 
N+ 16 11 (69) 5 (31) 
GI' 21 ) (14) 18 (86) 
G2 104 )) ()2) 71 (68) 
GJ 4) 20 (47) 2J (53) 
Local rccurrcncet 
present 19 9 (47) iO (53) 
absent 153 4J (1I) 106 (69) 
Distant mctastasest 
Ml 27 11 (41) 16 (59) 
MO 145 45 (1I) 100 (69) 
f Four patients had no tumour in the radical prostatectomy 
specimen. 
t local reCurrences and progression to MI occurred after 23.2 
(range 1-109) and 32.9 (range 4-142) months. 
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71% of the T2 tumours were upstaged to pT3. In 
Figure 2 the Kaplan-Meier curves for overall 
progression for pT3-4 with positive margins and 
for pT0-2 and pT3-4 with negative margins are 
shown. The difference between the positive and 
negative margin groups in category pT3---4 was 
statistically significant (P=O.05), whereas the dif-
ference between pT0-2 and pT3-4 with negative 
margins was not. No positive margins occurred in 
the pTO-2 group. 
Fig. I Kaplan·Meierprojectionsoftime toprogrcssion(distant, 
local, o\'erall). Note the cut"'Offvaiue at 50% of the yaxis. 
Thecorrelation between seminal vesicle invasion 
and the margin status is shown in Table 4. 
Table 2 PSA, PAP and Prostatic Volume Determined by TRUS in Pre·operative Staging, Related to ~Iargins of 
Resection after Radical Prostatectomy 
Margins 
Difference 
POlitire Negetire ber ... ·een mean 
No. (!'Ollle) No. (ralue) ralues 0/ grOUPJ 
Mean value of pre·operative PSA level 
(0=62) 25 (29.0) 37 (\6.6) P=O.OI 
Mean valueofpre·operative PAP level 
(n=126) 45 (3.6) 81 (2.0) P=O.OO6 
Mean value of pre·operative prostatic 
volume delennined byTRUS (0=72) 32 (31.4) 40 (25.5) P=0.053 
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Table 3 Correlation or pT Categories and Surgical 
~'Iargins 
pro·f pTl pT3 pT4 
"/argin! No.(%) No. (};) ,\'0.(%) ,\'0.(%) 
Positive o (OJ 0(0) 53 (45) 3 (100) 
Negati~'e 9 (100) 42 (100) 65 (55) o (0) 
Total 9 42 118 3 
Table 4 Correlation Between Seminal Vesicle Invasion 
and Surgical Margins 
,\/argilll 
Semillalreside Positir!' Negatire 
illrasion No.(%) No.(%) Total 
Posith'e 30 (50) 30 (50) 60 
Negath'e 26 (23) 86 (77) 112 
Total '6 116 
X!= 12.8; P<O.OOI. 
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Flg.2 Kaplan·Meier proje~tjonsoftime to overall progression 
for pTO-2 and pT3-4 with negati~'e margins and ror pT3-4 with 
positi\'e margins or resection. Note the ,ut·off value at 50% of 
the y a:o;is. 
Table 5 Correlation between Degree or Capsular Inva-
sion and Status or Surgical Margins 
Margins 
The degree of capsular invasion increased with Positire Nega/h-e 
the occurrence of positive surgical margins Capsular inrosion Total No. (%) No. (%) (Table 5). 2 ________________ ...:.:: ________ = __ 
Table 6 shows the distribution of lateral and None 21 0 (0) 21 (100) 
Up to 14 0 (0) 14 (100) 
apical margins. There was a significant correlation Into 2))' (13) 20 (87) 
between the lateral and apical margin status Fat/penetration 114 53 (47) 61 (53) 
(P<O.OOl) independent of the pT category. 
In Figure 3 the KapJan~Meier projections of the Total 172 116 
time to progression for the different locations of • All apical positive margins. 
positive margins are shown. It is evident that lateral 
margins and both positive margins were associated 
with a shorter time to progression, whereas this was 
not the case for positive apical margins. A positive 
apical margin, defined as tumour in the most distal 
5 mm of the prostate, contributed little to the 
progression rate. 
The relation between nerve-sparing radical pros-
tatectomy and the status of surgical margins is 
shown in Table 7. There was no significant differ-
ence in the incidence of positive margins between 
nerve-sparing (34%) and non nerve-sparing groups 
(JO%). 
After 1987, serum PSA was determined during 
every follow-up investigation. PSA values were 
Table 6 Correlation between Status or Lateral and 
Apical Margins 
Apical margin 
Positive 
Negative 
Total 
Xl =32.0; P<o/}.OOI. 
Lateral margin 
Posilire 
22 
2J 
4' 
Nega/ire 
11 
116 
127 
Total 
33 
1)9 
172 
available on 165 patients; 30 of these suffered I to4yearsafterradicalprostatectomy,aneievated 
disease recurrence. In 10 patients progression PSA serum level> 1.0 ng/ml was detected in 17 
occurred before PSA determination became avail- patients, 6 of whom showed recurrence (Table 8). 
able. The remaining 20 patients all had PSA levels In 62 patients with a serum PSA < 1.0 ng/ml no 
> 1.0 ng/ml at the time of progression. In a separate recurrence was evident. The difference between the 
analysis in which 79 patients were followed up for groups was significant (P <D.D05). Positive margins 
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Table 8 PSA Levels in 79 Patients 1-4 Years aner 
Radie-al Prostatectomy 
PSA 
PSA~l.Ong/m( PSA?:J.Ong/ml 
No. (X) No. (X) Tolal 
NED' 62 (85) II (IS) 7J 
Recurrence 0(0) 6 (100) 6 
Total 62 17 79 
• NED=no evidence of disease. 
n 
l ~'~-~o, Positive margins of resection are likely to be seen 
<·,,",e in patients with extensive tumours. since the 
Fig. 3 Kaplan-Meier projections of time to progression for anatomy of the area allows only a limited resection 
different sites of posili\·e margins of resection (n = 56). Note the 
cut-<Jffvalue at 50%ofthe y axis. of healthy tissue between the prostatic capsule and 
the margins of resection. The tenn "radical" 
therefore has a different meaning from the usual 
Table 7 Nerve-sparing Radical Prostatectomy and 
Status or Surgical r-.·fargins 
,Hargill! 
Positire Negatire 
Total No. (X) No.(::') 
Nen·e-sparing' 108 37 (34) 71 (66) 
Bundle resection 64 19 (30) 45 (70) 
Tota\ 56 116 
X!=O.S; P> 0.2. 
• Includes 24 unilateral cases. 
of resection occurred in 10 patients in this elevated 
PSA group and in lOin the normal PSA group. 
In 6 patients with progressive disease, elevation 
of PSA predicted recurrence of prostate cancer at a 
mean period of II months before residual disease 
was evident. In the elevated PSA group the average 
follow-up was 24 months for patients with no 
evidence of disease and 32 months for patients with 
recurrence. 
Discussion 
The incidence of positive margins of resection 
described in the Iilerature varies from 7% (Eggles-
ton and Walsh, 1985) to 46% (Jones, 1990). These 
differences are the result of variations in surgical 
indications and techniques, differences in histolog-
ical preparation and evaluation of radical prostat-
ectomy specimens (Epstein, t 990). 
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one in oncological surgery, when at least one or 
more centimetres of healthy surrounding tissue are 
resected. Furthermore, preservation of the delicate 
neurovascular bundles close to the lateral margins 
of resection may limit the resection of extra prostatic 
tissue in this area (Catalona and Bigg, 1990). 
Epstein (1990). however, found residual tumour in 
the neurovascular bundle in only 6 of 10 patients 
with positive margins when the bundle was re-
moved (during the same session). In the present 
series the incidence of positive margins was similar 
with and without nerve-sparing surgery. 
McNeal et at. (1990) described the apex as the 
most common site of positive margins of resection; 
56% of these resulted from resection through the 
capsule into the tumour and 44% of capsular 
penetration by the tumour into the periprostatic 
fat. In this series the urethra was usually clearly 
seen distal to the apex prior to determining the 
dorsal plane of resection, and resection through the 
capsule was rare. 
Jones (1990) described a significant correlation 
between the incidence of positive margins of 
resection and seminal vesicle invasion, capsular 
penetration, tumour volume and decreasing histo-
logical grade of differentiation. In our series the 
correlation between the occurrence of positive 
surgical margins was significant for seminal vesicle 
invasion. capsular penetration and increasing T, G 
and N categories, indicating that tumour extent 
and differentiation are of major importance for the 
occurrence of positive margins of resection. Fur-
thermore, the mean PSA and PAP values were 
significantly different for groups with positive and 
negative margins, whereas tumour volume meas-
ured by ultrasonography approached significance 
(P~O.053). 
In the pT3 category 53 patients (45%) had 
positive margins. Penetration through the prostatic 
capsule and into the fat occurred in 53 of 56 patients 
with positive margins (95%), but in 3 patients (5%) 
there was only invasion of the capsule. AU3 patients 
had, however, only an apical positive margin. In 
53% of the patients with capsular perforation no 
positive margins were found. 
Nerve-sparing radical prostatectomy was per-
formed in 108 patients, of whom 24 had only a 
unilateral bundle-sparing procedure. There were 
no significant differences in the occurrence of 
positive margins and progression between those 
who had a nerve-sparing operation and those who 
did not (Eggleston and Walsh, 1985). 
Progression occurred significantly more fre-
quently and earlier in patients with positive surgical 
margins than in those who appeared to have 
negative margins after surgery during a mean 
follow-up of 42.6 months. This indicates an in-
creased risk of progression in patients with positive 
margins of resection. 
In the present series, 79 patients were followed 
up for I to 4 years with PSA monitoring after 
radical prostatectomy. All patients with tumour 
recurrence had an elevated PSA level, while none 
of the patients with normal PSA showed recurrence. 
Elevation of serum PSA level preceded evidence of 
recurrence by a mean interval of II months. 
Lightner et at. (1990) showed that 40% of patients 
with an elevated PSA after radical prostatectomy 
had tumour recurrences in the urethrovesical 
anastomotic area, regardless of the finding at rectal 
examination. In the present series tumour recurr-
ence was found in 6 of 17 patients with elevated 
PSA (35%). 
Our data show that the TNM system differen-
tiates only roughly between potentially curable 
disease (pT2 = carcinoma without penetration of 
the capsule) and non-curable disease (pT3=carci-
noma with invasion beyond the capsule and/or 
invasion of the seminal vesicles). Table 5 shows 
that 53% of patients with penetration through the 
capsule had negative margins of resection. Should 
the status of margins be used to differentiate 
between pT2 and pT31 
In conclusion, the occurrence of positive margins 
of resection after radical prostatectomy is associ-
ated with significantly more frequent and earlier 
progression. than in patients with negative margins. 
Longer follow-up is necessary to identify the true 
correlation and to establish whether adjuvant 
treatment is warranted in all patients with positive 
margins of resection. 
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ABSTRACT. 
Purpose: To investigate the clinical significance of vascular invasion in prostate cancer pa-
tients, treated by radical prostatectomy for clinically localized and locally advanced disease. 
Materials and methods: Vascular invasion was detennined during a routine work-up of radical 
prostatectomy specimens of273 patients who underwent surgery for prostatic carcinoma. The 
correlation with other pathological variables was investigated. The prognostic influence for 
clinical progression, local recurrence, distant metastases, biochemical progression, overall 
survival and cancer specific survival was detennined. 
Results: Vascular invasion was present in 33 patients (12%). Vascular invasion correlated 
significantly with capsular perforation, seminal vesicle invasion, positive margins of resection. 
perineural invasion, high grade, and pathological stage. Vascular invasion was a significant 
prognostic factor for clinical progression (p<O.OOI), local recurrence (p~O.007), distant 
metastases (p<O.OOI), biochemical progression (p<O.OOI), overall survival (p~O.02), and 
cancer specific survival (p<O.OOI). The multivariate analysis, adjusting for capsular perforation, 
high grade, and positive margins of resection, showed that vascular invasion was associated 
with a 2.5 fold increased risk for clinical progression. This relative risk was 2.3 for biochemical 
progression, and 2.7 for cancer specific survival. 
Conclusion: Vascular invasion is a very important pathological variable for progression and 
survival, and must be evaluated on a routine basis during the work-up of radical prostatectomy 
specimens. 
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INTRODUCTION 
The invasion of tumor cells into blood- and lymphatic vessels is generally known to be the first 
step of the metastatic process, and is associated with progression of the malignant disease '. 
The effects of vascular invasion on progression have been studied for various tumors 2,3, .. , 
indicating that it is an important prognostic factor. Only one study in the literature reports the 
effects of vascular invasion in prostatic carcinoma: Bahnson found a fourfold greater incidence 
of progression and death in patients with vascular invasion (VI) present in the radical prosta-
tectomy specimen, compared to those without VI '. Despite this finding vascular invasion is 
rarely reported in prostatic carcinoma. In 1994 the Cancer Conunittee ofthe College of 
American Pathologists advised to report vascular invasion as a routine variable in the examina-
tion of the radical prostatectomy specimen in patients with prostatic carcinoma '. 
This study aims to detennine the prognostic significance of vascular invasion in patients with 
clinically localized prostate cancer, and investigates the correlation between vascular invasion 
and the other established pathological variables. 
MATERIAL AND METHODS. 
Between 1977 and 1994, 273 patients underwent a pelvic lymph node dissection and radical-
retropubic prostatectomy for clinically localized or locally advanced carcinoma of the prostate. 
Originally, 375 patients were scheduled for surgery, but 102 patients appeared to have lymph 
node positive disease, detected by frozen sections, and therefore no radical prostatectomy was 
performed. 
Preoperative evaluatioll. This included a digital rectal examination, histological biopsy ofthe 
prostate, detennination of serum alkaline phosphatase and prostatic acid phosphatase,(from 
1987 on replaced by prostate specific antigen:PSA), a bone scan, CT-scanning of the pelvis 
and abdomen, and a transrectal ultrasonography. 
Patiellt-group characteristics. The median patient age was 63.8 years,(range 45-75 years). 
Staging was performed according to the TNM classification of 1992 7 ;twenty-seven patients 
were classified TI (9,9%); 162 as T2 (59,3%); 83 as T3 (30,4%); and one as T4 (0.4%). No 
subclassification in a,b or c was made, because of the small numbers in each group. The 
preoperative histological grading was done according to the MD Anderson system' ; 68 
patients had well differentiated carcinoma (GI:25%); 161 moderately differentiated carcinoma 
(G2: 59%); and 44 poorly differentiated carcinoma (G3: 16%). All patients were classified as 
MO. All patients underwent a pelvic lymph node dissection, before proceeding with the radical 
prostatectomy. In 9 treated patients a single microscopic metastasis had been detected in the 
lymph nodes. Because of the young age, and good health of these patients, it was decided 
intra-operatively to proceed ,vith the radical prostatectomy. In 18 patients, who had no eviden-
ce of tumor in the frozen sections, microscopic metastases were found on the paraffin sections; 
therefore 27 patients (10%) that underwent surgery had lymph node metastases. All patients 
underwent a radical retropubic prostatectomy; the technique has been described before' .In 
143 patients an attempt was made to save the neurovascular bundles: in 84 patients bilaterally, 
and in 59 patients unilaterally. In 130 patients the bundles were sacrificed, because of suspicion 
of tumor growth in the area of the bundle. No patient received adjuvant treatment. 
Pathological evaluation. The radical prostatectomy specimen was submitted in its entirety and 
cut in 5 mm thick slices, all of which were embedded in paraffine. Several 5 I,m thick slides 
91 
were taken of each slice and stained with haematoxylinleosine for pathological review. The 
parameters studied were: vascular invasion, histopathological grade (MD Anderson), capsular 
perforation, apical and lateral margins of resection, seminal vesicle invasion, perineural invasi-
on, and pT category. The pelvic lymph node specimens were embedded in paraffine and 
entirely sectioned and evaluated to detect micro metastases. All pathological infonnation was 
obtained during routine evaluation of the radical prostatectomy specimen. 
Vascular invasion was defined as unequivocal presence of tumor cells \vithin endothelial-lined 
spaces. No attempt was made to differentiate between vascular and lymphatic channels, 
because of the difficulty and the lack of reproducibility ofthese observations by routine light 
microscopic examination 10, 
FollOW-lip. The median follow-up was 49 months (range 1-206 months).Patients were foUo-
wed at regular intervals of3 months during the first 2 years; of6 months during year 3 till 5 
and once a year during further foliow-up.During each visit a digital rectal examination was 
perfonned, and serum PSA and alkaline phosphatase was detennined. Bone scanning, compu-
ter tomography and mUS-guided biopsy were only perfonned when progressive disease was 
suspected. No additional treatment was started until clinical progression was proved. 
All data were collected prospectively, and stored in a computer database which was especially 
designed for this study. 
Study endpoints and definitions. Clinical progression, local recurrence, distant metastases, 
biochemical progression, overall survival, and cancer specific survival were studied. Clinical 
progression was defined as histologically confirmed evidence of local recurrence, 
andlor the presence of distant metastases diagnosed by bone scans, ultrasonography or CT-
scanning. Local recurrence was defined as the presence of tumor cells around the bladder-
urethra anastomosis, proved by biopsy. Distant metastases were considered by the presence of 
new hot spots on the bone scan, or by other imaging techniques (ultra sonography, chest X-
rays, CT-scans). The presence of an elevated PSA alone was not considered clinical progressi-
on. Biochemical progression as a first sign of recurrent disease was defined as the first occur-
rence of two consecutive PSA values >0,1 ng/mi. To avoid biased selection of patients, only 
those were studied who had regular PSA determinations during follow-up. Therefore only the 
patients who had their first PSA measurement within 12 months afier the operation were 
evaluated for biochemical progression (n~ 173). Overall survival was defined as the percentage 
of patients who did not die of any cause at a certain time post surgery. In calculating cancer 
specific survival patients were considered \vithdrawn from study at the time when they died 
from causes not related to prostate cancer, post-operative deaths were counted as death due to 
prostate cancer. 
Statistical allalysis. The difference between the preoperative PSA of patients with and with-
out vascular invasion was tested by the Mann Whitney U-test. The relation between vascular 
invasion and the other pathological vanables was detemlined by the chi-square test. Kaplan 
Meier projections of time to clinical progression(CP),local recurrence(LR),distant 
metastases(DM),biochemical progression(BP),overali survival(OS),and cancer specific survi-
val(CSS) were used to calculate the actuanal progression and survival percentages at 5 and 10 
years.For the univanate analyses the statistical significance of differences was determined by 
the log-rank test. The Cox proportional hazards model was used to perfoml multivanate 
analyses. P-values (two-tailed)<0.05 were considered significant. 
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RESULTS 
Incidence. Vascular invasion was present in 33 (12%), and absent in 240 patients (88%) in tillS 
group of273 patients with clinically localized and locally advanced prostatic careinoma. 
Preoperative PSA. The preoperative PSA was known in 164 patients, who were diagnosed 
since 1987, when the deternlination ofPSA became a routine laboratory investigation in our 
clinic. The relation between preoperative PSA and vascular invasion is shown in table I. PSA-
values tended to be higher in patients with VI as compared to those without. The difference is 
however not statistically significant (p~O.1 0). Considering the wide range of PSA-values, this 
finding has no practical value. 
Correlation between pre-operative prostate specific antigen (PSA) and the occurrence 
of vascular invasion in 164 patients with prostate cancer. 
vascular PSA (nglml) 
invasion N 
Median range p-value* 
present 20 14.9 2.2-89.0 
absent 144 11.1 0-181.4 
p~O.1 
*: Mann Whitney U-test (two-tailed) 
Table I. 
Correlation to other pathological variables. The relation between vascular invasion and the 
other pathological variables is shown in table 2. It appears that there is a strong correlation 
between the presence of vascular invasion and the occurrence of capsular perforation, seminal 
vesicle invasion, positive margins of resection (Jateral and apical). perineural invasion. high 
grade, and advanced stage. No significant correlation was found with pN-category .. 
Progression alld survival. Clinical progression occurred in 75 patients (27%), local recurrence 
in 18 (7%), distant metastases in 45 (17%), and 12 patients had both (4%). In the group of 173 
patients who had regular PSA determinations, 66 patients experienced biochenlical progression 
(38%). During follow-up 53 patients died (19%). Of those who died 19 died of prostatic 
cancer, 3 died in the postoperative period due to complications (2 died of pulmonary embo-
lisms, one of sepsis), and 31 died of other causes not related to prostate cancer. The 6-week 
postoperative mortality was 1 %. 
Actuarial progression and sun/ivaI. The actuarial cumulative percentages for progression and 
survival are listed in table 3. The 10-year BP-rate is not evaluable, since the number ofpatients 
at that time in follow-up is too low to produce reliable results. It is evident that the presence of 
vascular invasion has a negative influence on prognosis for all parameters. The Kaplan Meier 
curves for the different outcome-parameters are shown in figure 1-6. It is clear that the presen-
ce of vascular invasion is a significantly unfavourable prognostic factor in all aspects studied. 
Multivariate analyses. Multivariate analysis of the various pathological variables regarding 
their relation with clinical progression showed that the factors most strongly related to CP 
were: the presence of VI: relative risk (RR)~ 2.5 (p~O.OOI), capsular perforation: RR~2.5 
(p~O.OI), grade 3:RR~1.8 (p~0.02), and positive margins of resection: RR~1.6 (p~0.05).ln 
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Correlation orvascular invasion and pathological variables in 273 radical prostatecto-
my specimens or patients with prostate cancer. 
vascular invasion 
pathological variable N(%)* 
absent present 
p-value (X') 
N(%)' N(%), 
capsular present 175 (64) 145 (83) 30 (17) 
perforation 
absent 98 (36) 95 (97) 3 (3) p~O.OOI 
seminal vesicle present 78 (29) 57 (73) 21 (27) 
invasion 
absent 195 (71) 183 (94) 12 (6) p<O.OOI 
positive margin present 92 (34) 75 (82) 17 (18) 
of resection 
absent 181 (66) 165 (91) 16 (9) p~0.02 
positive apex present 113(41) 92 (81) 21 (19) 
resection margin 
absent 160 (59) 148 (93) 12 (7) p~0.006 
perineural present 207 (76) 175 (85) 32 (15) 
invasion 
absent 66 (24) 65 (98) 1(2) p~0.002 
0lIl2 86 (32) 85 (99) I (I) 
pT 
3/4 187 (68) ISS (83) 32 (17) p<O.OOI 
0 246 (90) 218 (89) 28 (II) 
pN 
1/2 27 (10) 22 (82) 5 (18) p~O.28 
01 6 (2) 6 (100) 0(0) 
I 38 (14) 38 (100) 0(0) p<O.OOI 
grade 2 168 (62) lSI (90) 17 (10) 
3 61 (22) 45 (74) 16 (26) 
N~number of patients 
*=colunm percentage 
#=row percentage 
§: in 6 patients no tumor was found in the prostatectomy specimen 
Table 2. 
'addition to VI (RR~2.3; p~O.007), the only variable significantly related to BP was capsular 
perforation (RR~2.6; p~O.OI). For cancer specific survival the only other predictive factor in 
addition to VI (RR~2.7; p~0.03) was positive margins of resection (RR~2.5; p~0.05). None of 
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the other pathological variables added significant information for the occurrence of either CP, 
BP, and CSS. 
Actuarial 5 and 10 year cumulative percentages of clinical progression, local recurrence, 
distant metastases, biochemical progression, overall survival, and cancer specific survival 
according to the presence or absence of vascular invasion. 
N CP(%) LR(%) DM(%) BP(%) OS(%) CSS(%) 
vascular present 33 
invasion 
absent 240 
N~number of patients 
CP~clinical progression 
LR~local recurrence 
DM~distant metastases 
Table 3. 
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DISCUSSION. 
Vascular invasion and hematogenous dissemination Vascular invasion is one ofthe first steps 
in the development of metastases I. The metastatic process starts with invasion of the tumor 
ceHs in the periglandular stroma; the next step is tumor angiogenesis, which facilitates the 
invasion of tumor cells into the vascular spaces, because these tumor-induced blood vessels are 
fragile and highly permeable, with a discontinuous basement membrane II . After invasion of 
the blood vessels the tumor ceHs are transported by the ciculatory system, and arrest in the 
capillary bed of the target-organ, where extravasation occurs and growth in the target-organ I 
The process of vascular invasion was studied by Liotta ", who identified 3 steps: I :tumor ceH 
attachment to components of the matrix via ceH surface receptors; 2: secretion of hydrolytic 
enzymes which can 10caHy degrade the matrix; 3: tumor ceHlocomotion into the vessel. The 
basement membrane is a meshwork of type IV collagen, which can be degraded by a type IV 
collagenolytic metaHoproteinase that is identified in highly metastatic tumor cells 12.13. Tumor 
ceHs with metastatic potential represent a subpopulation with special properties II : theyare 
able to dcgrade the basement membrane and survivc the traumata of dissemination. This 
explains why only 1 of 1000 tumor cells is able to produce a metastasis I Vascular invasion 
correlates with high grade prostate cancer (Bahnson " Salomao 10, present series). The meta-
static 'subpopulation may be relatively more numerous in poorly differentiated tumors, which 
occur more frequently in the later phases of the tumor development, after dedifferentiation. 
This hypothesis may explain why distant metastases are relatively infrequent after radical 
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prostatectomy, since it is known that hematogenous dissemination occurs in 25% ofthe 
patients during radical prostatectomy, due to intraoperative manipulation of the prostate H.". 
Furthermore tumor cell clumps produce a significantly greater number of metastatic foci than a 
similar number of single tumor cells "; whether patients with intraoperative dissemination have 
tumor clumps or single cells in their circulation is not known, since the investigation was 
performed with electrophorese, following amplification of the tumor cell RNA by the polyme-
rase chain reaction technique, and not by light microscopy H. It seems that the hematogenous 
dissemination that occurs during surgery due to manipulation ofthe tumor has less impact on 
progression than the vascular invasion found by light microscopy, because the latter is due to 
invasion of a selected subpopulation with a high metastatic potential, whereas the disseminated 
tumor cells during operation can be of several different tumor cell populations. 
Neoollgiogellesis. Although prostatic carcinomas are generally not considered to be very 
vascular tumors, neoangiogenesis is a frequent event. Bigler 16 and Brawer 11 found it to be 
present in 14 of 15 patients who underwent a radical prostatectomy for prostate cancer. 
Patients with prostate cancer had a significantly higher vascular density than those with benign 
prostatic hyperplasia (BPH); they also found a different microcirculation and different morpho-
logy in BPH, as compared to prostate cancer. In BPH the localization of capillaries was at the 
interface of the glands and the stroma; in tumors the distribution of capillaries was more at 
random, depending on the site of the tumor. In BPH the vessels were uniform in size and 
caliber, whereas in carcinoma they were variable in size with tiny or inconspicuous lumens 16. 
Weidner compared the tumor angiogenesis in patients with prostatic carcinoma with and 
without metastases, by counting the microvessels within the initial invasive carcinomas IS, and 
found a significantly higher microvessel density in metastatic carcinomas. The microvessel 
counts correlated with increasing Gleason score, and added significant additional information 
for progression as determined by multivariate analysis. The observation that the microvessel 
density was greatest in poorly differentiated tumors, suggests that the highly angiogenic 
phenotype occurs relatively late in the natural history of the disease, as well differentiated 
tumors dedifferentiate to poorly differentiated tumors is. 
Incidellce o/vascular invasion The incidence of vascular invasion in the present series was 
12%. This incidence is considerably lower then reported by Bahnson' (51%), and Salomao iO 
(53%). The reasons for this are probably differences in definition, and the fact that the radical 
prostatectomy specimen in the present study was evaluated in a routine matter, without 
elaborate sampling, and without extra attention for vascular invasion. No specimen was 
reviewed for this study. Bahnson differentiated between invasion of vascular and lymphatic 
vessels, and defined invasion as presence of tumor in the lumen or cellular reaction around or 
in the lymphatic or venous channel.A differentiation was made between rare (71%), mullifocal 
(19%), and diffuse vascular invasion (10%) '. Multifocal and diffuse vascular invasion were 
present in 16% ofhls patients; this number approaches the 12% in the present series. Salomao 
defined vascular invasion as presence of tumor within endothelial-lined spaces, and did not 
differentiate between vascular or lymphatic channels. They did however differentiate between 
focal and extensive vascular invasion, the latter was present in 33%. ]n the present study 
vascular invasion was simply defined as presence of tumor within endothelial-lined spaces. 
PrognostiC significance of .. 'oscular invasion. The simplicity ofthe definition and the routine 
way in which the radical prostatectomy specimen was evaluated did not harm the prognostic 
significance. Clemente investigated vascular invasion in patients with lymph node negative 
mammary duct carcinoma and found an incidence of6.9% after routine evaluation; vascular 
invasion was a highly significant prognostic factor for progression and survival. However when 
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a randomly selected part of the specimens was reviewed with special attention given to the 
presence of vascular invasion, the incidence rose to 20%, but the prognostic significance for 
survival was lost'. Bahnson reported a fourfold increased risk for progression in patients with 
vascular invasion, compared to those without, however after adjusting for grade and pathologi-
cal stage, no additional prognostic value resulted s. In the present series vascular invasion was 
the most significant prognostic variable for CP, BP, and CSS, followed by capsular perforati-
on, high grade and positive margins of resection, as detennined by the multivariate analysis. In 
the univariate analysis vascular invasion was a significant prognostic factor for CP, LR, DM, 
BP, OS, and CSS. 
Correlatioll a/vascular invasion with other pathological variables. Vascular invasion is 
reported to correlate with high grade and advanced pathologic stage S,IO, and also with capsular 
perforation, seminal vesicle invasion, surgical margin status, and lymph node involvement 10 In 
the present series vascular invasion correlated with all evaluated pathological variables (see 
table 2) except lymph node involvement. This is surprizing, since no differentiation was made 
between vascular and lymphatic channels in this study. This means that in some cases the vessel 
involved by vascular invasion is probably a lymphatic vessel, which should result in lymph node 
positive disease and therefore a positive correlation could be expected. The reason for the lack 
of a correlation may be that the lymph node positive patients in this study-group represent a 
highly selected group of patients, with very small metastases. 
Defemlinatioll a/vascular invasion.In this series vascular invasion was evaluated during a 
routine work-up of the radical prostatectomy specimen. No special coloring of the slides beside 
the standard hematoxilinleosine coloring was necessary, and no elaborate sampling was perfo-
med. Since the majority of the vascular invasion sites are in the area of the tumor, no painsta-
king revision of slides is necessary. This means that vascular invasion can be evaluated during 
the routine work-up of the radical prostatectomy specimen, without investing extra time and 
costs, and without delay of the pathologists report. Given the highly prognostic significance of 
vascular invasion, we underline the suggestion of the Cancer Committee of the College of 
American Pathologists of reporting vascular invasion for all prostatic specimens, using routine 
light microscopic examination 6. 
CONCLUSIONS. 
Vascular invasion detennined in the radical prostatectomy specimen of patients operated for 
clinically localized and locally advanced prostate canccr is easy to evaluate, without investing 
extra time and costs. This variable correlates significantly with capsular perforation, seminal 
vesicle invasion, positive margins of resection, perineural invasion, histological grade and 
pathological stage. In the univariate analysis vascular invasion is strongly predictive for pro-
gression and decreased survival. In the multivariate analysis vascular invasion proved to be the 
most significant prognostic factor for progression and survival. Vascular invasion should be 
reported on a routine basis during examination of radical prostatectomy specimens. 
REFERENCES. 
1. Paste, G., Fidler, U.: The pathogenesis of cancer metastasis. Nature, 283: 139, 1980. 
100 
2. Clemente, C.G., Boracchi, P., Andreola, S., DelVecchio, M., Veronesi, P., Rilke, F.O.: 
Peri tumoral lymphatic invasion in patients with node-negative mammary duct carcinoma. 
Cancer,69: 1396, 1992. 
3. Chodak, G.W., Haudenschild, C., Gittes, R.F., Folkmans, J.: Angiogenic activity as a 
marker of neoplastic and preneoplastic lesions ofthe human bladder. Ann. Surg., 192: 
762, 1980. 
4. Sillman, F., Boyce, J., Fruchter, R.: The significance of atypical vessels and neovasculari-
sat ion in cervical neoplasia. Am. J. Obstet. Gyneco!., 139: 154, 1981. 
5. Bahnson, R.R., Dresner, S.M., Gooding, W., Becich, MJ.: Incidence and prognostic 
significance of lynlphatic and vascular invasion in radical prostatectomy specimens. The 
Prostate, IS: 149,1989. 
6. Henson, D.E., Hutter, R.U.P., Farrow, G.: Practice protocol for the examination of 
specimens removed from patients with carcinoma of the prostate gland. A publication of 
the Cancer Committee, College of American Pathologists. Arch. Patho!. Lab. Med., 118: 
779, 1994. 
7. U.I.C.C.: TNM classification of malignant tumours. 4th edition, second revision. New 
York: Springer, 1992. 
8. Brawn, P.N., Ayala, A.G., Von Eschenbach, AC., Hussey, D.H., Johnson, D.E.: histolo-
gic grading of prostate adenocarcinoma. The development of a mew system and compa-
rison with other methods. A preliminary study. Cancer, 49: 525, 1982. 
9. Schroder, F.H.: Radical retropubic prostatectomy. In: Genito-urinary surgery, 5th 
edition. Edited by H.N. Whitfield. Oxford. Butterworth-Heinemann. Vo!.lII, 419-434, 
1993. 
10. Salomao, D.R., Graham, S.D., Boshvick, D.G.: Microvascular invasion in prostate 
cancer correlates ,vith pathological stage. Arch. Patho!. Lab. Med., 119: 1050, 1995. 
II. Blood, C.H., Zetter, B.R.: Tumor interactions with the vasculature: angiogenesis and 
tumor metastasis. Biochim. Biophys. Acta., 1032: 89, 1990. 
12. Liotta, L.A.: Tumor invasion and metastases-role of the extracellular matrix: Rhoads 
memorial award lecture. Cancer Res., 46: I, 1986. 
13. Liotta, L.A, Tryggvason, K., Garbisa, S., Hart, I., Foltz, C.M., Shafie, S.: Metastatic 
potential correlates ,vith enzymatic degradation of basement membrane collagen. Nature, 
284: 67, 1980. 
14. Oefelein, M.G., Kaul, K., Herz, B., Blum, M.D., Holland, J.M., Keeler, T.C., Cook, 
W.A, Ignatoff, J.M.: Molecular detection of prostate epithelial cells from the surgical 
field and peripheral circulation during radical prostatectomy. J. Uro!., ISS: 238, 1996. 
101 
15. Liotta, L.A., Kleinerman, J., Saidel, G.M.: The significance of hematogenous tumor cell 
clumps in the metastatic process. Cancer Res., 36:889, 1976. 
16. Bigler, S.A., Deering, R.E., Brawer, M.K.: Comparison of microscopic vascularity in 
benign and malignantprostate tissue. Hum. Pathol., 24:220,1993. 
17. Brawer, M.K., Bigler, S.A., Deering, R.E.:Quantitative morphometric analysis of the 
microcirculation in prostate carcinoma. J. Cell. Biochem., suppJ. 16H:62, 1992. 
18. Weidner, N., Caroll, P.R., Flax, J., Blumenfeld, W., Folkman, J.: Tumor angiogenesis 
correlates with metastasis in invasive prostate carcinoma. Am. J. Pathol., 143:401, 1993. 
102 


PART 3 
LYMPH NODE POSITIVE PROSTATIC 
CANCER: INFLUENCE ON PROGRESSION 

CHAPTERS 
Deoxyribonucleic acid ploidy of core biopsies and metastatic lymph 
nodes of prostate cancer patients: impact on time to progression. 
D. van den Ouden, B. Tribukait, J.H.M. Blom, S.D. Fossa, KH. Kurth, 
F.J.W. ten Kate, T. Heiden, N. Wang, F.H. SchrOder, and the EORTC-
Genitourinary Group. 
Department of Urology, Erasmus University and Academic Hospital 
Rotterdam; Department of Urology, University of Amsterdam and 
Academic Hospital Amsterdam, the Netherlands; Department of 
Radiobiology, Karolinska Institute, Stockholm, Sweden; Department 
of Radiotherapy, Norwegian Radium Hospital, Oslo, Norway. 
Journal of Urology, 150: 400-406, 1993. 
DEOXYRIBONUCLEIC ACID PLOIDY OF CORE BIOPSIES AND 
METASTATIC LYMPH NODES OF PROSTATE CANCER PATIENTS: 
IMPACT ON TIME TO PROGRESSION 
DIES VAN DEN OUDEN, BERNHARD TRlBUKAIT, JAN H. M. BLOi\·I, SOPHIE D. FOSSA, 
KARL H. KURTH, FIEBO J. W. TEN KATE. THOMAS HEIDEN, NAIXING WANG, 
FRITZ H. SCHRODER AND THE EUROPEAN ORGANIZATION FOR RESEARCH AND 
TREATMENT OF CANCER GENITOURINARY GROUP 
From the Department of Urology and Nephrowgy, E."mmus Uniwrsily and Accdemic Hospital, Rotterdam and J)qxlrtment of Urology, Academic 
Medical Center, Unit'enily of A1715ferdam, Amsterdam, The Netherlands; Department of RtJdiOOiology, KarofillSm Instilllle, Stockholm, Su:eden, 
and D'pGf/rnenl r;/ Radiolheupy, Noru.'egian Radium Hospital, Oslo, NO,/J;<lY 
ABSTRACT 
We studied 98 patients with locally confined but lymph node positive prostatic cancer (l stage 
TI, 29 stage T2, 55 stage T3 and 2 stage T4) who were not treated by radical prostatectomy. A 
retrospective analysis was done of deoxyribonucleic acid (DNA) ploidy of pretreatment core biopsies 
of the primary tumor and lymph node metastases. While DNA ploidy has been shown to be an 
important prognostic factor if applied to radical prostatectomy spedmens, core biopsy specimens 
and nodal metastases have rarely been studied. Of the 98 patients 87 Were evaluable for DNA ploidy: 
45 (52%) had diploid, 13 (15%) had tetraploid and 29 (33%) had aneuploid tumors. The ploidy of 
the primary tumor and of the lymph node metastases correlated significantly with the rate of 
progression and interval to progression. Also, significant correlations were noted between the 
percentages of cells in the S phase or S plus G2 phases of the cell cycle and interval to progression. 
~'Iost patients in this study are part of the European Organization for Research and Treatment 
of Cancer protocol 30846, a prospective randomized study of early versus delayed treatment in 
lymph node positive, othenvise locally confined prostate cancer. This study is ongoing. Early 
endocrine treatment was associated with a significantly longer interval to progression. In a Cox 
regression analysis of the prognostic factors involved in this study, early endocrine treatment was 
more important than ploidy Or proliferation patterns. Stage (T category) and histopathological 
grade did not show a correlation with progression. Followup is still too short and the numbers of 
patients are too small for relevant subgroup analysis. 
DNA ploidy measurement by flow cytometry On archival (paraffin embedded) core biopsy and 
lymph node material is possible, and produces meaningful results in predicting the prognosis of 
prostatic cancer. Since this information can be made available before treatment decisions, its exact 
value in the management of locally confined prostate cancer can be determined. 
KEY WORDS: DNA, neoplasm; prostatic nMplasms; ploidi~s; lymph nodes; bio~-y 
The patient material collected y,ithin the institutions in-
volved in the European Organirotion for Research and Treat-
ment of Cancer (EORTC) protocol 30846, which compares early 
versus delayed endocrine treatment in lymph node positive 
prostatic cancer, offers a unique opportunity to compare prog· 
nostic factors that relate the primary tumor and the lymph 
nodes in node positiVe prostate cancer patients. Most recent 
articles on deoxyribonucleic acid (DNA) ploidy of prostate 
cancer are related to ,adical prostatectomy specimens.1•1 Only 
a few investigators report on the ploidy of lymph node 
metastases~ and prostatic aspiration biop5ies.~-u Recently, 
static cytometry on core biopsies was described, n whereas no 
information is yet available of flow cytometry on core biopsies. 
Only 1 report re\'iewed in the literature refers to a comparison 
betwe~n the ploidy of the primary tumor and lymph node 
metastases?" 
DNA ploidy can be determined in fresh or paraffin embedded 
material. The latter method enables the analysis of larger series 
with several years of followup, Se"'eral im'estigators have de· 
scribed the technical difficulties encountered in determining 
DNA ploidy on histological biopsy specimens. To establish 
DNA ploidy as an important, clinically useful prognostic factor, 
it will be necessary to show prognostic relevance for ploidy 
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determinations on biopsy specimens rather than on radical 
prostatectomy specimens, which .... ill only be available after 
treatment decisions ha\'e already been made. Considering the 
setup of EORTC protocol 30846 and the treatment policies 
fol!owed at the involved institutions, radical prostatectomy is 
not done in the presence of lymph node metastases. Patients 
with positive lymph nodes are either randomized to early en· 
docrine treatment versus delayed endocrine treatment or are 
treated according to their personal preference. 
Considering the eXisting controversy On whether early or 
delayed endocrine treatment might be more effecti\'e, it will be 
important to be able to correct for relevant prognostic factors, 
such as ploidy. In fact, Myers et al produced long· term folloy,'Up 
data comparing ploidy, and early and delayed endocrine treat· 
ment with progression and survi\'al rate3,1 Unfortunately, our 
folloy,up is short and amounts to an average of 32 months 
(range 2 to 115). For this reason the interval to progression is 
used as the end point for reporting in om study. 
More and more evidence is accumulating that the size of the 
primary tumor and other related parameters are important 
prognostic factors, at least in locally confined disease. Tumor 
volume calculated on radical prostatectomy specimens corre-
lates with the grade of malignancy, incidence of lymph node 
metastases, peripheral prostate specific antigen (PSA) levels 
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and incidence of metastases as shown by Stamey et al. 21 Ho ..... -
ever, there is also evidence that the primary tumor progression 
rate and response to endocrine treatment are different from 
those of distant metastases. Carpentier et al haw shown that 
while 20 patients who were observed prospecti\'ely showed 
progression to metastatic disease, only 2 of those had local 
progression during the same period {24 months).n Also, the 
EDRTC Genitourinary Group protocol 30761 demonstrated 
different response and progression rates of the primary tumor 
as compared to distant metastases.'lJ The different behavior of 
the primary tumor under treatment, especially under endocrine 
treatment, may also eventually limit the prognostic significance 
obtained from biopsies or radical prostatectomy specimens. 
In our series the feasibility of using archival core biopsies for 
flow cytometry is studied, and the results are compared to 
ploidy in lymph node metastases in the same patients. Fur-
thermore, the significance for the rate of progression and in-
terval to progression of ploidy and S phase or S plus G2 
percentages of cells is determined in primary carcinoma and 
lymph node metastases. 
these data are incomplete and the numbers are too small to be 
meaningful. 
Core biopsies. In each patient 4 biopsies were obtained trans-
perineally, using a 14 gauge Tru-Cut· needle. The specimens 
were fixed in formalin and embedded in paraffin. AU specimens 
were investigated by a reference pathologist and the histopath· 
ological grade (according to the Mostofi system) was deter-
mined. Biopsy material was a\'ailable in 54 cases, 53 of which 
(98%) were evaluable. 
Transureth ral resection material. A total of 18 patients under-
went resection of the prostate before entering the study. Of 
these patients 10 were evaluable for ploidy analysis. Unfortu-
nately, no core biopsy material was available in these patients. 
Lymph node metastases. This material was obtained by peh'ic 
lymph node dissection in 72patients. A totalof87 lymph nodes 
containing metastases and 39 normal lymph nodes was inves-
tigated, 
DNA ploidy determinations. DNA flow cytometry of primary 
tumors and/or metastases was evaluable in 87 of 98 patients. 
The most undifferentiated part of the tumor was identified by 
light microscopy and used for DNA ploidy determination, 
MATERIAl.. AND METHODS For the preparation of suspensions of cell nuclei, a modifi. 
Patients. Between 1981 and 1991, 98 patients with lymph cation of the basic Hedley method was used.27 Sections (100 ~.) 
node positive prostate cancer were studied; 87 of them had of the paramn blocks were placed into fine mesh bags, which 
evaluable ploidy measurements and were included in this study. were placed into a cassette, and then dewaxed and rehydrated 
The lymph node status was determined by pelvic lymph node in a tissue processor, Enzymatic digestion was done with 
dissection in the area between the bifurcation of the common Subtilisin Carlsberg (Sigma Protease Type XXIV) and all 
iliac artery, entrance of the lacuna vasorum, external iliac win centrifugation steps were omitted. In this manner cell loss was 
and obturator \·essels. According to the tumor, nodes and minimized, and nuclei suspensions with extremely low smounts 
metastasis system of 1978/1982, which is used throughout this of clumped nuclei and debris were obtained. The nuclei were 
report, 34 patients were classified as having stage N1, 48 stage stained with DAP!. final concentration 6 ~M., and analyzed 
N2 and 3 stage N3 disease,u In 2 patients the N category was with a PAS llt flow cytometer. The representatj\'eness for 
unknown. The dinical stage was TI in 1 patient, T2 in 29 tumor cells of the tissues used for preparation of the cell 
patients, 'f3 in 55 patients and T4 in 2 patients. Four patients suspensions from the blocks was determined in a contiguous 6 
had a well differentiated (grade I), 46 a moderately differen- ~m. section, In addition, the proportion of tumor cell nuclei 
liated (grade 2) and 37 a poorly differentiated (grade 3) carci- was counted in an aliquot of the stained suspension of nuclei 
noma. Mean patient age was 63.9 years (range 41 to 80). Dflhe by light microscopy. The mean ratios of tumor cell nuclei per 
98 patients 81 are included in EORTC protocol 308-16. This normal nuclei were 32% (range 2 to 95%) for prostatic biopsies 
protocol was reviewed and approved by the Protocol Review and 75% (range 18 to 88%) for lymph node metastases, respec-
Committee of the EORTC. In this study patients are random- tively. To confirm the ploidy of the near diploid aneuploid cell 
ized between immediate and delayed endocrine treatment. In populations the DNA content of identified nuclei from normal 
the delayed group endocrine treatment is initiated at the time and malignant cells was measured by means of a static image 
of objecti\'e progression. Since delayed endocrine treatment analysis system. Tumors were considered diploid if only 1 01 
wasonlyinitiatedafterprogressionoccurred,delayedendocrine peak was present. For determination of the DNA index in 
treatment patients in this evaluation are untreated. This grossly aneuploid cell populations the first peak to the left was 
EORTC study is unfinished; survival data and other results of assumed to represent diploid cells. Samples with peaks in the 
this protocol will be subject to reporting after completion of tetraploid position (DNA index 1.95 to 2.05, more than 15% of 
the protocol. A total of 17 patients received eariy endocrine the total cells) and a corresponding octoploid G2 peak were 
treatment outside the EORTC protocol. classified as tetraploid. This 15% boundary was arbitrarily 
Fo/lou·up. Patients were followed by their own urologist at 3- chosen because no core biopsies from benign lesions of the 
month intervals during the first 2 years and e\'ery 6 months prostate were twailabJe to determine the normal range of G2 
during further followup. Followup consisted of physical exam- values. 
ination, including digital rectal examination, ultrasonography For the deter mination of the percentage of cells in the S plus 
of the prostate (not at all centers), and determination of serum 02 phases of the cell cycle the multicycle program by 
alkaline phosphatase, prostatic acid phosphatase (PAP) or PSA Rabinovitch was used. The usliced·nuclei" option of the pro· 
le\'eI5. The latter was determined only after it became a routine gram applied pro\'ides a background fit model, which includes 
laboratory investigation in 1987. Computerized tomography a compensation for the effects of cutting of nuclei during 
and bone scanning were done only on indication of increasing sectioning of the paraffin embedded samples.21 
serum markers or specific complaints of the patients.21. l ' Pro- In suspensions of cell nuclei prepared from aneuploid primary 
gression was defined as the occurrence of metastases, proved tumors and aneuploid metastases the proportions of aneuploid 
by physical examination, bone scans and imaging. An elevation nuclei as measured by flow cytometry were compared with the 
of serum markers alone was not considered as progression. proportions of microscopically identified tumor cell nuclei. 
Prognostic parameters. The prognostic parameters studied Mean values were 30 ± 29% (range 1 to 95) for flow cytometry, 
are the T category according to International Union Against and 50 ± 30% (range 2 to 93) for microscopical counts. The 
Cancer criteria of 1982, histopathological grade according to difference in the indh'idual tumors between the results of the 
the Mostofi system, early versus delayed endocrine treatment, 2 counts was highly significant (p <0.001). On the average, an 
ploidy, and the proportions of S phase cells and S plus G2 aneuploid tumor with 30% aneuploid cells thus contains in 
phase cells determined by DNA flow cytometry, PSA was not addition 20% of diploid tumor cells. Particularly in tumors with 
evaluated because it was not yet available for routine use at all • Tra\'eno! Laooratoties. Deelfield, Illinois. 
participating centers at the initiation of this study, Therefore, f Partee, Miinstff, Federal R~pubHc of Germany. 
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tetraploid DNA content, a large number of diploid tumor cells 
were observed. Cell loss can be excluded, since flow cytometry 
and measurement of tumor ceU nuclei were done in the same 
cell nuclei suspension. 
Stotis/ica/ me/hods. Interval T to progression was estimated 
by the Kaplan-Meier technique.n Differences between cur .... es 
were evaluated for statistical significance using the log·rank 
test. The prognostic variables were analyzed by the Cox 
regression analysis. 
RESULTS 
Among the 98 patients ploidy was not evaluable in 11: in 5 
no adequate histological matedal was available and in 6 the 
DNA histogram was of poor quality. These patients .... -ere ex' 
cluded from the evaluation of ploidy. In the overall analysis 
tumors are considered diploid if the primary tumor and lymph 
nodes or, in case of lacking information, 1 of the samples (either 
the primary tumor Or the lymph nodes) was classified as diploid. 
In case of a mixed result the poorer ploidy was always used as 
definitive classification. In the 87 patients in whom either the 
ploidy of the primary and/or the ploidy of the lymph nodes 
were evaluable the tumors were classified as diploid in 45 (52%), 
tetraploid in 13 (15%) and aneuploid in 29 (33%). Figure 1 
shows representative DNA histograms for diploid, tetraploid 
and aneuploid tumors. 
The ploidy of the primary tumor was evaluable in 63 patients: 
36 (57%) had diploid, 15 (24%) tetraploid and 12 (19%) aneu· 
ploid tumors. Among 87 evaluable lymph nodes in 71 pati~nts 
th~ ploidy was determined as diploid in 54 (62%), tetraploid in 
8 (9%) and aneuploid in 25 (29%). All samples from 39 normal 
lymph nodes were diploid. 
In 46 patients the ploidy of the primary tumor and the lymph 
node metastases could be obtained. A comparison of the clas· 
sification by ploidy is given in table 1. Of the diploid and 
aneuploid primary tumors 8.1% and 89%, respectively, had 
equally classified metastases. In ea<:h of the 25 diploid primary 
tumors and the 27 diploid lymph node metastases 1 aneuploid 
cell population was found. In the tetraploid primary tumors, 
however, a wide variation of the ploidy of the lymph node 
metastases is ob\,tous. Nonrepresentative cell material of the 
primary tumor or further clonal development of the tetraploid 
lymph node metastases can be discussed. When diploid and 
tetraploid are combined into 1 group conformity is noted in 
86% of the samples. 
When ploidy was compared to T category, grade and nodal 
status, no statistically significant Or clinically relevant corre· 
lations could be found. However, there wasa trend toward more 
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FIG. 1. DNA histograms repre;entati\·e of diploid fA), tetraploid (B) and aneuploid (e) tumors. 
TABlE 1. PlOidy ra[ue of 46 primar)' tumor .. and their lymph node 
metll$tll$e .. 
Lymph Node )"IHil.l!"--~$ 
Primar}' 
Total; Tum·Jr. D;ploid Tetraploid Aneuploid 
No.(,<) '-:0. ('<) /'{o_HH 
Diploid 21 (S-H 3 (\"2) lW 
" Turap!old 5(421 2 (16) 5 (421 
" Aneuploid IIIIl 8 (&91 , 
Tot.\; r,- -,- rr-
" 
extensi\'e growing tumors being aneuploid more frequently than 
locally confirmed tumors. Aneuploid tumors were, however, 
equally distributed between moderately differentiated and un. 
differentiated lesions. No meaningful correlation with the N 
status (Nl, N2, N3) was noted. 
Prognostic factors and infen·at to progression. Of the 87 
patients available 3 died of cancer of the prostate and 1 died 
intercurrentiy. Mean follov.1Jp was 33.4 months (range 3 to 
116). The results from the bh'ariate analysis of the various 
progl'lostic factors are listed in table 2. 
T category and histopathological grade. Tumors of stages Tl 
and T2, and stages T3 and T4 were combined into 2 groups. 
The 4 patients with grade 1 tumors were combined with those 
with grade 2 tumors. No statistically significant differences for 
stage and grade were found. 
Ploidy of the primary tumor. In 63 patients in whom the 
ploidy of the primary tumor was known the influence of the 
ploidy classification of diploid, tetraploid or aneuploid on in. 
ten'al to Progression was tested. There was no significant 
difference in interval to progression between diploid and tetra. 
ploid (p = 0.47), and between tetraploid and aneuploid (p '" 
0.l8) but a significant difference was found in the comparison 
of the diploid and aneuploid groups (p = 0.02). When the 
diploid and tetraploid groups were combined and tested against 
the aneuploid group, a significant difference was also noted 
(p = 0.023, fig. 2). 
The percentage of celts in the S phase in primary tumor. As a 
measurement of proliferation, the percentage of cells in the S 
phase of the cell cycle was evaluated in the primary tUmors of 
54 patients. The mean values and range in relation to the 
different ploidy classifications are listed in table 3 together 
with the corresponding values for G2 cells of t he cell cycle. It 
can be seen that the mean numbers of cells in the S phase 
increased from 0.7% in the diploid to 5.2$0 in the aneuploid 
cell populations. When a division is made into 2 groups, 1 group 
with an S phase percentage of cells of 4.0% or less and 1 group 
with an S phase percentage of more than 4%, a significant 
difference is found for inten'al to progression (p = 0.013). 
When the values for S phase and the G2 cells of the cell cycle 
were combined, and a division was made into 2 groups with 
percentages of S plus G2 cells of 6% or less and greater than 
6%, again a significant difference was found for interval to 
progression (p = 0.0015, fig. 3). 
Ploidy of lymph node metastases. A similar pattern was ob· 
sen'ed in the 71 patients with known ploidy of the lymph node 
metastases. When interval to progression was compared for 
diploid versus tetraploid and tetraploid \'ersus aneuploid tu· 
mors, no significant differences were found (p = 0.8.1 and p = 
TABLE 2. Bit-ariar .. analysis of ~'arioU$ prognostic fat/ors for inlen'al 
to progre;sion 
Factor< No. Cni·Sq",,~ P Value 
Tn<tapy (eady n. d<JayKl en· 81 17.59 0.0001 
d<xrin~lh."'pyl 
M...:Iian age (65 or !e" "~. mOre 81 
'''' 
0_25 
tnan (5) 
Primar)' tumor; 
Stag~ tTl + 2, ... iJ + n) 81 
."" 0.9~ GracleO+2H_31 
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O_~~ 0.46 
Ploidy (diploId + UtrJp!oid 
'" 
5.t7 0_013 
,s.antup!oid'j 
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" 
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FIG. 2. Kaplan-Meier cUPo'eg for interval to pwgression in 48 pa· 
tients with diploid or diploid-tetraploid (-land 15 v.ith aneuploid 
(. - - •• ) primary tumors. Numbers in parentheses indicate number of 
patients at risk at certain time. 
TABLE 3. Rdolulriship bflueen the percentage 0/ ails in the S and G2 
phll$es 0/ the (fll c)de and the ploidy cfu..'sllicoliQII in 54 primory 
lumor .. 
Ploid,· No. S Phase' (range) G-2 Phase' /range) 
Diploid 
" 
0.7 ± 0.7 lO.1-3.11 n ± 2.5 (0.:2-13.2) 
Tetraploid 12 3A ± 1.3 ([,8-5.9) 2.1 ± 1.6 (().i-Sm 
AMuploid 13 5.2 ±:H 0.8--13.8) U ± 3.2 1O.2-9.6J 
• :\(un ph15 or minu. otandard delia!ion. 
0.32), The difference between diploid and aneuploid tumors 
was again significant (p '" O.039IJ. Combining the diploid and 
tetraploid groups and testing them against the aneuploid group 
also resulted in a significant difference (p = 0.0348). 
The percentage of cdls in the S phase in lymph node metas-
tases. A similar pattern is observed in the 66 patients with 
lymph node metastases in whom the percentage of cells in the 
S phase could be e\·aluated. The mean \'a[ues and ranges are 
shown in table 4 in relation to ploidy. The values from 39 
benign lymph nodes are included for comparison. The mean 
number of ce1ls in the S phase increases from 1,4% for diploid 
to 3.9% for aneuploid cell lines. When a division is made 
between groups with S phase percentage of 4% or less and 
greater than 4%. a significant difference is found (p = 0.005) 
for interval to progression (table 2). By combining the percent-
ages of S phase and G2 cells, and taking 6% as the dividing 
A 
'" 
80 
\ '''' S 
" 
[1 10 
" l.. .. ,) 
'" " 
0 
no 1. ~ 
20 ~·OOll 
0 
0 , 6 
" YEARS 
line for the 2 groups, the signifiC'ance for the interval to pro-
gression further increased {p =- 0.000-0. 
Early L'efSUS delayed endocrine treatment. A highly significant 
difference in interval to progression resulted when patients 
receiving early endocrine treatment were compared to those in 
whom treatment was delayed (p = 0.0001, fig. 4). Since delayed 
treatment was only initiated at the time of progression, the 
patients in the delayed endocrine treatment group were un-
treated up to this point. 
Regression analysis. A Cox multivariate regression analysis 
for the different prognostic factors for interval to progression 
re\'ealed that therapy is the most import<'lnt factor_ This was 
the case for progression of the primary tumor and for progres-
sion to distant disease, with p values of 0.004 and 0.0057, 
respectively. 
Irrespecti\'e oflhe treatment, the ploidy ofthe primary tumor 
was significantly correlated with progression (p "" 0.0107). 
However, this was not the case for the ploidy of lymph node 
metastasis (p = 0.25). The S plus G2 phase percentage of cells 
(~6.0% and >6.0%) showed significant differences for time to 
progression in lymph node metastases (p = 0.03), but not in 
the primary tumors (p = 0.35). Clinical stage and grade, in 
confirmation of the results of the mon-ovariate analysis, did not 
reach significance in the regression analysis. 
The 37 patients in the early endocrine treatment group wele 
subjected to a separate regression analysis. In this group, ploidy 
was a significant predictor of progression in the primary tumor 
and in the lymph node metastases (p = 0.02 and p = O.O·i). 
Also. the S plus G2 percentage was significant for lymph node 
metastases (p =- 0.02) but not for the primary tumors (p = 
0.095). Clinica I stage and grade again did not reach significance. 
DtSCUSSiON 
DNA ploidy of the primary tumor in locally confined prostate 
cancer and in lymph node positive disease has been shown to 
be an important, if not the most important. prognostic factor. 
Relevant data are summarized in table 5.2-$·1.8.0. 2"1·)) However, 
most of the information on ploidy has been obtained on radical 
prostatectomy specimens. Obviously. this information is only 
available after treatment decisions have aheady been made. It 
is unknown at this moment how reliably DNA ploidy can be 
determined on biopsy material by flow cytomelry, especially on 
core biopsies. Ideally, DNA ploidy determined on core biopsies 
should be compared for this purpose with DNA ploidy deter-
mined on radical prostateetomy specimens. In our study the 
policy was not to remove the prostate in case of the presence 
ofIymph node mela:Hases. These lymph node metastases wele 
available for comparison with biopsy material of the primary 
tumor. This material and all clinical information were collected 
within a prospective randomiled EORTC protocol. The data 
were under EORTC policy subject to external quality control. 
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TABLE ~. Relationship betu:een the f'€rcentoges at cd/s in the S (llld 
G2 phllSe5 at the c~1I C}'Cle (lIld the plaidy t/rusi/iCiltian in 66 lymph 
node metol5taseS and 39 benign, diploid I>'mph nodes 
Ploidy 1\0. S Phllt' (range) G2 Pha.!e' (range) 
Dip!oid 
" 
1.4 ± 0.1 WA-3.8) 1.3 ± 0,' (0.2-3.3) 
Tmap!oid , 2.1 ± 1.8 (0.1-4.~) 1.8 ± 1.1 (O.1~5.3) 
Aneuploid 
" 
3.9 ± 3.\ {0.7-12.01 3.0 ± 3.6 (0.3-16.2) 
Benign 
" 
0.9 ± 0.6 (0.3-1.7) 0.5 + 0.2 (0.1-1.5) 
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FIG. 4. Kaplan·M~ier CUrves for interval t(l progression in 50 pa-
tients who received ~arly (_) and 34 who ucel\"ed delayed ( .••• -) 
endocdne treatment. 
OUr results show that the determination of DNA ploidy on 
core biopsy material is technically feasible. The results correlate 
v.ith DNA ploidy obtained from lymph node metastases and 
with inten'al to progres,;ion. The distribution of DNA ploidy 
for primary tumors, primary tumor biopsies and lymph node 
metastases that were found in the literature are shown in table 
5.H1.s,u.n.:n Our results have been added to this table. Db· 
viously, there is considerable variation of the distribution of 
ploidy from series to series. Since tumor stage and grade are 
significantly related with ploidy,1 1 differences in stage and grade 
by selection of the tumors studied must be one of the main 
reasOns for the differences in ploidy composition of the various 
series. In our im'estigation patients with manifest distant me· 
tastases were excluded. The frequency of distant metastases in 
relation to ploidy of the prostate has been studied pre\'iously 
in 490 patients with newly detected carcinomas. The frequency 
increased from 7% in diploid and 17% in tetraploid tumors to 
28% and 52% in those with 1 Or multiple cell populations"~ 
Thus, exclusion of patients with distant metastases in our series 
resulted in a predominance of diploid tumors but of relati\'ely 
high grade and stages-43% of the tumors were poorly differ· 
entiated and 66% were stage T3 or more. Another possible 
explanation may result from the variation in the percentage of 
tetraploid cases in the different investigations. A reason for 
this finding is that there is no uniform definition for the 
assignment of tetraploidy. However, this uncertainty is more 
likely to inOuence the rate of diploid cases diagnosed. It is 
remarkable that the inter laboratory "ariability in DNA ploidy 
determination is slight. Still, technical variations and differ-
ences in interpretation may lead to a different allocation of 
ploidy in 10 to 15% of the case$.~l The 15% boundary for 
tetraploidy in our study was chosen arbitrarily be('ause no 
normal range of G2 values was known for core biopsy material. 
The boundary for stage D1 prostate carcinoma of the ~Iayo 
Clinic report was 1:1%, which therefore can only partly explain 
the lower proportion of tetraploid tumors in our study (15%) 
c<lmpared with the Mayo Clinic material (45o/c).' 
We found that all tetraploid tumors contained large popula· 
tions of diploid cell lines and that, in the analysis for prognostic 
importance, tetraploid tumors can best be combined with dip. 
loid tumors. Montgomery et al also found no significant differ· 
ence in progression rates between diploid and tetraploid card· 
nomas.l1 The high percentage of aneuploidy as found previously 
in a large number of unselected high grade, high stage tumors l7 
was not found in our study. Stephensonet al also studiedlymph 
node metastases and found a rate of aneuploidy that is similar 
to our study.8 
A major concern in using biopsy material to determine plOidy 
is whether the tissue or cells obtained are representative for 
the tumor as a whole. Pleomorphism has been shown by MiilIer 
et ailS and several others to be the reason for under grading of 
radical prostatectomy specimens by means of core biopsies. In 
this situation grade 3 tumors may frequently be missed. The 
possibility of missing aneuploid tumors with core biopsies must 
be im'estigated further. Our data, which confirm a good corre-
lation between the ploidy in biopsies and the ploidy in lymph 
node metastases, do not suggest an under determination of 
aneuploidy by core biopsy. The data are documented in table 
1. 
At least in EUrope, aspiration biopsy of the prostate is still 
done frequently and is considered to be an important diagnostic 
tool. 'The possibility has been raised that cell sampling is more 
emcient and representative for the whole of a gi~'en tumor than 
core biopsy. Adolfsson et al found a significant correlation 
~tween ploidy and interval to progression in 146 untreated 
low grade, low stage tumors with the use of fine needle aspira-
tion biopsy,u 
In our study a significant correlation between DNA ploidy 
determined by means or archival material of core biopsies and 
interval to progression is described. This finding reproduces 
the results of studies using radical prostatectomy specimens for 
retrospective analysis and shows that the pretreatment evalu· 
ation of DNA ploidy by flow cytometry is feasible. In our series 
of lYmph node posith"e patients the T category and grade of 
differentiation of the primary tumor were not shown to be 
relevant prognostic factors. Also, there was no strong correia· 
tion between DNA ploidy, and the T and 0 categories. 
In our series the significance of proliferation for interval to 
progression was also found for the parameter of the proportion 
of cells in the S phase or S plus 02 phases of the cell cycle. A 
highly statistically significant separation was achieved when 
patients were separated according to a percentage of cells in 
the S phase Or S plus G2 phases of 4% Or less and mote than 
4%, and 6.0% or less and greater than 6.0%, respecti\"ely. These 
findings were confirmed in the lymph node metastases. More 
recent techniques aHow the determination of the proliferating 
fraction of primary tumors by use of the antibody Ki·67 react· 
ing with a protein that is not expressed in the GO phase of the 
cell cycle. Subsequent to preliminary studies/oS attempts to 
correlate this parameter to ploidy and to the percentage of cells 
in the Sand G2 phases of the cell cycle are in progress. Scrivner 
et al did DNA flow cytome!ry and bromodeoxyuridine labeling 
on 44 fresh biopsies of prostatic carcinoma, of which 37 were 
evalllable.37 They found a significant correlation between the 
bromodeox-YUIidine labeling index and the DNA index but not 
between the labeling index and the percentage of cells in S plus 
G2 phases, as determined by flow cytometry. As an explanation 
in this study the high noise·to·signal ratio and the inability to 
discriminate between neoplastic and nonneoplastic cells was 
offered" No fol\owup data on the patients recruited to this study 
are available. 
Early endocrine treatment turned out to have the strongest 
impact on interval to progression of all parameters analYled in 
this study. This finding is not surprising and confirms a pre· 
vious report from this institution.M However, this difference 
was never demonstrated previously in a prospective randomized 
fashion. Myers et a1 studied DNA ploidy in 62 stage 01 cancer 
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TABLE 6. DNA ploidy analysis, irlck/eMe, material inre$ligalwn aM progMstit significance for progression oM/or SUfVit'a/ jn prostate caMet 
Reference No. PIS. Materiallnn~tigAted 
" 
fordham el a!' 72 Radicd prostatf(tomy 
Winkln et aI' 
" 
Radiul prol!A!f(!Omr 
Ritchieet aI' 
'" 
RadiNI prOst.lll'<lomy 59 (54) 
Nativet .01" 
'" 
Radical proltatl'<tomy 67(6) 
Mon!gorne!), Hal" 
'" 
Radical prolt.t~lomy In (63) 
M)·tr!dal' 
" 
Radical ptoitatl'<tomy 14 (SO) 
9 (26) 
Zincke et alu 370 Radkd proltat~tom)' 138(371 
Ado!f •. son et a1" 
'" 
Aspiration biop,y WB7) 
Stepbenwn d al' 52 L)Olph node me!a!la~. 33 (~O) 
Mdntir~.ta!" 39 Transurdhralres«tiQn 10 (91) 
cbips 13(59) 
Nonaneuploid 
Lundberg et aI" 
" 
Tran.urttbral re~~lion 19 (33) 
57e,'atu.te<! chips, (25), tn,,,,· .. ;_ 
cal 1es«lion (79) 
Ptt><1nt suiu ., Tro·Cut biopsy 3$ (57) 
" 
L)"Il1pb r.od. melasta ... M (62) 
• Early endocrine treatment. 
t Ddayed end«rine treatment. 
patients treated with radical prostatectomy and early or delayed 
endocrine treatment, with a median follo .... llp of greater than 
10 years: The subgroup analysis showed a much more favorable 
outcome according to progression for the diploid early endo· 
crine treatment group compared to other groups. Unfortu-
nately, in our study the number of patients and the short 
foliov.1Jp are considered to be prohibitive for a meaningful 
subgroup analysis. 
In conclusion, it can be slated that DNA ploidy can be 
determined on archival core biopsy material of prostate cancer 
and on lymph node metastases, and that the results correlate 
significantly with interval to progression. Besides DNA ploidy 
the percentage of cells in the S phase or S plus G2 phases 
of the cell cycle indicates a significant difference for interval to 
progression. Stage and grade in the presence of lymph node 
metastases were not significantly correlated with interval to 
progression in our study. Patients receiving early endocrine 
treatment were shown in a prospective randomized study to 
have a prolonged interval to progression compared to patients 
receiving delayed treatment. The question of whether early and 
delayed treatment will have an impact on cancer-related or 
overall survival may be answered in the futUre by this ongoing 
study, Our results encourage further studies of DNA ploidy on 
biopsy material to establish the role of this important prognos-
tic factor in the pretreatment evaluation of patients with pros-
tate cancer. 
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CHAPTER 9 
General Discussion. 
GENERAL DISCUSSION, 
INCREASING IMPORTANCE OF PROSTATE CANCER IN THE MALE POPlJLATfON 
The incidence of prostatic carcinoma in developed coutries is rising'. This increase in inciden-
ce appears to be due to the induction of screening programs, which leads to earlier detection of 
prostate cancer, and increasing public and doctors awareness of the disease'. In 1991 14.1% 
of all diagnosed malignant tumors in the Netherlands were prostatic carcinomas, and the 
mortalitylincidence ratio was 0.49, meaning that 50% ofthe patients actually died because of 
their prostatic tumor'. Furthermore the age-adjusted mortality-rate for prostate cancer increa-
sed with 1% per year from 1950-1989 in the Dutch male population '. These numbers indicate 
that prostate cancer can no longer be discounted as " the disease that strikes only old men who 
will probably die of intercurrent causes ". Due to earlier detection the incidence oflocalized 
disease at the time of diagnosis has increased from 27.7% in 1985, to 48.5% in 1990 5. This 
increase has caused a rise in radical prostatectomy treatments in the past decade I, since this is 
the treatment of choise for patients with localized prostate cancer who are able to undergo 
surgery and have a life-expectancy of at least 10 years. Generally patients under the age of70, 
who are in a good physical condition are considered candidates for radical prostatectomy. This 
age limit may however be too low for a substantial part of the patients with newly diagnosed 
prostate cancer. In the United States of America the average life-expectancy ofa 75 years old 
man is 12 years, and therefore men of75 years old who are in an excellent condition (the 
'biologic elite') may still be proper candidates for radical surgery '. 
STAGING ERRORS IN PROST ATE CANCER' INFLUENCE ON TREATMENT DECI-
Slilllli 
Like in most tumors, orgaoMconfined disease has a better prognosis than tumor extension 
outside the organ in prostate cancer patients. The resection ofa wide margin of healthy tissue 
around a tumor to achieve radical resection is a well established surgical oncological principle. 
The anatomical structures surrounding the prostate allow however only a resection margin of a 
few milimeters, which means that tumors with extraprostatic extension present a risk of 
positive margins of resection and the associated risk of early local recurrence '. Because of 
these difficulties radical prostatectomy is not considered standard treatment for patients with 
locally advanced disease (T3 '); most of these patients are treated by radiotherapy. The discri-
mination between organ-confined and locally advanced prostatic tumors is therefore of major 
importance in making a treatment decision. Unfortunately the staging techniques are not very 
reliable in detecting extraprostatic extension (capsular perforation). In 43-75% of the tumors 
staged as pT2 (organ-confined), the pathological evaluation of the radical prostatectomy 
specimen shows capsular perforation (pT3)"IO,". On the other hand, 17-30% ofthe T3 tumors 
are overstaged, and appear to be locally confined 12,13,,,. These patients may be denied a 
curative operation because of staging errors. Neither digital rectal examination 15, nOf transrec-
tal ultrasonography 15,16.17, nor magnetic resonance imaging 17, nor preoperative PSA 18,19, nor 
combinations of these techniques can accurately predict the presence of capsular perforation 
1~.16.11. Since the results of radiotherapy for progression and survival in prostate cancer patients 
seem to be worse than the results obtained by surgery 2 •• 21 , the results of surgery for T3 
prostate cancer should be carefully evaluated to determine the best treatment method for these 
patients. 
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SUROER YIN LOCALLY AnY ANCED PROSIAIIC CARCINOMA 
Only a few studies report on surgery for 13 carcinoma of the prostate. In all studies, except the 
one conducted by Jewett ", a substantial part ofthe patients received adjuvant therapy, which 
can influence the progression-rates reported, since hormonal therapy is known to prolong the 
interval to progression 12,23,2-1,2S.26,27,28,29,JO. The study by Jewett 22 was perfonned in 1958, when 
staging methods were less reliable: no lymph node dissection was done, so this patient-group 
may contain many patients with lymph node metastases unnoticed at the time of surgery. lhis 
may explain the poor overall survival of 12.5% after 10 years. We investigated the results of 
surgery as a monotherapy in 13 patients, and found an overall survival of 83% at 5 years, and 
a cancer specific survival of90% at 5 years ". Ihese results are comparable to those in patient-
groups treated by surgery and adjuvant treatment, which indicates that hormonal adjuvant 
therapy does not prolong survival. Clinical progression occurred in 36% ofthe patients at 5 
years, and biochemical progression (2 consecutive PSA-values >0.1 nglml postoperatively) in 
63% at 5 years, in patients without adjuvant therapy 13. Only the outcome for biochemical 
progression was worse in patients not treated by hormonal adjuvant therapy, which is no 
surprise, since the PSA-level drops to female levels after hormonal therapy, and rises only 
when the effect is tenninated by the outgrow of androgen-independent tumor cell-populations. 
At that time the androgen sensitivity of the tumor is lost, and progression is inevitably. Patients 
treated by surgery only can have hormonal therapy when biochemical (or clinical) progression 
occurs, to suppress tumor growth, and to prolong the disease-free interval. During the analysis 
of the patients who received radical prostatectomy as a monotherapy for 13-carcinoma, the 
subgroup of patients with 1303 turned out to have a very unfavourable prognosis with early 
progression. Patients with 1301-2 tumors did not difter significantly in prognosis from pa-
tients with 1<3 tumors, but 93% of the patients with 1303 suffered progression, and most 
patients did so within the first 2 years post-surgery. We concluded that radical prostatectomy is 
not indicated in this group of patients, altough it can be tried in young patients. In that case we 
advise immediate adjuvant hormonal therapy, to delay progression. 
Patients with pathological pI3 prostate cancer (preoperatively staged as organ-confined) 
treated by surgery only IO,II,31.32,3J.l~.lS,36,37.n,39,4o.41, have survival and progression-rates that are 
comparable to those of clinical 13 patients; only the local recurrence-rate is higher in p13 
patients. Patients treated by radiotherapy only for T3 prostate cancer 42,4J,4,J,45.46,47,48,4?,SO,SI,52 
have lower survival and higher progression-rates than patients treated by surgery (see table 
12,13, chapter 2). Iherefore radical prostatectomy is beneficial in 13-patients with a good 
general condition, who are fit to undergo a surgery. Adjuvant therapy in pI3-patients seems to 
have a beneficial effect on clinical progression during the first 10 years offollow-up, but not 
for the years 10-15 post-surgery. Ihere was however a substantial benefit for local recurrence 
in patients undergoing adjuvant radiotherapy (see table 13, chapter 2). No significant differen-
ces occurred in overall and cancer specific survival. A comparison for survival and progression 
in patients treated by surgery and for those treated conservatively (i.e. hormonal therapy at the 
time of progression or when the patient has complaints), cannot be made because the studies 
reporting conservative management contain either several stages in one group ~3,}I,S5 , or 
contain only patients with low and intermediate grade "''". 
Despite the fact that 13-tumors are generally larger than organ-confined tumors, which should 
make the resection more difficult, the complication rate showed no statistically significant 
difference between T<3 and T::d tumors .51. Intraoperative complications occorred in 3.7%, 
incontinence after one year was II % (6% became dry after implantation of a sphincter-prothe-
sis); potency was preserved in 43%, and 32% had stenosis of the anastomosis requiring dilata-
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tion ". There was a trend towards a lower complication rate over the years, with a growing 
experiance. The mortality-rate was 1.5%. These mortality- and complication-rates seem 
acceptable. 
THE IMPORTANCE OF PATHOLOGICAL VARIABLES FOR PROGRESSION AND 
SURVIVAL IN PROST A TIC CARCINOMA 
Pathological variables are important indicators for the course of the disease after radical 
prostatectomy (chapter 5). Unfortunately the major treatment decision has already been made 
at that time, since the pathological variables are detennined in the radical prostatectomy 
specimen. Efforts to detemUne some of these variables preoperatively were not always succes-
full, due to the sampling errors ofthe biopsies. This is illustrated by the undergrading of27%, 
when the grades of the preoperative biopsies were compared to those of the radical prostatec-
tomy specimens. On the other hand, DNA-ploidy proved to be a significant prognostic factor 
when detennined on pre-operative biopsie-material ". For daily practice the importance of the 
pathological variables may be that they can influence the decision to administer adjuvant 
therapy. In patients with T3G3 tumors for example, adjuvant therapy is adviseble because early 
progression can be expected. 
In general pathological variables can be divided in two groups, 1: those conceming local tumor 
extension (capsular perforation, perineural invasion, seminal vesicle invasion, positive margins 
of resection, and pT-category); and 2: those related to the biological agressiveness ofthe 
tumor (grade, vascular invasion, DNA-ploidy,pN-category). 
In the univariate analysis all pathological variables evaluated were significant prognostic 
factors for clinical and biochemical progression, and all except perineural invasion and pN-
category were significant for cancer specific survival. In the multivariate analysis however 
vascular invasion, capsular perforation, high grade, and positive margins of resection were the 
most important variables, indicating that both local extension and biological behaviour of the 
tumor are important for progression and survival (chapter 5). The role of local tumor extension 
was further evaluated for positive margins of resection (chapter 6). All positive margins of 
resection occurred in pathologically locally advanced carcinoma (pTJ-4); but 53% of the 
patients with capsular perforation had negative margins of resection, indicating that radical 
surgery is possible in T3-disease. There was a significant correlation between positive margins 
and seminal vesicle invasion, capsular perforation, and apical positive margins. Saving the 
neurovascular bundle had no influence on the occurrence of positive margins: this means that 
the decision to save the bundle (this decision was taken intraoperatively) was made only when 
the risk of extracapsular extension (and therefore positive margins) was very low'. The event 
of positive margins of resection was a significant prognostic factor, independant of the patho-
logical stage: patients with pT3-4 and positive margins had significantly more progression than 
those without positive margins. 
Vascular invasion is only rarely reported in the litterature, despite the suggestion ofthe Cancer 
Committee of the College of American Pathologists to report this variable ". Only one study 
reports on vascular invasion 59, and in this study it is not a significant independent variable for 
progression. Salomao investigated the correlation of vascular invasion with other pathological 
variables, but did not test for prognostic significance for progression and survival 60. In our 
study vascular invasion was the most significant variable in the multivariate analysis for 
clinical- and biochemical progression, and for cancer specific survival (chapter 7). There was a 
correlation with all other pathological variables, except with the pN-category. The lack ofa 
correlation with the lymph node status is not understood, but is perhaps a consequence of the 
120 
selection of the patients with positive lymph nodes in this group of patients. Given the excellent 
prognostic value for disease recurrence and survival, vascular invasion can be considered one 
of the most important pathological variables, which gives an indication of the agressiveness of 
the tumor. 
LYMPH NODE POSITIVE DISEASE AND PROGRESSION 
Lymph node metastases are rrequently found in locally advanced prostatic carcinoma, percen-
tages of33%-56% are reported 11,13,61,". These metastases cannot adequately be predicted by 
CT-scanning ", or Magnetic Resonance Imaging ". Therefore a lymph node dissection with 
evaluation ofti'ozen sections prior to the radical prostatectomy is essential to eliminate the 
possibility of lymphatic metastases. Once the pelvic lymph nodes are involved, the disease is no 
longer localized, but systemic, and local radical therapy can not control the disease ". We 
reported on 98 patients with lymph node positive disease, who did not undergo radical prosta-
tectomy, but who were treated with early (immediate) or delayed (at the time of progression) 
hormonal therapy; most patients were part of the EORTC study 30846, which compares 
progression and survival for patients with early versus delayed hormonal therapy. Hormonal 
therapy proved to be the most important prognostic factor in this group; in patients with early 
treatment 50% had progression at 5 years, compared to about 100% in the untreated group. 
This is not surprizing, considering the short follow-up in tllis group of patients, and the fact 
that horolonal therapy is known to prolong the disease-rree interval to progression ". The 
results for survival are not yet evaluable, given the short follow-up. 
RECENT DEVELOPMENTS IN THE TREATMENT OF LOCALLY ADVANCED PROS-
TATE CANCER 
The established treatments for the treatment of locally advanced prostate cancer are: radiothe-
rapy, radical prostatectomy, and hormonal therapy at the time of progression. Recently there 
has been a revival ofcryosurgery for ablation of the prostate in prostate cancer. Nowadays this 
technique is combined with ultrasonography 67, so that the formation of the ice-ball can be 
followed with real-time imaging. This should prevent damage to the rectal wall, because the 
procedure can be stopped when the ice-ball extends outside the prostate. Shinohara reported 
on a group of 102 patients undergoing cryosurgery ofthe prostate; 57% ofthese patients had 
locally advanced disease ". At 3-6 months postoperatively 23% had residual cancer in I or 
more biopsies, and in 71% prostatic epithelial elements were present. At 6 months postoperati-
velyabout 50% of the patients with TJa-b, and 70% of those with T3c had detectable PSA, 
despite the fact that all patients with locally advanced disease received complete androgen 
blockade for at least 3 months prior to cryosurgery. Lymph node dissections were only perfor-
med in patients who had a PSA> 15 ng/ml, or who had a Gleason score> 7; despite the high 
percentage of patients with locally advanced tumors, lymph node metastases were found in 
only 3 patients. Complications occurred in 51% of the patients; 23% required TUR of the 
necrotic prostatic tissue because of obstruction, 15% had some degree of incontinence, and 
84% was impotent (of those potent preoperatively). These complication-rates are worse than 
those reported for radical prostatectomy". Because follow-up is short, results for progression 
and survival can not be evaluated, however the high percentages of patients ,vith residual 
disease, and detectable PSA at 6 months postoperatively indicate that the results may be 
discouraging. Basically cryosurgery of the prostate meets the same problems in treating 
patients with tumor extension outside the capsule as do radical prostatectomy and radiothera-
py: the anatomical situation does not allow extension ofthe ice-ball ( resection / radiation) in a 
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wide margin of healthy tissue around the prostate. Therefore this therapy has the same limitati-
ons as the established techniques. The administration of preoperative hormonal therapy does 
not result in significant downstaging of locally advanced disease to organ-confined disease, as 
discussed in chapter 2 (see table 6). It is not to be expected that cryosurgery will be the 
solution for patients with locally advanced prostate cancer, and neither radiotherapy, nor 
radical prostatectomy is the definite answer to the problem of locally advanced disease. A 
better therapy is urgently needed for this stage T3 prostate cancer, which is present in 12% to 
40% of all newly diagnosed prostate cancer patients 69,70,71. 
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CHAPTER 10 
Summary and Conclusions. 
SUMMARY AND CONCLUSIONS 
The incidence and mortality of prostatic carcinoma is rising in developed countries. Nowadays 
prostate cancer makes up 14% of all diagnosed malignant tumors in men in the Netherlands, 
with a mortality/incidence ratio of 0.5, which means that 50% of the patients will die because 
of prostatic cancer. This means that prostatic carcinoma can no longer be considered a relati-
vely benign tumor that strikes most men when they reach a high age; but it should be conside-
red the second most common cause of death in men with malignant tumors (after pulmonary 
carcinoma). In the last decade the introduction of Prostate Specific Antigen (PSA) has stimula-
ted the introduction of screening programs for prostate cancer, which has caused an increase in 
detection of patients with locally confined and locally advanced disease, who are candidates for 
radical, curative treatment. The optimal treatment for patients with locally advanced prostate 
cancer is however still a matter of debate, since the extension of tumor outside the prostate, 
and the anatomical situation of the surrounding structures may prevent radical excision. 
Therefore many urologists consider surgery unsuitable for locally extensive disease. This thesis 
evaluates the limits and possibilities of radical prostatectomy for locally advanced prostate 
cancer, by describing the progression and survival after radical surgery, the influence of 
pathological variables, and the complications ofthe procedure. 
The history and contemporary developments in radical prostatectomy are described in chapter 
1. In the last decade better understanding ofthe anatomy of the surrounding structures of the 
prostate has lead to modifications of the surgical technique, which resulted in a lower compli-
cation rate. This fact has promoted the use of radical prostatectomy, and has resulted in a steep 
increase of the number of radical prostatectomies performed. 
Chapter 2 reviews the literature on the treatment of locally advanced carcinoma. The natural 
ltistory and results of conservative (hormonal) therapy are correlated, since most patients 
receiving expectant treatment experience progression, requiring (honnonal) treatment. The 
results of radical prostatectomy for clinically advanced (stage T3/C) prostate cancer in terms of 
tumor control and survival are evaluated. This evaluation is difficult. since almost all studies 
deliver adjuvant (hormonal) therapy to a substantial part of their patient-population, which 
influences (short-term) progression-rates. There is however no influence of adjuvant hormonal 
therapy on survival. Overall survival ranged from 64%-95% at 5 years, from 12%-72% at 10-, 
and from 20%-51 % at IS years. Cancer specific survival ranged from 85%-92% at 5 years, 
from 79%-82% at 10-, and from 68%-70% at IS years. Clinical progression (i.e. local recur-
rence and/or distant metastases) varied from 12%-45% at 5-, 39%-49% at 10-, and 50%-7\% 
at IS years. Biochemical progression is evaluated seperately, and means elevated PSA after 
surgery. The biochemical progression-rates vary from 48%-63% at 5-, and from 59%-62% at 
10 years. Long-term results are not available, because PSA is oniy used on a routine basis since 
1986 in most clinics. The results of radiation treatment oflocally advanced prostate cancer are 
compared to those of radical prostatectomy. It appears that radiation therapy leads to higher 
progression and lower survival rates, indicating that this treatment is inferior to surgery. It 
must however be remembered that there are differences between the populations undergoing 
surgery and radiation therapy, which may account for some of these differences in tumor 
control and survival. 
Many patients staged as locally confined disease tum out to have locally advanced disease (up 
to 70%). The results of tumor control and survival in pathological advanced disease (pTJ)are 
also evaluated in tltis chapter. Because many patients with this condition receive radiation 
andlor hormonal adjuvant therapy, patient-groups treated with and without adjuvant therapy 
are evaluated seperately. Adjuvant therapy offers some advantage for progression, and especi-
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ally for local recurrence. Also survival-rates are better afier the administration of adjuvant 
therapy. However no prospectively randomized studies have been published yet, so these 
results have to be interpreted with caution. The results of preoperative hormonal therapy with 
the intention of downstaging the disease, are discouraging; the percentages oflocally confined 
carcinoma after neoadjuvant therapy are about equal to the overstaging percentages in popula-
tions treated without preoperative hormonal therapy. 
Chapter 3 describes the results of radical prostatectomy as a monotherapy in 100 patients with 
clinical T3-prostate cancer. In 39 patients lymph node metastases were found, and 2 patients 
had evidence of pT4-tumors at surgical exploration. These patients were not treated by radical 
prostatectomy, because of these findings. In 3 young patients with a single microscopic lymph 
node metastasis a radical prostatectomy was performed. Of the 59 patients who underwent 
radical prostatectomy 9 had positive lymph nodes, which were not detected on frozen sections. 
The pathological stage in patients without lymph node metastases was pT2 in 9 patients, pT3 
in 39-, and pT4 in 2 patients. Only one of the 9 patients with lymph node metastases is free of 
progression. Progression occurred in none of the pT2 patients, in 27 of39 patients with pD, 
and in both patients with pT4. A total of22 patients were free of clinical and biochemical 
progression at an average follow-up of 44 months. The data on D-patients were compared to 
a group of 129 patients with TO to T2 disease. There was a significant difference in interval to 
clinical progression between those groups (p=O.OO I), but this difference disappeared once the 
T3G3 patients were excluded. Prognostic factors analyzed were the pretreatment and posttre-
atment histological grade, pretreatment PSA and prostatic acid phosphatase levels, positive 
margins of resection, seminal vesicle invasion, and lymph node status. It was concluded that 
radical prostatectomy is an effective treatment in patients with T3G 1-2 prostate cancer; the 
results for progression are comparable to those for patients with TO-T2 disease. In patients 
with T3G3 disease the results are however discouraging: 93% of the patients with T3pDG3 
sufiered progression during the observation period. Effective adjuvant treatment is urgently 
needed in this patient-group. 
In chapter 4 the mortality and morbidity associated with radical prostatectomy is investigated. 
In a group of 188 patients undergoing radical prostatectomy 3 patients died in the postoperati-
ve period (1.5%): 2 patients died ofa pulmonary embolus, and one because of sepsis. There 
were 7 intraoperative complications: 4 cases of rectal injury, 2 external iliac vein injuries, and 
one ureter lesion. All injuries were recognized immediately and repaired without further 
consequences. The most common short-term complications were wound infection (17%), 
prolonged lymph drainage (17%), lymphocele (7%) and bleeding (6%). The long-term compli-
cations were incontinence (11% at one year postoperatively; 50% of these patients became 
continent after implantation of an artificial urinary sphincter), stenosis of the urethro-vesical 
anastomosis (32%, most patients were cured by one or two dilatations in the outpatient clinic), 
and impotence (57% after a bilateral nerve-saving procedure). There were no significant 
differences in complication-rates in patients with T3-disease compared to those with T<3-
disease. The complication-rate decreased in more recent years with growing experience. 
Radical prostatectomy in locally advanced disease can therefore be performed with acceptable 
mortality and morbidity. 
Chapter 5 is an account ofthe different pathological variables determined in the radical prosta-
tectomy specimen, and their influence on tumor progression and survival. In 273 patients the 
131 
radical prostatectomy specimen was evaluated for: pathological stage, histological grade, 
capsular perforation, positive lateral and apical margins of resection, seminal vesicle invasion, 
perineural invasion, and vascular invasion. Furthermore the lymph node status was evaluated. 
The frequency of the pathological variables was: pT-category: pTO: 2%, pTl: 0%, pT2: 29%, 
pT3: 63%, pT4: 5%; histological grade: GO: 2%, GI: 14%, G2: 62%, G3: 22%; capsular 
perforation: present: 64%, absent: 36%; positive lateral margins: present: 34%, absent: 66%; 
positive apical margins: present: 41 %, absent: 59%; seminal vesicle invasion: present: 29%. 
absent: 71%; perineural invasion: present: 76%, absent 24%; vascular invasion: present: 12%, 
absent: 88%.Positive lymph nodes were present in 10% of the patients. 
For the patient-group as a whole the progression and survival rates at 5-, 10-, and 15-years 
were; for clinical progression: 27%,53%, and 63%; for local recurrence: 11%,24%, and 24%; 
for distant metastases: 21%, 41%, and 53%; for biochemical progression: 52% at 5 years; for 
overall survival: 82%,63%, and 55%; and for cancer specific survival: 92%,82%, and 82%. 
In the univariate analysis all evaluated pathological variables were significant prognostic 
factors for clinical and biochemical progression, and all except perineural invasion and the pN-
category were significant for cancer specific survival. In a multivariate analysis vascular 
invasion was the most significant variable for clinical and biochemical progression and cancer 
specific survival; other significant prognostic factors for clinical progression were: capsular 
perforation, high grade, and positive lateral margins of resection. For biochemical progression 
capsular perforation was the only other significant prognostic factor, and for cancer specific 
survival only positive lateral margins were significant beside vascular invasion. The other 
evaluated variables added no significant prognostic information. It was concluded that the 
evaluation of pathological variables is usefull to estimate the risk for progression and survival, 
and especially vascular invasion, capsular perforation, high grade, and positive lateral margins 
of resection. 
In chapter 6 the influence of positive margins of resection on local and distant progression, and 
the correlation with the other pathological variables is evaluated. Positive lateral margins of 
resection correlates significantly with advanced stage, high grade, the presence of seminal 
vesicle invasion, capsular perforation, and positive apical margins. There was no correlation 
between the saving of the neurovascular bundles and the occurrence of positive margins. 
Positive lateral margins of resection was an independant prognostic factor for local and distant 
progression; there was no significant difference in progression in patients with pTO-2 and pT3-
4 and negative margins, but there was when these groups were compared to patients with pT3-
4 with positive margins. Contrary to positive lateral margins, positive apical margins of resecti-
on did not influence progression. This may be due to the definition used: positive apical 
margins were defined as the presence of tumor in the most distal slice taken from the radical 
prostatectomy specimen. This finding resulted in a change in the protocol for evaluation of the 
apical margin: from that time on the apical slice of the specimen is cut in several slices, in the 
sagital plane, to get a more clear impression ofthe tumor extent in the apical margin. 
Chapter 7 reports on the influence of vascular invasion on progression and survival, and 
describes the correlation between vascular invasion and the other pathological variables. 
Vascular invasion is defined as the presence of tumor cells in endothelial-lined spaces; no 
differentiation is made between vascular and lymphatic vessels. Vascular invasion occurred in 
12% of the patients. The presence ofvascular invasion correlated significantly with the presen-
ce of capsular perforation, seminal vesicle invasion, positive lateral and apical margins of 
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resection, perineural invasion, high grade, and advanced stage, but not with the presence of 
lymph node metastases. Ihere was no significant difference in preoperative PSA-value in 
patients with and without vascular invasion. Vascular invasion was a significant prognostic 
factor for clinical and biochemical progression, local recurrence, distant metastases, overall 
survival, and cancer specific survival. In the multivariate analysis vascular invasion was the 
most significant prognostic factor for clinical and biochemical progression, and cancer specific 
survival. Vascular invasion can be detennined during the routine work-up of the radical 
prostatectomy specimen, without investing extra time and costs; therefore it should be reported 
on a routine basis during examination of the radical prostatectomy specimen. 
Chapter 8 deals with the patient-group who did not undergo radical prostatectomy because 
lymph node metastases were found during the lymph node dissection. Ihose patients were 
treated by early or delayed hormonal therapy (most patients were enrolled in EDRIC protocol 
30846, wlllch evaluates the infiuence of early versus delayed hormonal therapy for progression 
and survival). Patients treated with early homlOnal therapy had a significantly longer interval to 
progression, but follow-up is still too short and patient numbers too small for a relevant 
subgroup analysis. Furthermore the DNA ploidy was detennined in the prostatic biopsies and 
the lymph node metastases (DNA ploidy determination was performed in the Karolinska 
Institute, Stockholm, Sweden, department of Radiobiology, chairman: prof B. Iribukait), to 
evaluate ifthis produces relevant prognostic information. Also the percentage of cells in the S-
and G2 phase of the cell cycle was detennined. In 98 patients the ploidy was evaluable in 87 
cases; tumors were diploid in 52%, tetraploid in 15%, and aneuploid in 33%. In the primary 
tumor 57% diploid, 24% tetraploid, and 19% aneuploid tumors occurred; in the lymph node 
metastases these numbers were: 62%, 9%, and 29%. No statistically significant relation was 
found between the ploidy-status and I-category, grade, and lymph node status. Iherapy, 
ploidy, percentage of cells in the S-phase, and S- and G2-phase were significant prognostic 
factors for progression. In the multivariate analysis therapy, ploidy ofthe primary tumor (but 
not ploidy of the lymph node metastases), and percentage ofceUs in the S-and G2-phase of the 
lymph node metastases (but not of the primary tumor), were significant prognostic factors for 
progression. It was concluded that ploidy of core-biopsies and lymph node metastases are 
significant prognostic factors for progression, and that early hormonal therapy prolongs the 
interval to progression. Ihe relevance of ploidy performed on core-biopsies is that prognostic 
information, which may infiuence treatment decisions is available before the actual start of the 
treatment. 
CONCLUSIONS 
Radical prostatectomy is possible in patients with clinically locally advanced prostatic carcino-
rna (stage T3), with acceptable mortality and morbidity. Ihe results for progression are compa-
rable to those in patients with locally confined (I2) tumors, when patients with I3G3 are 
excluded. Ihis group ofT3G3 patients represents a subgroup with very high progression-rates 
after radical prostatectomy; therefore radical prostatectomy is not reconmlanded in these 
patients. 
Pathological variables determined in the radical prostatectomy specimen (capsular perforation, 
positive margins of resection. seminal vesicle invasion. perineural invasion. vascular invasion. 
grade, pI-category) are relevant prognostic factors for progression and survival. Vascular 
invasion is the most significant prognostic factor. and should be determined on a routine basis 
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during examination of the radical prostatectomy specimen. 
DNA-ploidy can be determined in paraffin-embedded core-biopsies, and is a significant pro-
gnostic factor for progression. In patients with lymph node metastases immediate hormonal 
therapy prolongs the interval to progression, the effects on survival are not yet known, because 
follow-up is too short. 
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CHAPTER 11 
Samenvatting en Conclusies. 

SAMENVAITING EN CONCLUSIES 
De incidentie en mortaliteit van prostaatkanker stijg! in ontwikkelde landen. Van aile maligne 
tumoren in mannen (in Nederland) is 14% prostaatkanker; de incidentie!mortaliteits verhou-
ding is 0.5: dit betekent dat 50% van de mannen die prostaatkanker hebben, hieraan zal ster-
ven. Dit betekent dat prostaatkanker niet langer beschauwd mag worden als een relatief 
goedaardig carcinaom, dat voarnamelijk mannen op hage leeftijd treft, bij wie dit weinig 
consequenties heeft, maar dat prostaatkanker oa bronchuscarcinoom de meest voorkomende 
daadsoorzaak is in mannen met maligne tumoren. In de afgelopen 10 jaar heeft de introductie 
van Prastaat Specifiek Antigeen (PSA) geleid tot het start en van screening progranuna's vaor 
prostaatkanker. Hierdoar worden meer lokaal beperkte en lokaa! uitgebreide carcinomen 
gevanden, welke in aanmerking komen voor curatievc behandeling. De optimale behandeling 
van patienten met lokaal uitgebreide carcinomen is nog onderwerp van discussie, amdat de 
uitbreiding van de tumor buiten de prostaat, en de anatomisch situatie van de omliggcnde 
structuren cen radicalc excisie onmogeJijk kan maken. Daarom aehlen vee! urologen chirurgi-
sche behandeling ongeschikt voor patienten met lakaal uitgebreide prostaatkanker. Dit proef-
schrift evalueert de grenzen en mogelijkheden van radicale prostatectomie als behandeling voar 
lokaal uitgebreid prostaatcarcinoom, d.m. v. beschrijving van de progressie en overleving oa 
radicaic chirurgische resectie, de invloed van pathologische variabelen, en de complicaties van 
de operatie. 
De geschiedcnis en de reccnte ontwikkelingen van de radicale prostatectomie worden beschre-
ven in haafd,tuk I. In de afgelopen 10 jaar heeft een beter begrip van de anatomie van de 
omliggcnde structuren gclcid tot vcranderingen in de chirurgische techniek, waardoor nu 
minder complicaties voorkomen. Dit feit heeft de toepassing van radicale prostatectomie 
gestimuleerd, hetgecn geresulteerd is in een sterke toename van het aantat radicale prostatecto-
mieen. 
Haofdstuk 2 geeft een overzicht van de literatuur over de behandeling van lokaal uitgebreid 
prostaatcarcinoom. Het oatuurlijk beloop en de resultaten van conservatieve (hormonate) 
behandeling hangen samen, omdat de meeste patienten die zander behandeling gevolgd wor-
den, progressie krijgen, welke behandeld wordt met hormanale therapie. De resultaten van 
radicale prostatectornie als behandeling voor lokaal uitgebreid prostaatcarcinoorn (stadium 
T3/C) in termen van tumor controle en overleving worden geevalueerd. Deze evaluatie wordt 
gecompliceerd door het feit dat in de meeste studies een aanzienlijk deet van de onderzochte 
populatie adjuvante (hormonale) behandeling krijgt, hetgeen de (korte ternlljn) progressie 
belnvloed. Er is echter geen invloed van adjuvante harmon ale therapie op overleving. De totale 
overleving varieert van 640/0-950/0 na 5 jaar, van 12%-72% na 10-, en van 20%-51% na 15 
jaar. De kanker specifieke overleving varieert van 85%-92% oa 5 jaar, van 79%-82% oa 10-, 
en van 68%-70% oa 15 jaar. Klinische progressie (= lokaal recidiefenlofmetastasen op 
afstand) varieert van 12%-45% na 5 jaar, van 39%-49% na 10-, en van 50%-71% na 15 jaar. 
Biochemische progressie wordt afzonderlijk geevalueerd, en bestaat uit verhoogd PSA na 
operatic. Biochemisch progressie tradt op in 48%-63% oa 5 jaar, en in 59%-62% na 10 jaar. 
Lange termijn resultaten zijn niet beschikbaar, omdat PSA pas sinds 1986 routinematig wordt 
bepaald. De resultaten van radiotherapie als behandeling vaor lokaal uitgcbreid prostaatcarci-
no om wordell vergcleken met die van radicale prostatectomie. Radiotherapie lijkt te leiden tot 
meer progressie en slechtere overleving van patienten met lokaa! uitgebreid prostaatcarcinoom, 
zodat operatie een betere behandeling lijkt voar deze groep patient en. Er moet echter wei 
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bedacht worden dat er verschillen (in maligniteitsgraad, leeRijd, conditie) zijn tussen de popu-
laties van patienten die radiotherapie en radicale prostatectomie ondergaan, waardoor cen 
gedeelte van de slechtere resultaten van radiotherapie verklaard kan worden. 
Veel patienten die gestageerd zijn als hebbende lokaal beperkt carcinoom (stadium T2), blijken 
een lokaal uitgebreide tumor te hebben (tot 70%). De progressie en overleving van patient en 
met pathologisch lokaal uitgebreid prostaatcarcinoom (pT3) worden in dit hoofdstuk geevalu-
eerd. Omdat veel patienten met dit stadium adjuvante radiotherapie enlof hormonale therapie 
krijgen, worden patienten-groepen behandeld met en zonder adjuvante therapie apart geevalu-
eerd. In deze retrospectieve studie biedt adjuvante therapie enig voordeel voor wat betreft 
progressie, en vooral ten aanzien van lakaal recidief. Oak overlevings percentages lijken beter 
na het geven van adjuvante behandeling. Er zijn echter geen prospectieve gerandomizeerde 
studies gerapporteerd, dus deze resultaten moeten met eruge reserve geInterpreteerd worden. 
De resultaten van preoperatieve (neoadjuvante) hormonale therapie, met het doel de tumor 
lokaal beperkt (en dus beperkt tot de prostaat) te maken zijn ontmoedigend; het percentage 
lokaal beperkte tumoren na neoadjuvante therapie is ongeveer gelijk aan het percentage 
overstagering in de populatie patienten die geen preoperatieve hormonale therapie ontvangen. 
Hoofdstuk 3 beschrijft de resultaten van radicale prostatectomie als enige behandeling (zonder 
adjuvante therapie) in 100 patienten met klinisch T3 prostaatkanker. In 39 patienten werden 
Iymfeklier metastasen gevonden, en 2 patienten bleken intraoperatiefT4 tumoren te hebben. 
I.v.m. deze bevindingen ondergingen deze patienten geen radicale prostatectomie. In 3 jonge 
patienten met cen enkele microscopisch kleine Iymfeklier metastase weed wei cen radicale 
prostatectomie verricht. Van de 59 patienten die cen radicale prostatectornie ondergingen, 
had den 9 patienten positieve Iymfeklieren, welke gemist waren tijdens het vriescoupe onder-
zoek. Het pathologische stadium van de patienten zonder Iymfeklier metastasen was pT2 in 9 
patienten, pT3 in 39-, en pT4 in 2 patienten. Slechts een van de 9 patienten met Iymfeklier 
metastasen heefi geen progressie gckregen. Progressie trad op in geen van de patienten met 
pT2, in 27 van de 39 patienten met pT3, en in beide patienten met pT4. In totaal hadden 22 
patienten geen klinische ofbiochemische progressie na een gemiddelde follow-up van 44 
maanden. De gegevens van de T3-patienten werden vergeleken met die van cen groep van 129 
patienten met stadium TO-T2, welke evcneens behandeld werden met cen radicale prostatecto-
mic. Er was cen significant verschil in interval tot klinische progrcssic tussen deze groepen 
(p~O.OOI), maar dit verschil verdween als de patienten met T3G3 uitgesloten werden. De 
geanalyseerde prognostische faktoren waren: pre- en post-operatieve histologische grade ring, 
pf(!operatieve serumspiegels van PSA en Prostaat Zure Fosfatase. positieve snijvlakken, 
zaadblaas invasie, en lymfeklier status. De conclusie is dat radicale prostatectomie ceo effect ie-
ve behandeling is voor patienten met T3GI-2 prostaatkanker; de progressie is vergelijkbaar 
met die van paticnten met TO-T2 tumoren. Bij paticnten met T3G3 tumoren zijn de resultaten 
echter slecht: 93% van de patienten met T3pT3G3 prostaatkanker krijgt progressie tijdens de 
geobserveerde periode. Eftectieve adjuvante behandeiing is dringend no dig voar deze 
patienten-groep. 
In hoofdstuk 4 worden de met radicale prostatectomie geassocieerde mortaliteit en morbiditeit 
ondcrzocht. In een groep van 188 patienten die een radicale prostatectomie ondergingen, 
overleden er 3 in de postoperatieve periode (1.5%): 2 patienten overleden Lg.v. een longembo-
lie, en cen patient Lg.v. sepsis. Er traden 7 intraoperatieve complicaties op: rectumperforaties 
in 4 patienten, beschadiging van de vena iliaca extema in 2 patient en, en een ureterlaesie. AHe 
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laesies werden direct ontdekt en hersteld, zonder verdere consequenties. De meest voorkomen-
de complicaties waren: wondinfectie (17%), langdurige Iymfe drainage via de wonddrain 
(17%), lymfocele (7%), en bloeding (6%). De lange termijn complicaties waren: incontinentie 
(11 % na een jaar postoperatief, 50% van deze patienten werd continent na de implantatie van 
een sfincter prothese), stenose van de urethro-vesicale anastomose (32%, de meeste patienten 
waren genezen oa een oftwee poliklinische dilataties), en impotentie (57% oa een bilateraal 
zenuwsparende operatie). Er waren geell significante verschillen in aantal complicaties tussen 
patienten met T3 turnoren en patienten met T<3 tumoren. Het percentage complicaties nam af 
in de latere jaren van de stud ie, met toenemende ervaring. Radicale prostatectomie in patienten 
met lokaal uitgebreid prostaatcarcinoom kan verTicht worden met een acceptabele mortaliteit 
en morbiditeit. 
Hoofdstuk 5 is een evaluatie van de vcrschillende pathologische variabelen die in het radicale 
prostatectomie preparaat onderzocht worden, en hun invloed op progressie en overleving. In 
273 patienten werd het radicale prostatectomie preparaat geevalueerd voor: pathologisch 
stadium, histologische gradering, kapsel perf ora tie, positieve laterale en apicale snijvlakken, 
zaadblaas invasie, perineurale invasie, en vasculaire invasie. Verder werd de Jymfk1ier status 
geevalueerd. De frequentie van de pathologische variabelen was: pT -categorie: pTO: 2%, pT I: 
0%, pT2: 29%, pT3: 63%, pT4: 5%; histologische gradering: GO: 2%. GI: 14%, G2: 62%, 
G3: 22%; kapsel perforatie: aanwezig: 64%, afwezig: 36%; positieve laterale snijvlakken: 
aanwezig: 34%, afwezig: 66%; positieve apicale snijvlakken: aanwezig: 41%, afwezig: 59%; 
zaadblaas invasie: aanwezig: 29%, afwezig: 71 %; perineurale invasie: aanwezig: 76%, afwezig: 
24%; vasculaire invasie: aanwezig: 12%, afwezig: 88%. Lymfklier metastasen waren aanwezig 
in 10% van de patient en. 
Voor de gehele groep waren de progressie en overlevings percenlages na 5-,10-, en 15 jaar: 
klinische progressie: 27%, 53%, en 63%; lokaal recidief: 11%,24%, en 24%; metastasen op 
afstand: 21%,41%, en 53%; biochemische progressie: 52% na 5 jaar; totale overleving: 82%, 
63%, en 55%; cn kanker specifieke overleving: 92%, 82%, en 82%. In de univariate analyse 
waren aile onderzochte pathologische variabelen significante prognostische faktoren voor 
klinische en biochemische progressie, en aIle variabelen behalve perineurale invasie en de pN-
categorie waren significant voar kanker specifiekc overleving. In de multivariate analyse was 
vasculaire invasie de meest signiftcante prognostisch faktor voor klinische en biochemische 
progressie en kanker specifieke overleving; de andere significante prognostische faktoren voor 
klinische progressie waren: kapsel perforatie, slecht gedifferentieerd carcinoom, en positieve 
laterale snijvlakken. Voor biochemische progressie was kapsel perforatie de enige andere 
significante prognostische faktor, en voor kanker specifieke overleving waren aileen positieve 
laterale snijvlakken significant naast vasculaire invasie. De andere gee.valueerde variabelen 
voegden geen significante prognostische informatie toc. Geconcludeerd kan worden dat de 
evaluatie van pathologische variabelen nuttig is om het risico VODr progressie en overleving in 
te schatten, en dat vODral vasculairc invasie, kapsel perforatie, stecht gedifierentieerd carci-
noom, en positieve laterale srujvlakken belangrijke prognostische infonnatie geven. 
In hoofdstuk 6 wordt de invloed van positieve snijviakken op lokale progressie en progressic 
op afstand geevalueerd, en wordt de correlatie van deze variabele met de andere pathologische 
variabelen onderzocht. De aanwezigheid van positieve laterale snijvlakken correleert me·t de 
aanwczigheid van cen hoog tumor-stadium, slecht gedifferentieerd carcinoom, zaadblaas 
invasie, kapsel perforatie, en een positief apicaal snijvlak. Er was geen verband tussen het 
141 
sparen van de neurovasculaire bundels en het optreden van positieve snijvlakken. Positieve 
laterale snijvlakken waren een onathankelijke prognostische faktor voor lokale progressie en 
progressie op afstand (metastasen); er was geen significant verschil in progressie tussell 
patienten met pTO-2 en pT3-4 tumoren zonder positieve snijvlakken, maar wei tussen deze 
groepen en patienten met pT3-4 en positieve snijvlakken. In tegensteHing tot laterale positieve 
snijvlakken, beinvloeden apicale positieve snijvlakken de tijd tot progressie niet. Dit is mogelijk 
het gevolg van de gebmikte definitie: positieve apicale snijvlakken werden gedefinieerd als 
tumor in het meest distale sneevlak van het radicale prostatectomie preparaat. Deze bevinding 
heeft geresulteerd in een aanpassing van het protocol voor de beoordeling van het apicale 
snijvlak; tegenwoordig wordt het meest distale gedeelte van het preparaat in diverse plakjes 
opgesneden, in het sagitale vlak. Dit maakt een bet ere beoordeling van het apicale snijvlak 
mogelijk. 
Hoofdstuk 7 rapporteert over de invloed van vasculaire invasie op progressie en overleving. en 
beschrijft de correlatie van deze variabele met de andere pathologische variabelen. Vasculaire 
invasie wordt gedefinieerd als de aanwezigheid van tumor cellen binnen mimtes welke worden 
omgeven door endotheel; er wordt geen onderscheid gemaakt tussen bloed- en Iymfe- vaten. 
Vasculaire invasie was aanwezig in 12% van de patient en. De aanwezigheid van vasculaire 
invasie correleert met de aanwezigheid van kapsel perforatie. zaadblaas invasie. positieve 
laterale en apicale snijvlakken. perineurale invasie, slecht gedifferentieerd carcinoom, en een 
hoog tumor-stadium, maar niet met de aanwezigheid van Iymfeklier metastasen. Er was geen 
significant verschil in de preoperatieve PSA-waarde tussen patienten met en zonder vasculaire 
invasie. Vasculaire invasie is een significante prognostische variabele voor het optreden van 
klinische en biochemische progressie, lokaal recidie£: metastasen op afstand, totale overleving, 
en kanker specifieke overleving. In de multivariate analyse was vasculaire invasie de meest 
significante prognostische faktor voor kJinische en biochemische progressie. en kanker speci-
fieke overleving. Vasculaire invasie kan bepaald worden tijdens de routinematige evaluatie van 
het radicale prostatectomie preparaat, zander extra tijd en kasten te investeren; daarom zou het 
routinematig gerapporteerd moeten worden bij het onderzoek van radicale prostatectomie 
preparaten. 
Hoofdstuk 8 beschrijft de patienten-groep die geen radicale prostatectomie onderging, omdat 
tijdens de Iymfklierdissectie positieve Iymfklieren werden gevonden. Deze patienten werden 
behandeld met onmiddelijke ofuitgestelde hormonale therapie (de meeste patienten maakten 
deel uit van de EORTC-studie 30846, welke de invloed van onmiddelijke versus uitgestelde 
hormonale therapie vergelijkt voor progressie en overleving in patienten met lymfklier metasta-
sen bij prostaat carcinoom). De patienten welke behandeld werden met onmiddeHijke hormona-
Ie therapie hadden cen significant langer interval tot progressie, maar de follow-up is te kort, 
en de patienten-aantatlen te klein. om een relevante subgroep analyse te doen. Verder werd de 
DNA-ploidy bepaald in de prostaatbiopten en de Iymfklier metastasen (de DNA-ploidy bepa-
ling werd uitgevoerd in het Karolinska Instituut, Stockholm, Zweden, op de afdeling Radiobi-
ology, hoofd: prof. B. Tribukait) om te onderzoeken ofdit relevante prognostische informatie 
zou opleveren. Ook werd het percentage eeHen in de S-en G2-fase van de cel cyclus bepaald. 
In 87 van de 98 patienten was de ploidy te evalueren; 52% van de tumoren waren diploid, 15% 
tetraploid, en 33% aneuploid. In de biopten van de primaire tumor was 57% van de tumoren 
diploid, 24% tetraploid, en 19% aneuploid; in de lymfkJier metastasen waren deze percentages 
respectievelijk 62%, 9%, cn 29%. Er was geen statistisch significante retatie tusseo de ploidy-
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sIal us en hellumor-sladium (T-calegorie), demalignileilsgraad.endelymfklierslalus.De 
Iherapie, de ploidy, hel percenlage cellen in de S-fase, en de S-en G2-fase waren significanle 
prognostische faktoren voar progressie. In de multivariate analyse waren therapie, ploidy van 
de plimaire tumor (maar niet van de lymJklier metaslasen), en percenlage cellen in de S-en G2-
fase van de lymtklier metastasen (maar niet van de primaire tumor), significante prognostische 
fakloren voor progressie. De conelusie luidl dal ploidy bepaald op proslaalbiopten en in 
Iymfklier metastasen cen significante prognostische faktor is vocr progressie van prostaatkank-
er, en dat onmiddelijke hormonale therapie hel inlerval tot progressie verlengt. De betekenis 
van ploidy bepaald in prostaatbiopten is dat hiermee prognostische informalie verkregen kan 
worden, voordal belanglijke beslissingen worden genomen I.a.v. de behandeling van palienlen. 
CONCLUSIES 
Radicale proslaleclomie is mogelijk bij palienten mel klinisch lokaaluilgebreid prostaal carci-
noom (sladium T3), mel acceplabele mortalileit en morbidileill.g.v. de operalie. De resullalen 
I.a.v. progressie zijn vergelijkbaar met die van palienlen mellokaal beperkle lumoren (T2), 
mits patienten met T3G3 turnoren worden uitgesloten van operatic. Patienten met T3G3 
prostaatcarcinoom vorrnen eeo subgroep met ceo zeer haag risiko voor progressie oa radicale 
prostatectomie; daarom wordt radicale prostatectomie afgeraden voor deze groep patient en. 
De palhologische valiabelen welke bepaald worden in hel radicale proslatectomie preparaal 
(kapsel perforatie, positieve snijvlakken, zaadblaas invasie, perineurale invasie, vasculaire 
invasie, histologische graad, en pT-categorie) zijn relevante prognostische faktoren voar 
progressie en overleving. Vasculaire invasie is de meest significante prognostische faktor, en 
zou roulinematig bepaald moelen worden lijdens hel pathologisch onderzoek van hel radicale 
prostatectamie preparaat. 
DNA-ploidy kan bepaald worden op paraftine behandeld materiaal van prostaalbioplen, en is 
een significante prognostische falior veer progressie. In patienten met lymfklier metastasen 
verlengl onmiddellijke hormonale Iherapie hel inlervallo! progressie, de effeclen op overleving 
zijn nog niet bekend, daar de follow-up op dil moment nog Ie kort is. 
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APPENDIX 1 
Data checklist for enrollment of patients in the prospective study. 
REGISTRATIE LYMFKLIERDISSECTIE 
PID! NAAM 
Hoofdstuk klinische stagering. 
02 Dlagnosedaturn : maand 
03 Diagnose n.a.v. 
04 Voorafg.beh.prost.probl. 
05 Performance (WHO klasse) 
06 Nacht. erecties 
07 Erecties met sex.stlmulatie 
08 Sexueel actief 
RADICALE PROSTATECTOHIEEN 1 I 7. 
I I 
GEB 
! I ! ! jaar 
1 Prostaat klachten 
I [ ~ Rectaal onderz. toeval Incidenteel (TUR) Prost. screening studie 
Verhoogd PSA 
[ 
o Geen 
1 Hormonaal 
2 TUR-prostaat 
3 Radiotherapie 
4 Anders 
0 Normaal 
1 - 4 klasse 1 tro 4 
0 Nee, 1 Ja 
0 Nee, 1 Ja 
0 Nee, 1 Ja 
I I 09 Bereikt orgasme --------~~- 0 Nee, 1 Ja 
[ 1 Eigen poll 2 Rotterdam I I 3 Regio 4 Elders 
5 Buitenland 
10 Herkomst 
Hoofdstuk rectaal toucher. 
[ 0 Nee I 1 <~ 1/2 kwab 
2 > 1/2 kwab 
11 Tumor palpabel links 
[ 0 Nee I 1 <= 1/2 kwab 
2 > 1/2 kwab 
12 Tumor palpabel rechts 
[ 0 Nee 1 Rechts 2 Links 
3 Beiderzijds 
13 Kapsel doorbraak 
[ 0 Nee 1 Rechts 2 Links 
3 Beiderzijds 
14 Vesicula invasie 
[ 0 Nee 1 Blaashals, rectum, ext. sphincter 
2 Levator, bekken 
15 Fixatie, ingroei 
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REGISTRATIE LYMFKLIERDISSECTIE RADICALE PROSTATECTOMIEEN 2 7. 
[ 1 Geen maligniteit I 2 TUR-pT <= 5% 3 TUR-pT > 5% 
9 Onbekend 
16 Indien TUR-p 
17 T-categorie (TNH 92) I I [ TO;TxiT1ajT1biT1ciT2aiT2biT2ci T3ajT3biT3ciT4a;T4b 
0 Normaal [ I 18 IVP, echo -----------------------"-"-i 1 stuwing 1 kant 
19 Botscan 
20 Bot; X-ray/MRI/CT 
21 Bot biopsie 
22 CT/Echo/MRI abdomen 
23 punct.cyt nay CT/Echo/HRI 
24 Volume prostaat echo 
25 Serum kreatinine 
26 Alkalische fosfatase 
27 Testosteron 
28 PSA 
[ 
[ 
[ 
2 stuwing bdz 
9 Niet gedaan 
0 Normaal 
1 Hotspots, meta's 
2 Hotspots deg.afw. 
3 Hotspots, andere afw. 
4 Toename hotspots t.o.v. eerdere 
scan 
9 Niet gedaan 
0 Negatief 
1 Blastische meta's 
2 Lytische meta's 
3 Degeneratieve veranderingen 
4 Andere afwijkingen 
9 Niet gedaan 
0 Negatief 
1 Positief 
9 Niet gedaan 
o Normaal 
1 Reg.klieren verdacht 
2 And.klieren verdacht 
3 Reg.en and. klieren verdacht 
4 Niet lymfogene meta's 
5 Andere afwijkingen 
9 Niet gedaan 
[ 
0 Negatief 
-----'-'--I 1 Posi tief 
9 Niet gedaan 
I I 
I t 
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REGISTRATIE LYMFKLIERDISSECTIE [ RADICALE PROSTATECTOMIEEN 
rechts ~ 0 Negatief 1 pos.G1 29 Prostaat biopsie 2 pos.G2 
3 pos.G3 
4 pos.zonder G 
9 onbekend 
~ 0 Negatief 1 pos.G1 30 Prostaat biopsie links 2 pos.G2 3 pos.G3 4 pos.zonder G 9 Onbekend 
rechts 4 0 Negatief 31 cyt.punctie prostaat 1 Verdacht 
2 Positief 
9 Onbekend 
~ 0 Negatief 32 cyt.punctie prostaat links 1 Verdacht 2 Positief 9 Onbekend 
33 Graad maligniteit TUR 
[ 
; G1 
------"---"--1 ~ ~~bekend 
Hoofdstuk operatie. 
34 Operatiedatum maand I ! jaar 
2 Gast 
35 Operateur -----------...L...L-1 3 Staf 
[ 
1 FHS 
36 Lymfklier dissectie 
4 Assistent 
5 Anders 
------'---'---- 0 Nee, 1 Ja 
3 7. 
37 Palpatie rechts 
r 0 Negatief 
________ L-"-~ 1-8 verdachte lymfklier(en) 
38 Doorsnede grootste klier o - 98 mm, 99 onbekend 
39 Palpatie links 
r 0 Negatief 
________ L-L-L 1-8 verdachte lymfklier(en) 
40 Doorsnede grootste Klier ---',--','-'---- o - 98 mm, 99 onbekend 
r 0 Negatief 
41 Vriescoupe rechts ______ -L-L-L 1-8 verdachte lymfklier(en) 
42 Vriescoupe links 
r 0 Negatief 
_______ -L-L-L 1-8 verdachte lymfklier(en) 
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REGISTRATIE LYMFKLIERDISSECTIE RADICALE PROSTATECTOHIEEN 4 I 7. 
43 Radicale prostatectamie I I 0 Nee, 1 Ja 
[ 0 Nee 52 Paging zenuwsp.operatie 1 Rechts 2 Links 
3 Beiderzijds 
-~[ 0 Geen 1 Vaatletsel 2 Darmletsel 44 complicatie peroperatief 3 Ureterletsel 4 Anaesthesiologie 
5 Overleden 
6 Anders 
45 Geschat bloedverlies ml. 
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REGISTRATIE LYHFKLIERDISSECTIE RADICALE PROSTATECTOHIEEN 5 7. 
PID# NAAM _______________________ GEB 
Hoofdstuk pathologische anatomie. 
46 Paraff.coupe lymfkl. rechts 
o Negatief 
1 1 Klier <= 2 cm 
2 1 klier > 2 cm en <= 5cm 
of meerdere klieren <= 5 cm 
3 klier meta > 5 cm 
4 extra regionale Klier positie 
47 Afmetingen grootste Klier __ ~I~IL-IL-_ ° - 98 rom; 99 Onbekend 
48 Paraff,coupe lymfkl. links 
49 Afmetingen grootste klier __ ~~IL-LI --
50 Grootte metastase in lymfklier ~ 
51 pN categorie (TNM 92) 
53 Tumor links [ 
54 Tumor rechts [ 
[ 55 Kapsel doorbraak ---------------"-"-i 
56 Vesicula invasie [ 
57 Fixatie cq ingroei I [ 
58 pT-categorie (TNM 92) [ 
lSI 
o Uegatief 
1 1 klier <= 2 em 
2 1 klier > 2 em en <= Scm 
of meerdere klieren <= 5 em 
3 klier meta > 5 cm 
4 extra regionale klier positief 
o - 98 rom; 99 Onbekend 
1 Sol meta <= 2 mm 
2 Sol meta > 2 mm en < 20 mm 
3 Sol meta >= 20 mm en <= 50 mm 
4 Mult meta <= 2 mm 
5 Mult meta > 2 mm en <"'" 50 mm 
6 Heta > 50 mm 
pNO,pN1,pN2,pN3 
0 Nee 
1 <= 1/2 kwab 
2 > 1/2 kwab 
0 Nee 
1 <= 1/2 kwab 
2 > 1/2 kwab 
0 Nee 
1 Rechts 
2 Links 
3 8eiderzijds 
0 Nee 
1 Rechts infiltratie 
2 Links infiltratie 
3 8eiderzijds infiltratie 
0 Nee 
1 Blaashals, rectum, ext. sphincter 
2 Levator, bekken 
TO;Tx;T2a;T2b;T2c; 
T3ajT3biT3ciT4aiT4b 
REGISTRATIE LYMFKLIERDISSECTIE I RADICALE PROSTATECTOllIEEN 6 7. 
[ 0 Negatief 59 G categorie I I 1 G1 2 G2 
3 G3 
[ 0 Negatief 60 Vasculaire infiltratie 1 Positief 
[ 0 Negatief 61 Perineurale infiltratie 1 Positief 
[ 0 vrij van tumor 62 Resectievlak 1 Niet vrij van tumor 
[ 0 Vrij van tumor 63 Resectievlak apex 1 Niet vrij van tumor 
U 
Geen 
Tot aan kapsel 
64 Kapsel infiltratie Invasie kapsel 
Door kapsel (in peripr. vet) 
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REGISTRATIE LYMFKLIERDISSECTIE I RAOICALE 
comglicaties {binnen 2 mnd. QostoQ. } 
65 Infectie wond I I 0 
66 Drain > 2 weken 0 
67 Extravasaat op eu na 3 weken 0 
68 Drainage lymfocele 0 
69 Bloeding 0 
70 Fistel 0 
71 Pneumonie 0 
72 Thrombose I ! 0 
73 Embolie 0 
74 stuwing nier 0 
75 Myocardinfarct 0 
[ 0 76 Na verw. cath. incont. 1 8 
77 Anastomose dilatatie I I 0 
78 Andere 0 
79 Aantal p.e. gegeven 
80 Dagen catheter a demeure 
-
-------<--Y[ :~ 81 Therapie achteraf . 
82 Dagen opnarne r r 
83 PSA 
(le binnen 3 mnd. postop.) 
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PROSTATECTOHIEEN 7 7. 
Nee, 1 Ja, 2 Overleden aan 
Nee, 1 Ja 
Nee, 1 Ja 
Nee, 1 Ja 
Nee, 1 Ja, 2 overleden aan 
Nee, 1 Ja, 2 Overleden aan 
Nee l 1 Ja, 2 Overleden aan 
Nee, 1 Ja, 2 Overleden aan 
Nee, 1 Ja, 2 Overleden aan 
Nee, 1 Ja 
Nee, 1 Ja, 2 Overleden aan 
Nee 
tm 7 weken = duur in weken 
8 of meer weken 
Nee, 1 Ja 
Nee, 1 Ja, 2 Overleden 
Geen 
Orchidectomie 
Endocrien 
Bestraling 
Anders 
aan 


APPENDIX 2 
Data checklist follow-up visits of patients in the prospective study. 
"'t"m;J.,OW UP REGISTRATIE RADICALE PROSTATECTOMIEEN 1 2. 
PIO! 1 ! ! I [ 1 I NAAM : GEB 
02 Follow up datum : maand __ -,--,--,1 ! , ! jaar 
OJ Performance (WHO klasse) [ 
0 Normaal 
, 1 - 4 Klasse 1 tm 4 
~ 0 Nee 1 Perineaal 2 Bot 3 Elders 4 Meerdere plaatsen 04 pijn 
05 Nacht. erecties _________ 'L-L' _ 0 Nee, 1 Ja, 9 Onbekend 
06 Erecties met sex.stimulatie --~~-- 0 Nee, 1 Ja, 9 Onbekend 
07 sexueel actief _______________ -"'--L-_ O.Nee, 1 Ja, 9 Onbekend 
08 Bereikt orgasme ________________ 'L-L' - 0 Nee, 1 Ja, 9 Onbekend 
09 Incontinent [ 
[ , , 10 obstructieve mictie ___________ -L-L--j (eventueel therapie) 
11 status localis na Rad.Prost. 
0 Nee 
1 Ja, <= 2 verb/dag 
2 Ja, > 2 verb/dag 
3 sph. proth. droog 
4 sph. proth. lekt 
0 Nee 
1 Ja, dilataties 
2 Ja, operatie 
3 Ja, andere therapie 
4 Ja, geen therapie 
o RT normaal 
1 RT verdenking recidief 
2 Echo verdenking recidief 
3 Recidief/bevestigd biopsie 
9 Geen RT gedaan 
12 Rectaal toucher zonder RP. 
(TNM 92) 
TOjT2 a iT2bjT2c; 
[ TJaiT3bjT3cjT4aiT4b 
12a Gesehat volume RT (ern3] 
12b[ Totaal volume TRUS em3 
Volume adenoom TRUS cm3 
Laesie! (max.afm.) --'--'--"x L' --'--'-- mm 
Laesie2 (max,afm.) 'x, mm 
00 indieatie 
13 X-Thorax. 
dd : 
14 Botscan. 
dd : 
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[ 
0 Negatief 
-----------------------'--'-j 1 Pos i tief me tas tasen 
2 Andere afwijkingen 
[ 
0 Normaal 
1 Hotspots, meta I s 
-----------------------'---'----l 2 Hotspots deg.afw. 
3 Hotspots andere 'afwijkingen 
4 Toename hotspots tov eerdere 
scan 
,l.LOW UP REGISTRATIE RADICALE PROSTATECTOMIEEN 2 I 2. 
15 
16 
17 
Bot: X-ray/MRI/CT ____________ ~t~t-1[ 
dd : ___ __ 
o Normaal 
1 Blastische metals 
2 Lytische metals 
3 Degeneratieve Yeranderingen 
4 Andere afwijkingen 
0 Normaal 
1 Reg. klieren yerdacht 
2 And. klieren yerdacht 
CT/Echo/MRI abdomen 3 Reg. en and. klieren Yerd. 
dd : 
-- ---
M-cat. (TNM 92) 
dd : 
4 Niet lymfog. metastasen 
5 Andere afwijkingen 
6 Lokaal recidief 
[ 
0 MO 
-----------------'---'---1. 1 MIa I 
2 Mlb , 
3 Mle, 
nlet regionale lymfklieren 
bot-metastasen 
andere m~tastasen 
Behandeling. 
17a Motivatie Yoor in te stellen behandeling : 
1S Orchideetomie 0 Nee , 1 Ja 
19 Anti-androg. 0 Nee , 1 Ja 
20 Horm.anders (LHRH) 0 Nee, 1 Ja 
21 Chemotherapie 0 Nee , 1 Ja 
22 Bestraling prost. regio 0 Nee, 1 Ja 
23 Bestraling elders 0 Nee, 1 Ja 
2' TUR 0 Nee, 1 Ja 
25 Anders 0 Nee, 1 Ja 
26 In trialYerband 0 Nee, 1 Ja 
27 Alkalische fosfatase 
(aIleen prikken op indica tie I ) 
2S Testosteron I I I I I 
(aIleen prikken op indica tie ! ) 
28 PSA I ! 
01-12 AZR controle na .. mnd. 
[ 
00 AZR, Korte termijn 
33 Poli controle 
-----------------'--'--'---1. 96 Verw i j zing naar elders 
97 Elders 
98 Ontslag 
99 Onbekend 
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DANKWOORD 
Graag wil ik van deze gelegenheid gebruik maken iedereen te bedanken die aan dit proefschrift 
een bijdrage heeft geleverd. Zonder te suggereren volledig te zijn, wil ik met name noemen: 
• mijn promotor, prof. Dr. F.H. Schroder, zonder wie dit proefschrift er zeker niet gekomen zou 
zijn. Allereerst was het zijn idee het onderzoek dat reeds verricht was, uit te breiden en te 
bundelen in dit proefschrift. Verder heb ik veel gehad aan zijn begeleiding bij het schrijven van 
de eerste artikelen, toen bleek dat het schrijven van een wetenschappelijke publicatie niet z6 
eenvoudig was. Tot slot was het vaststellen van een promotiedatum het laatste zetje dat nodig 
was am te komen tot afronding van het boekje, na een peri ode waarin het werk had stilgele-
gen. De begeleidende gesprekken met hem leidden steevast tot nieuwe ideeen voor onderzoek 
en artikelen. 
• mijn co-promotor, Dr. W.C.J. Hop, welke zeer veel werk verzet heeft door het grootste 
gedeelte van de statistiek in dit proefschrift voor zijn rekening te nemen. Daar klinisch werkza-
me artsen vaak weinig onderlegd zijn in de statistiek, stelden de uitkomsten in de begin-periode 
mij nog wei eens voor verrassingen, welke extra werk noodzakelijk maakten. Uiteindelijk is dit 
proefschrift door zijn bijdrage echter zeker een beter boekje geworden, dat de toets der 
(statistische) kritiek kan doorstaan. 
• de overige leden van de promotiecommissie: Prof. Dr. K.H. Kurth, Prof Dr. Th.H. van der 
Kwast, en Prof Dr. G. Stoter, voor het snelle beoordelen van het proefschrift. 
• de co-auteurs van de diverse artikelen: PJ.T. Davidson, welke een belangrijke bijdrage leverde 
aan hoofdstuk 3 en 4; R. Kranse, die medewerkte aan hoofdstuk 5 en 7; F.M. Bentvelsen en 
E.R. Boeve, voor hun bijdrage aan hoofdstuk 6; en aan de medewerkers aan hoofdstuk 8: Prof 
B. Tribukait, T. Heiden en N. Wang (Afdeling Radiobiologie, Karolinska Institute, Stockholm, 
Zweden), welke de bepaling van de Ploidy en de statistische analyse deden; Dr. ].H.M. Blom 
voor zijn bijdrage aan de tekst, Dr. S.D. Fossa (Afdeling Radiotherapie, Norwegian Radium 
Hospital, Oslo, Noorwegen) en Prof Dr. K.H. Kurth (Afdeling Urologie, Academisch Medisch 
Centrum, Amsterdam) voor het beschikbaar stellen van hun gegevens en hun kritische com-
mentaar. 
• R. Kranse voor het beheren en bewerken van de data waarap dit proefschrift gebaseerd is; en 
het verder ontwikkelen van de databank. 
• Marjan Hettinga en Annet Verkerk voor het invoeren van de gegevens in het databestand. 
• de secretaresses Els Forman en Karin van Alphen voor het vele typwerk dat ze gedaan hebben 
om de (aanvankelijk eenvingerig typende) promovendus te helpen. 
• de sponsors die de publica tie van dit proefschrift ondersteunden; De Stichting Urologisch 
Wetenschappelijk Onderzoek (SUWO) Rotterdam, de Stichting Urologie 1973, Yarnanouchi 
Pharrna , Pfizer, Hoechst Marion Roussel, Merck Sharp & Dohme, Schering Nederland. 
• mijn ouders, welke mij in staat stelden am onbezorgd te studeren. 
• Lillian, die ondaoks de drukte van haar eigen baan, kans zag een gezin met kinderen te run-
nen,en mij zo in staat stelde aan dit proefschrift te werken. Zonder haar inzet en stirnulerende 
woorden zou ik dit werk nooit hebben kunnen schrijven. Hopelijk breken nu rustiger tijden 
aan! 
160 

CURRICULUM VITAE 
The author was born on june 17, 1961, in Delft, The Netherlands. After graduation from the 
Groen van Prinsterer college in Vlaardingen in 1979 (Gymnasium P), he studied medicine at 
the University of Leiden from 1979-1988. During his student years he participated in the 
clinical investigation of a micro-processor controlled uroflowmetry system. After his graduati-
on from the medical school, he performed as a general practitioner during his military service 
years (1988-1989), in the 'stafcompagnie of the first Anny-Corps' in Apeldoorn. In 1990-1991 
he worked as a resident not in training (AGNIO) at the Urology department ofthc Academic 
Hospital Rotterdam (chairman: Prof.Dr. F.H. Schroder). In these years the study resulting in 
this thesis was initiated. 
After being admitted for the Urological training program, he spent two years (1992-1993) as a 
resident in training in the department of Surgery of the Leyenburg Hospital in The Hague 
(chairman: Dr. Oosterwijk). In 1994 started his residency in Urology in the Academic Hospi-
tal Rotterdam (chairman: Prof Dr. F.H. Schroder), and the Sophia Childrens Hospital (head: 
Dr Nijman). 
He is married to Lillian van Oosterbos, and has three children. 
162 
PUBLICATIONS 
H.1. Rollema, C. Frimodt-Moller, A.EJ.L. Kramer, D. van den Ouden : Der hamflu3klassifi-
kationsfaktor (KF): Eine hilfe in der standardisierten bewertung von flowkurven; anwendung 
bei frauen mit blasenhalsdyssynergie und nach radikaler hysterektomie. 
Verhandlungsbericht der Deutschen Gesellschaft fiir Urologie, 38. Tagung, 1986, WOrzburg, 
444-446, Springer Verlag, 1987. 
HJ. Rollema, AEJ.L. Kramer, D. van den Ouden : Improved selection and follow-up of 
prostatectomy patients by on-line assessment ofuroflow classification factors. 
Neurourol. Urodyn., 6: 218-219, 1987. 
HJ. Rollema, AE.J.L. Kramer, D. van den Ouden : Hamflu3-Klassifikationsfaktoren (KF) 
vcr und nach prostatektomie. 
Verhandlungsbericht der Deutschen Gesellschaft flir Urologie, 39. Tagung, 1987, Stuttgart, 
470-473, Springer Verlag, 1988. 
HJ. Rollema, A W. Ambergen, D. van den Ouden : On-line uroflowmetry in males: Clinical 
application to small (-100 ml) voided volumes. 
Neurourol. Urodyn., 8: 407-408, 1989. 
D. van den Ouden, H.AM. Asbreuk, DJ. Versluis: Orale anticonceptie en thrombo-emboli-
sehe complicaties. 
Ned. Mil. Gnk. T., 43: 160-163, 1990. 
F.H. Schroder, D. van den Ouden, P. Davidson: The limits of surgery in the cure of prostatic 
carcinoma. 
European Urology Update Series, 1(3): 18-23, 1992. 
F.H. Schroder, D. van den Ouden : Rationale and results of radical surgery for prostatic cancer. 
Forum, Trends in Experimental and Clinical Medicine, 3: 252-263, 1993. 
F.Nt Bentvelsen, D. vnn den Duden, F.H. Schroder: Prostate specific antigen in monitoring for 
recurrence after radical prostatectomy for localized prostatic cancer. 
Br. J. Urol., 72: 88-91, 1993. 
D. van den Ouden, F.M. Bentvclsen, E.R. Boeve, F.H. Schroder: Positive margins after radical 
prostatectomy: correlation with local recurrence and distant progression. 
Br. J. Urol., 72: 489-494, 1993. 
D. van den Ouden, B. Tribukait, J.H.M. Blom, S.D. Fossa, KH. Kurth, FJ.W. ten Kate, T. 
Heiden, N. Wang, F.H. Schroder, and the EORTC Genitourinary Group: Deoxyribonucleic acid 
ploidy of core biopsies and metastatic lymph nodes of prostate cancer patients: impact on time to 
progression. 
1. Urol., 150: 400-406,1993. 
D. van den Ouden, PJ.T. Davidson, W. Hop, F.H. Schroder: Radical prostatectomy as a mono-
therapy for locally advanced (stage T3) prostate cancer. 
1. Urol., 151: 646-651,1994. 
163 
P.lT. Davidson, D. van den Ouden, F.H. Schroder: Radical prostatectomy: prospective asses-
sment of mortality and morbidity. 
Eur. Urol., 29: 168-173, 1996. 
D. van den Ouden, F.H. Schroder: Locally advanced disease: surgery: is there a rationale? 
In: Urologic Malignancies, Hamdy,F, Basler,J, Neal,D, Catalona,W. Churchill Livingstone Ed., 
chapter 2.6.2.2. In press. 
D. van den Ouden, W.C.J. Hop, R. Kranse, F.H. Schroder: Tumor control according to patholo-
gical variables in patients treated by radical prostatectomy for clinically localized carcinoma ofthe 
prostate. 
Br. J. UroL, in press. 
164 

